講座　精神疾患の臨床　5　神経認知障害群

出版社： 中山書店
著者：
発行日： 2023-05-25
分野： 臨床医学：内科  >  精神医学
ISBN： 9784521748252
電子書籍版： 2023-05-25 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

商品紹介

進歩が目覚ましい神経認知障害群では，最新の国際診断基準が時差なくICD-11の診断要件などに取り込まれ，病態解明や診断のためのバイオマーカー開発なども急速に進んでいる．
本書は，その最新知見の解説ならびに認知症医療にさまざまな立場から参画する際の手がかりとなる情報を提供している．
また，ICD-11より大きな変更があった「統合失調症又は他の一次性精神症群」の解説も盛り込まれている．

目次

  • 1章　概念・疫学
    2章　認知症の診断
    3章　認知症の症候群
    4章　認知症の鑑別診断
    5章　認知症の治療
    6章　認知症と社会
    7章　ICD-11における統合失調症以外の一次性精神症群

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 概念・疫学

P.13 掲載の参考文献
1) Mahendra B. Dementia. MTP Press ; 1984, pp1-18.
 
2) Menninger K, et al. The Vital Valance. Viking Press ; 1963, pp419-489.
 
3) Lipowski ZJ. Organic nebtal disorders : Theor history and classification with special reference to DSM-III. In : Miller NE, et al (eds). Clinical Aspects of Alzheimer's Disease and Senile Dementia. Raven Press ; 1981, pp37-45.
 
4) Rosen G. Madness in Society. University of Chicago Press ; 1968, pp229-262.
 
5) Pinel P. A Treatise on Insanity. Hafner ; 1962.
 
6) Esquirol JED. Des maladies mentales vol 2. Arno ; 1976, p261.
 
7) Defendorf AR. Clinical psychiatry : A textbook for students and physicians. Abstracted and adapted from the 6th German edition of Kraepelin's Lehrbuch der Psychiatrie. Macmillan ; 1902.
 
8) McHenry LC. Garrison's history of neurology. Thomas ; 1969, p86.
 
9) Major RH. Classic Descriptions of Disease. Thomas ; 1945, pp476-477.
 
10) Ferraro A. The neuropathology associated with psychoses of aging. In : Reiser MF (ed). American Handbook of Psychiatry, vol 4 : Organic Disorders and Psychosomatic Medicine. Basic Books ; 1975, pp90-133.
 
11) Torack RM. The Pathologic Physiology of Dementia : With Indications for Diagnosis and Treatment. Springer ; 1978.
 
12) Juergs M (著), 武田雅俊ほか (訳). アルツハイマー-無の世界への航跡. アークメディア ; 2006.
 
13) Kiloh LG. Pseudo-dementia. Acta Psychiatr Scand 1961 ; 37 (4) : 336-351.
PubMed
14) Steele JC, et al. Progressive supranuclear palsy : A heterogeneous degeneration involving the brain stem, Basal Ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964 ; 10 : 333-359.
PubMed
15) Adams RD, et al. Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure. A treatable syndrome. N Engl J Med 1965 ; 273 : 117-126.
PubMed
16) Benson DF. Aphasia, Alexia and Agraphia. Churchill Livingstone ; 1979.
 
17) Pullicino P, et al. Prevalence of Binswanger's disease. Lancet 1983 ; 1 (8330) : 939.
PubMed
18) 武田雅俊. 老年精神医学の源流. 120周年記念誌編集委員会 (編), 精神医学の潮流-大阪大学精神医学教室120年の歩み. 新興医学出版 ; 2014, pp309-316.
 
19) 厚生労働省審議会議事録「痴呆」に替わる用語に関する検討会報告書, 平成16年12月24日. https://www.mhlw.go.jp/shingi/2004/12/s1224-17.html
 
20) Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM-III). American Psychiatric Association ; 1980.
 
21) World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders : Clinical Descriptions and Diagnostic Guidelines. WHO ; 1992/融道男ほか (監訳). ICD-10 精神および行動の障害-臨床記述と診断ガイドライン, 新訂版. 医学書院 ; 1993.
 
22) McKahann G, et al. Clinical diagnosis of Alzheimer's disease : Report of the NINCDS-ADRDA work group under the auspices on department of health and human services task force on Alzheimer's disease. Neurology 1984 ; 34 : 939-944.
 
23) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
24) Petersen RC, et al. Mild cognitive impairment : Clinical characterization and outcome. Arch Neurol 1999 ; 56 (3) : 303-308.
PubMed
25) World Health Organization. ICD-11 Browser (Version : 02/2022). https://icd.who.int/browse11/l-m/en Further reading
 
Brice P (ed). Dementia. Churchill Livingstone ; 1987.
 
Takeda M, et al (eds). Molecular Neurobiology of Alzheimer Disease and Related Disorders. Karger ; 2003.
 
Juergs M (著), 武田雅俊ほか (訳). アルツハイマー-無の世界への航跡. アークメディア ; 2006.
 
P.23 掲載の参考文献
1) Lipowski ZJ. Delirium : Acute brain function faliue. Oxford University Press ; 1980.
 
2) Lipowski ZJ. Delirium ; Acute Confusional States. Oxford University Press ; 1990.
 
3) Adamis D, et al. A brief review of the history of delirium as a mental disorder. Hist Psychiatry 2007 ; 18 : 459-465.
PubMed
4) Lipowski ZJ. Transient cognitive disorders (delirium, acute confusional states) in the elderly. Am J Psychiatry 1983 ; 140 : 1426-1436.
PubMed
5) Meagher DJ, et al. Phenomenology of delirium : Assessment of 100 adult cases using standardised measures. Br J Psychiatry 2007 ; 190 : 135-141.
PubMed
6) Lipowski ZJ. Delirium (acute confusional states). J Am Med Assoc 1987 ; 258 : 1789-1792.
 
7) Meagher DJ, et al. Frequency of delirium and subsyndromal delirium in an adult acute hospital population. Br J Psychiatry 2014 ; 205 : 478-485.
 
8) Levkoff SE, et al. Subsyndromal Delirium. Am J Geriatr Psychiatry 1996 ; 4 : 320-329.
PubMed
9) Cole M, et al. The prognostic significance of subsyndromal delirium in elderly medical inpatients. J Am Geriatr Soc 2003 ; 51 : 754-760.
PubMed
10) Davis DHJ, et al. Delirium is a strong risk factor for dementia in the oldest-old : A population-based cohort study. Brain 2012 ; 135 : 2809-2816.
 
11) Perterson JF, et al. Delirium and its motoric subtypes : A study of 614 critically ill patients. J Am Geriatr Soc 2006 ; 54 : 479-484.
 
12) Meagher D, et al. A new data-based motor subtype schema for delirium. J Neuropsychiatry Clin Neurosci 2008 ; 20 : 185-193.
 
13) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
14) World Health Organization. ICD-11 Browser (Version : 02/2022). https://icd.who.int/browse11/l-m/en
 
15) 日本総合病院精神医学会 せん妄指針改訂班 (編). せん妄の臨床指針-せん妄の治療指針 第2版. 星和書店 ; 2015.
 
16) 日本集中治療医学会J-PADガイドライン作成委員会. 日本版・集中治療室における成人重症患者に対する痛み・不穏・せん妄管理のための臨床ガイドライン. 日集中医誌 2014 ; 21 : 539-579.
 
17) Sands MB, et al. Single question in delirium (SQiD) : Testing its efficacy against psychiatrist interview, the confusion assessment method and the memorial delirium assessment scale. Palliat Med 2010 ; 24 : 561-565.
PubMed
18) Inouye SK, et al. Clarifying confusion : The confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990 ; 113 : 941-948.
 
19) 町田いずみほか. せん妄スクリーニングツール (DST) の作成. 総合病院精神医学 2003 ; 15 : 150-155.
 
20) Breitbart W, et al. The memorial delirium assessment scale. J Pain Symptom Manage 1997 ; 13 : 128-137.
PubMed
21) Neelon VJ, et al. The NEECHAM Confusion Scale : Construction, validation, and clinical testing. Nurs Res 1996 ; 45 : 324-330.
PubMed
22) Trzepacz PTほか. 日本語版せん妄評価尺度 98年改訂版. 精神医学 2001 ; 43 : 1365-1371.
 
23) Figueroa-Ramos MI, et al. Sleep and delirium in ICU patients : A review of mechanisms and manifestations. Intensive Care Med 2009 ; 35 : 781-795.
PubMed
24) Alsop DC, et al. The role of neuroimaging in elucidating delirium pathophysiology. J Gerontol Med Sci 2006 ; 61 : 1287-1293.
 
25) Soiza RL, et al. Neuroimaging studies of delirium : A systematic review. J Psychosom Res 2008 ; 65 : 239-248.
PubMed
26) Rahkonen T, et al. Systematic intervention for supporting community care of elderly people after a delirium episode. Int Psychogeriatr 2001 ; 13 : 37-49.
PubMed
27) Fann JR. The epidemiology of delirium : A review of studies and methodological issues. Semin Clin Neuropsychiatry 2000 ; 5 : 64-74.
PubMed
28) Fick DM, et al. Delirium superimposed on dementia : A systematic review. J Am Geriatr Soc 2002 ; 50 : 1723-1732.
PubMed
29) 日本精神神経学会 (監訳), 粟田主一ほか (訳). 米国精神医学会治療ガイドライン せん妄. 医学書院 ; 2000.
 
30) Sandberg O, et al. Prevalence of dementia, delirium and psychiatric symptoms in various care settings for the elderly. Scand J Soc Med 1998 ; 26 : 56-62.
PubMed
31) Davis D, et al. The epidemiology of delirium : Challenges and opportunities for population studies. Am J Geriatr Psychiatry 2013 ; 21 : 1173-1189.
PubMed
32) Maldonado JR. Neuropathogenesis of delirium : Review of current etiologic theories and common pathways. Am J Geriatr Psychiatry 2013 ; 21 : 1190-1222.
PubMed
33) Maldonado JR. Delirium pathophysiology : An updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry 2018 ; 33 : 1428-1457.
PubMed
34) Stagno D, et al. The delirium subtypes : A review of prevalence, phenomenology, pathophysiology, and treatment response. Palliat Support Care 2004 ; 2 : 171-179.
PubMed
35) Gaudreau JD, Gagnon P. Psychotogenic drugs and delirium pathogenesis : The central role of the thalamus. Med Hypotheses 2005 ; 64 : 471-475.
PubMed
36) Flacker JM, et al. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998 ; 6 : 31-41.
PubMed
37) Mussi C, et al. Importance of serum anticholinergic activity in the assessment of elderly patients with delirium. J Geriatr Psychiatry Neurol 1999 ; 12 : 82-86.
PubMed
38) Yu A, et al. Cholinesterase inhibitors for the treatment of delirium in non-ICU settings. Cochrane Database Syst Rev 2018 ; 6 : CD012494.
PubMed
39) Trzepacz PT. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000 ; 5 : 132-148.
 
40) Boettger S, Breibart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care 2011 ; 9 : 351-357.
 
41) Cepeda C, Levine MS. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 1998 ; 20 : 1-18.
 
42) National Institute for Health and Care Excellence (NICE). 2018 surveillance of delirium : prevention, diagnosis and management (NICE guideline CG103). https://www.nice.org.uk/guidance/cg103/resources/2018-surveillance-of-delirium-prevention-diagnosisand-management-nice-guideline-cg103-pdf-8546233843141
 
43) 八田耕太郎. せん妄ハンドブック. 中外医学社 ; 2021.
 
八田耕太郎. せん妄ハンドブック. 中外医学社 ; 2021.
 
P.37 掲載の参考文献
1) Petersen RC, et al. Mild cognitive impairment : A concept in evolution. J Intern Med 2014 ; 275 : 214-228.
PubMed
2) Petersen RC, et al. Practice guideline update summary : Mild cognitive impairment : Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018 ; 90 : 126-135.
 
3) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition, DSM-5. American Psychiatric Association ; 2013.
 
4) World Health Organization. ICD-11 Browser (Version : 02/2022). https://icd.who.int/browse11/l-m/en (参照2022-03-31)
 
5) 日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
6) 西村勝治. ICD-11「精神, 行動, 神経発達の疾患」分類と病名の解説シリーズ : 各論 (16) ICD-11における症状性を含む器質性精神障害. 精神経誌 2022 ; 124 : 496-500.
 
7) Reisberg B, et al. Mild cognitive impairment (MCI) : A historical perspective. Int Psychogeriatr 2008 ; 20 : 18-31.
PubMed
8) Kral VA. Senescent forgetfulness : Benign and malignant. Can Med Assoc J 1962 ; 86 : 257-260.
PubMed
9) Gilles C. Age-related mild cognitive deficit : A ready-to-use concept? Dialogues Clin Neurosci 2003 ; 5 : 61-76.
PubMed
10) 布村明彦. MCIとプレクリニカルADの概念と疫学. 老年精医誌 2016 ; 27 : 607-615.
Medical*Online
11) Hughes CP, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982 ; 140 : 566-572.
PubMed
12) Reisberg B, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982 ; 139 : 1136-1139.
PubMed
13) Crook T, et al. Age-associated memory impairment : Proposed diagnostic criteria and measures of clinical changes. Report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986 ; 2 : 261-276.
 
14) Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994 ; 6 : 63-68.
PubMed
15) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. World Health Organization ; 1993.
 
16) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, DSM-IV. American Psychiatric Association ; 1994.
 
17) Ebly EM, et al. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 1995 ; 52 : 612-619.
PubMed
18) Petersen RC, et al. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999 ; 56 : 303-308.
PubMed
19) Winblad B, et al. Mild cognitive impairment-beyond controversies, towards a consensus : Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004 ; 256 : 240-246.
 
20) Reisberg B, et al. The pre-mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease. Alzheimers Dement 2008 ; 4 (1 Suppl 1) : S98-S108.
 
21) Reisberg B, et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev Res 1988 ; 15 : 101-114.
 
22) Reisberg B, et al. Staging dementia. In : Mohammed T, et al (eds). Principles and Practice of Geriatric Psychiatry, 3rd edition. John Wiley & Sons ; 2011, pp162-169.
 
23) Gurland BJ, et al. Criteria for diagnosis of dementia in the community elderly. Gerontologist 1982 ; 22 : 180-186.
PubMed
24) Roth M, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986 ; 149 : 698-709.
 
25) Blackford RC, La Rue A. Criteria for diagnosing age-associated memory impairment : Proposed improvements from the field. Dev Neuropsychol 1989 ; 5 : 295-306.
 
26) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition-revised, DSM-III-R. American Psychiatric Association ; 1987.
 
27) Zaudig M. A new systematic method of measurement and diagnosis of "mild cognitive impairment" and dementia according to ICD-10 and DSM-III-R criteria. Int Psychogeriatr 1992 ; 4 (suppl 2) : 203-219.
 
28) Petersen RC, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995 ; 273 : 1274-1278.
PubMed
29) Petersen RC, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001 ; 58 : 1985-1992.
PubMed
30) Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005 ; 62 : 1160-1163.
PubMed
31) Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 : 270-279.
PubMed
32) Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 : 280-292.
PubMed
33) Gorelick PB, et al. Vascular contributions to cognitive impairment and dementia : A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 ; 42 : 2672-2713.
PubMed
34) Litvan I, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease : Critical review of PD-MCI. Mov Disord 2011 ; 26 : 1814-1824.
PubMed
35) McKeith IG, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020 ; 94 : 743-755.
PubMed
36) Barker MS, et al. Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain 2022 ; 145 : 1079-1097.
PubMed
37) Petersen RC, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013 ; 74 : 199-208.
PubMed
38) Jessen F, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014 ; 10 : 844-852.
 
39) 朝田隆. 厚生労働科学研究費補助金 (認知症対策総合研究事業). 都市部における認知症有病率と認知症の生活機能障害への対応. 平成23～24年度総合研究報告書, 2013.
 
40) 日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院 ; 2017, pp145-160.
 
41) Petersen RC. Mild cognitive impairment : Epidemiology, pathology, and clinical assessment. UpToDate (last updated 2020-12-10) https://www.uptodate.com/contents/mild-cognitive-impairment-epidemiology-pathology-and-clinicalassessment (参照2022-03-31)
 
42) Mitchell AJ, Shiri-Feshki M : Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009 ; 119 : 252-265.
PubMed
43) 新井哲明. 軽度認知障害の神経病理. 臨精医 2018 ; 47 : 1363-1366.
Medical*Online
Iraniparast M, et al. Cognitive Reserve and Mild Cognitive Impairment : Predictors and Rates of Reversion to Intact Cognition vs Progression to Dementia. Neurology 2022 ; 98 : e1114-e1123.
PubMed
McGirr A, et al. Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms. Neurology 2022 ; 98 : e2132-e2139.
 
Ward DD, et al. Frailty and Risk of Dementia in Mild Cognitive Impairment Subtypes. Ann Neurol 2021 ; 89 : 1221-1225.
PubMed
布村明彦. うつ病性仮性認知症およびうつ病とMCIの併存. 老年精医誌 2018 ; 29 : 241-248.
Medical*Online
P.47 掲載の参考文献
1) Larner AJ, Gardner-Thorpe C. Robert Lawson (?1846-1896). J Neurol 2012 ; 259 : 792-793.
 
2) Kopelman MD. What does a comparison of the alcoholic Korsakoff syndrome and thalamic infarction tell us about thalamic amnesia? Neurosci Biobehav Rev 2015 ; 54 : 46-56.
PubMed
3) Race E, Verfaellie M. Remote memory function and dysfunction in Korsakoff's syndrome. Neuropsychol Rev 2012 ; 22 : 105-116.
PubMed
4) Victor M, et al. The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations. Contemp Neurol Ser 1971 ; 7 : 1-206.
PubMed
5) Mayes AR, et al. Location of lesions in Korsakoff's syndrome : Neuropsychological and neuropathological data on two patients. Cortex 1988 ; 24 : 367-388.
PubMed
6) Harding A, et al. Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. Brain 2000 ; 123 (Pt 1) : 141-154.
 
7) Sullivan EV, Pfefferbaum A. Neuroimaging of the Wernicke-Korsakoff syndrome. Alcohol Alcohol 2009 ; 44 : 155-165.
PubMed
8) Teuber HL. Disorders of memory following penetrating missile wounds of the brain. Neurology 1968 ; 18 : 287-288.
PubMed
9) Squire LR, et al. Description of brain injury in the amnesic patient N.A. based on magnetic resonance imaging. Exp Neurol 1989 ; 105 : 23-35.
 
10) Speedie LJ, Heilman KM. Amnestic disturbance following infarction of the left dorsomedial nucleus of the thalamus. Neuropsychologia 1982 ; 20 : 597-604.
PubMed
11) Van der Werf YD, et al. Deficits of memory, executive functioning and attention following infarction in the thalamus ; a study of 22 cases with localised lesions. Neuropsychologia 2003 ; 41 : 1330-1344.
PubMed
12) Nishio Y, et al. Multiple thalamo-cortical disconnections in anterior thalamic infarction : Implications for thalamic mechanisms of memory and language. Neuropsychologia 2014 ; 53 : 264-273.
PubMed
13) Carlesimo GA, et al. Vascular thalamic amnesia : A reappraisal. Neuropsychologia 2011 ; 49 : 777-789.
PubMed
14) Aggleton JP, O'Mara SM. The anterior thalamic nuclei : Core components of a tripartite episodic memory system. Nat Rev Neurosci 2022 ; 1-12.
 
15) Schmitt LI, et al. Thalamic amplification of cortical connectivity sustains attentional control. Nature 2017 ; 545 : 219-223.
PubMed
16) 西尾慶之. エピソード記憶の神経ネットワーク-視床健忘からの洞察. 高次脳機能研究 2019 ; 9 (3) : 306-313.
 
17) Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 1957 ; 20 : 11-21.
PubMed
18) Corkin S, et al. H. M.'s medial temporal lobe lesion : Findings from magnetic resonance imaging. J Neurosci 1997 ; 17 : 3964-3979.
 
19) Zola-Morgan S, et al. Human amnesia and the medial temporal region : Enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986 ; 6 : 2950-2967.
PubMed
20) Squire LR, et al. The medial temporal lobe. Annu Rev Neurosci 2004 ; 27 : 279-306.
PubMed
21) Zeman AZ, et al. Transient epileptic amnesia : A description of the clinical and neuropsychological features in 10 cases and a review of the literature. J Neurol Neurosurg Psychiatry 1998 ; 64 : 435-443.
 
22) Butler CR, Zeman AZ. Recent insights into the impairment of memory in epilepsy : Transient epileptic amnesia, accelerated long-term forgetting and remote memory impairment. Brain 2008 ; 131 : 2243-2263.
PubMed
23) Fisher CM, Adams RD. Transient Global Amnesia. Acta Neurol Scand Suppl 1964 ; 40 : 1-83.
 
24) Hodges JR, Warlow CP. Syndromes of transient amnesia : Towards a classification. A study of 153 cases. J Neurol Neurosurg Psychiatry 1990 ; 53 : 834-843.
 
25) Miller JW, et al. Transient global amnesia : Clinical characteristics and prognosis. Neurology 1987 ; 37 : 733-737.
PubMed
26) Arena JE, Rabinstein AA. Transient global amnesia. Mayo Clin Proc 2015 ; 90 : 264-272.
PubMed
27) Scheel M, et al. Magnetic Resonance Imaging in Transient Global Amnesia. Clin Neuroradiol 2012 ; 22 : 335-340.
PubMed
28) Jang JW, et al. Longitudinal Cerebral Perfusion Change in Transient Global Amnesia Related to Left Posterior Medial Network Disruption. PLoS One 2015 ; 10 : e0145658.
PubMed
29) Mimura Y, et al. Combined abnormal findings of MRI-SPECT-EEG suggest vulnerability to ischemia in transient global amnesia. J Neurol Sci 2022 ; 438 : 120273.
PubMed
30) Bartsch T, et al. Evolution of hippocampal CA-1 diffusion lesions in transient global amnesia. Ann Neurol 2007 ; 62 : 475-480.
PubMed
31) Akkawi NM, et al. Transient global amnesia : A clinical and sonographic study. Eur Neurol 2003 ; 49 (2) : 67-71.
 
32) Lindqvist G, Norlen G. Korsakoff's syndrome after operation on ruptured aneurysm of the anterior communicating artery. Acta Psychiatr Scand 1966 ; 42 : 24-34.
PubMed
33) Damasio AR, et al. Amnesia following basal forebrain lesions. Arch Neurol 1985 ; 42 : 263-271.
PubMed
34) Schnider A, et al. Recovery from spontaneous confabulations parallels recovery of temporal confusion in memory. Neurology 2000 ; 55 : 74-83.
PubMed
35) Fujii T, et al. The role of the basal forebrain in episodic memory retrieval : A positron emission tomography study. Neuroimage 2002 ; 15 : 501-508.
PubMed
36) Shingaki H, et al. Disturbance of time orientation, attention, and verbal memory in amnesic patients with confabulation. J Clin Exp Neuropsychol 2016 ; 38 : 171-182.
PubMed
37) Harrison NA, et al. Psychogenic amnesia : Syndromes, outcome, and patterns of retrograde amnesia. Brain 2017 ; 140 : 2498-2510.
PubMed
38) Markowitsch HJ, et al. Retrograde amnesia after traumatic injury of the fronto-temporal cortex. J Neurol Neurosurg Psychiatry 1993 ; 56 : 988-992.
PubMed
39) Tanaka Y, et al. Postencephalitic focal retrograde amnesia after bilateral anterior temporal lobe damage. Neurology 1999 ; 53 : 344-350.
PubMed
40) Kapur N, et al. Focal Retrograde Amnesia Following Bilateral Temporal Lobe Pathology. Brain 1992 ; 115 : 73-85.
PubMed
41) De Renzi E, et al. Persistent retrograde, amnesia following a minor trauma. Cortex 1995 ; 31 : 531-542.
PubMed
42) Markowitsch HJ. Psychogenic amnesia. Neuroimage 2003 ; 20 : S132-S138.
PubMed
43) Kopelman MD. Focal retrograde amnesia and the attribution of causality : An exceptionally critical review. Cogn Neuropsychol 2000 ; 17 : 585-621.
 
44) Brand M, et al. Functional brain imaging in 14 patients with dissociative amnesia reveals right inferolateral prefrontal hypometabolism. Psychiatry Res 2009 ; 174 : 32-39.
PubMed
45) Kikuchi H, et al. Memory repression : Brain mechanisms underlying dissociative amnesia. J Cogn Neurosci 2010 ; 22 : 602-613.
PubMed
46) 三村悠, 三村將. 今日の精神科治療ハンドブック. 第12章 神経認知障害群 健忘症候群の治療. 精神科治療学 2021 ; 36 (増刊) : 210-211.
 
山鳥重. 記憶の神経心理学 (神経心理コレクション). 医学書院 ; 2002.
 
P.59 掲載の参考文献
1) Kendell RE. The Role of Diagnosis in Psychiatry. Blackwell Scientific Publications ; 1975.
 
2) Robins E, Guze SB. Establishment of Diagnostic Validity in Psychiatric Illness : Its Application to Schizophrenia. Am J Psychiatry 1970 ; 126 : 983-987.
PubMed
3) 古茶大樹. セントルイス学派の思想とDSM分類. 精神医学史研究 2020 ; 24 : 39-45.
Medical*Online
4) Insel T. Transforming Diagnosis. National Institute of Mental Health 2013. http://psychrights.org/2013/130429NIMHTransformingDiagnosis.htm
 
5) Jablensky A. Psychiatric Classifications : Validity and Utility. World Psychiatry 2016 ; 15 : 26-31.
PubMed
6) Kendell RE. Clinical Validity. Psychol Med 1989 ; 19 : 45-55.
 
7) Kendell RE, Jablensky A. Distinguishing Between the Validity and Utility of Psychiatric Diagnoses. Am J Psychiatry 2003 ; 160 : 4-12.
 
8) Kendler KS. Toward a Scientific Psychiatric Nosology. Arch Gen Psychiatry 1990 ; 47 : 969-973.
 
9) Wakefield JC. The Concept of Mental Disorder : Diagnostic Implications of the Harmful Dysfunction Analysis. World Psychiatry 2007 ; 6 : 149-156.
PubMed
10) Hempel CG. Introduction to Problems of Taxonomy. In : Zubin J (ed). Field Studies in the Mental Disorders. Grune and Strutton ; 1961.
 
11) 古茶大樹. 臨床精神病理学-精神医学における疾患と診断. 日本評論社 ; 2019.
 
12) エーミール・クレペリン (著), 伊達徹 (訳). <精神医学> 5 精神医学. みすず書房 ; 1992.
 
13) 古茶大樹, 古野毅彦. 退行期メランコリーについて. 精神神経誌 2009 ; 111 : 373-387.
 
14) 古茶大樹. 高齢発症の精神病の歴史と精神病理学総論からみたその疾病分類学的問題点. 老年精神医学 2021 ; 32 : 603-610.
Medical*Online
15) Ouchi Y, et al. Redefining the elderly as aged 75 years and older : Proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol 2017 ; 17 : 1045-1047.
PubMed
16) Van de Leemput J, et al. Chapter Three - Genetics of Schizophrenia : Historical Insights and Prevailing Evidence. Adv Genet 2016 ; 96 : 99-141.
 
17) Van Os J, Tamminga C. Deconstructing Psychosis. Schizophr Bull 2007 ; 33 : 861-862.
PubMed
18) Insel T, et al. Research domain criteria (RDoC) : Toward a new classification framework for research on mental disorders. Am J Psychiatry 2010 ; 167 : 748-751.
 
Kendell RE. The Role of Diagnosis in Psychiatry. Blackwell Scientific Publications ; 1975.
 
Robins E, Guze SB. Establishment of Diagnostic Validity in Psychiatric Illness : Its Application to Schizophrenia. Am J Psychiatry 1970 ; 126 : 983-987.
PubMed
P.68 掲載の参考文献
1) Noguchi-Shinohara M, et al. Differences in the prevalence of dementia and mild cognitive impairment and cognitive functions between early and delayed responders in a community-based study of the elderly. J Alzheimers Dis 2013 ; 37 (4) : 691-698.
 
2) 厚生労働科学研究費補助金認知症対策総合研究事業 都市部における認知症有病率と認知症の生活機能障害への対応 平成24年度総合研究報告書. 2013.
 
3) Ohara T, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology 2017 ; 88 (20) : 1925-1932.
 
4) Ninomiya T, et al. Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan : The Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Environ Health Prev Med 2020 ; 25 (1) : 64.
PubMed
5) 小原知之. アルツハイマー病発症の危険因子とそのリスク低減. 医学と薬学 2022 ; 79 (1) : 49-56.
Medical*Online
6) 令和元年度 厚生労働省老人保健健康増進等事業. 海外認知症予防ガイドラインの整理に関する調査研究事業 WHOガイドライン「認知機能低下及び認知症のリスク低減」邦訳検討委員会. 認知機能低下および認知症のリスク低減 WHOガイドライン. https://www.jri.co.jp/MediaLibrary/file/column/opinion/detail/20200410_theme_t22.pdf
 
7) Ninomiya T. Diabetes mellitus and dementia. Curr Diab Rep 2014 ; 14 (5) : 487.
PubMed
8) Chu CS, et al. Use of statins and the risk of dementia and mild cognitive impairment : A systematic review and meta-analysis. Sci Rep 2018 ; 8 (1) : 5804.
PubMed
9) Ohara T, et al. Midlife and late-life smoking and risk of dementia in the community : The Hisayama Study. J Am Geriatr Soc 2015 ; 63 (11) : 2332-2339.
PubMed
10) Anstey KJ, et al. Alcohol consumption as a risk factor for dementia and cognitive decline : Meta-analysis of prospective studies. Am J Geriatr Psychiatry 2009 ; 17 (7) : 542-555.
PubMed
11) Xu W, et al. Alcohol consumption and dementia risk : A dose-response meta-analysis of prospective studies. Eur J Epidemiol 2017 ; 32 (1) : 31-42.
 
12) Prince M, et al. World Alzheimer Report 2014-Dementia and risk reduction. Alzheimer's Disease International ; 2014.
 
13) 令和元年度 厚生労働省老人保健健康増進等事業. 海外認知症予防ガイドラインの整理に関する調査研究事業 WHOガイドライン「認知機能低下及び認知症のリスク低減」邦訳検討委員会. 認知機能低下および認知症のリスク低減 WHOガイドライン. https://www.jri.co.jp/MediaLibrary/file/column/opinion/detail/20200410_theme_t22.pdf
 
14) Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease : A systematic review of prospective evidence. Psychol Med 2009 ; 39 (1) : 3-11.
PubMed
15) Kishimoto H, et al. The long-term association between physical activity and risk of dementia in the community : The Hisayama Study. Eur J Epidemiol 2016 ; 31 (3) : 267-274.
 
16) Ozawa M, et al. Dietary patterns and risk of dementia in an elderly Japanese population : The Hisayama Study. Am J Clin Nutr 2013 ; 97 (5) : 1076-1082.
 
17) Ngandu T, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : A randomised controlled trial. Lancet 2015 ; 385 (9984) : 2255-2263.
 
18) Moll van Charante EP, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA) : A cluster-randomised controlled trial. Lancet 2016 ; 388 (10046) : 797-805.
PubMed
19) Andrieu S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT) : A randomised, placebo-controlled trial. Lancet Neurol 2017 ; 16 (5) : 377-389.
 
20) Kivipelto M, et al. World-Wide FINGERS Network : A global approach to risk reduction and prevention of dementia. Alzheimers Dement 2020 ; 16 (7) : 1078-1094.
PubMed
Global action plan on the public health response to dementia 2017-2025. https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025. Accessed 2022. 02. 25
 
Livingston G, et al. Dementia prevention, intervention, and care : 2020 report of the Lancet Commission. Lancet 2020 ; 396 (10248) : 413-446.
PubMed
令和元年度 厚生労働省老人保健健康増進等事業. 海外認知症予防ガイドラインの整理に関する調査研究事業 WHOガイドライン「認知機能低下及び認知症のリスク低減」邦訳検討委員会. 認知機能低下および認知症のリスク低減 WHOガイドライン. https://www.jri.co.jp/MediaLibrary/file/column/opinion/detail/20200410_theme_t22.pdf
 
P.76 掲載の参考文献
1) Koopmans R, Rosness T. Young onset dementia--What does the name imply? Int Psychogeriatr 2014 ; 26 (12) : 1931-1933.
PubMed
2) van Vliet D, et al. Time to diagnosis in young onset dementia as compared with late-onset dementia. Psychol Med 2013 ; 43 (2) : 423-432.
PubMed
3) 粟田主一. 若年性認知症の疫学と社会政策. 医学のあゆみ 2012 ; 278 (12) : 1016-1022.
 
4) Last ML. A dictionary of epidemiology. Oxford University Press ; 1983, pp32-33.
 
5) 一ノ渡尚道. 若年痴呆の実態に関する研究. 厚生省科学研究費補助金 (精神保健医療研究事業) 平成8年度研究報告書 (研究代表者 : 一ノ渡尚道). 1997.
 
6) 宮永和夫ほか. 日本における若年期および初老期の痴呆性疾患の実態について. 老年精神医学雑誌 1997 ; 12 : 1317-1331.
Medical*Online
7) 朝田隆. 若年性認知症の実態と対応の基盤整備に関する研究. 厚生労働科学研究費補助金 (長寿科学総合研究事業) 平成20年度総括・分担研究報告書 (研究代表者 : 朝田隆). 2009.
 
8) 粟田主一. 若年性認知症の有病率・生活実態把握と多元的データ共有システムの開発. 日本医療研究開発機構長寿・障害総合研究事業 (認知症研究開発事業) 報告書 (研究開発代表者 : 粟田主一). 2020.
 
9) Awata S, et al. Prevalence and subtype distribution of early-onset dementia in Japan. Psychogeriatrics 2020 ; 20 (6) : 817-823.
PubMed
10) 粟田主一. わが国の若年性認知症の有病率と生活実態. 精神医学 2020 ; 62 (11) : 1429-1444.
 
11) 粟田主一. 若年性認知症研究. 老年精神医学雑誌 2022 ; 33 (2) : 156-166.
 
12) 多賀努. 若年性認知症の本人・家族の視点を政策に反映することの重要性と本人発意の制作形成の課題. 精神医学 2020 ; 62 (11) : 1517-1527.
 
13) Vieira RT, et al. Epidemiology of early-onset dementia : A review of the literature. Clin Pract Epidemiol Ment Health 2013 ; 9 : 88-95.
PubMed
14) Hendriks S, et al. Global incidence of young-onset dementia : A systematic review and meta-analysis. Alzheimers Dement 2022 Jun 17. doi : 10.1002/alz.12695. Epub ahead of print.
 
15) 粟田主一. 若年性認知症の人の生活実態調査と大都市における認知症の有病率及び生活実態調査. 厚生労働科学研究費補助金 (認知症政策研究事業) 令和元年度総括・分担研究報告書 (研究代表者 : 粟田主一). 2020.
 
16) Edahiro A, et al. Incidence and distribution of subtypes of early-onset dementia in Japan : A nationwide analysis based on annual performance reports of the Medical Centers for Dementia. Geriatr Gerontol Int 2020 ; 20 (11) : 1050-1055.
PubMed
17) 枝広あや子, 粟田主一. 認知症疾患医療センター実績報告書を用いた若年性認知症の疫学研究. 精神医学 2020 ; 62 (11) : 1529-1537.
 
18) Lambert MA, et al. Estimating the burden of early onset dementia : Systematic review of disease prevalence. Eur J Neurol 2014 ; 21 (4) : 563-569.
PubMed
19) Hendriks S, et al. Global prevalence of young-onset dementia : A systematic review and meta-analysis. JAMA Neurol 2021 ; 78 (9) : 1080-1090.
PubMed
20) Ahmad OB, et al. Age standardization of rates : A new WHO standard. GPE Discussion Paper Series No. 31. World Health Organization. 2001 ; 9 (10). https://www.who.int/healthinfo/paper31.pdf
 
21) Kvello-Alme M, et al. The Prevalence and Subtypes of Young Onset Dementia in Central Norway : A Population-Based Study. J Alzheimers Dis 2019 ; 69 (2) : 479-487.
PubMed
22) McGonigal G. Epidemiology of Alzheimer's presenile dementia in Scotland, 1974-88. Br Med J 1993 ; 306 (6879) : 680-683.
 
23) Newens AJ, et al. Clinically diagnosed presenile dementia of the Alzheimer type in the Northern Health Region : Ascertainment, prevalence, incidence and survival. Psychol Med 1993 ; 23 (3) : 631-644.
PubMed
24) Kvello-Alme M, et al. Incidence of Young Onset Dementia in Central Norway : A Population-Based Study. J Alzheimers Dis 2020 ; 75 (3) : 697-704.
PubMed
25) Rocca WA, et al. Incidence of Dementia and Alzheimer's Disease A Reanalysis of data from Rochester, Minnesota, 1975-1984. Am J Epidemiol 1998 ; 148 (1) : 51-62.
PubMed
26) Kay DWK, et al. Long-term survival, place of death, and death certification in clinically diagnosed presenile dementia in northern England : Follow-up after 8-12 years. Br J Psychiatry 2000 ; 177 : 156-162.
 
27) Knopman DS, et al. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 Through 1994. Neurology 2004 ; 62 (3) : 506-508.
PubMed
28) Knopman DS, et al. Incidence and causes of nondegenerative nonvascular dementia : A population-based study. Arch Neurol 2006 ; 63 (2) : 218-221.
PubMed
29) Bickel H, et al. Prasenile demenzen in gedachtnisambulanzen - Konsultationsinzidenz und krankheitscharakteristika [Presenile Dementia in Memory Clinics--Incidence Rates and Clinical Features] [Article in German]. Nervenarzt 2006 ; 77 (9) : 1079-1085.
PubMed
30) Mercy L, et al. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 2008 ; 71 (19) : 1496-1499.
 
31) Garre-Olmo J, et al. Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology 2010 ; 75 (14) : 1249-1255.
 
32) Abraham SM, et al. Incidence of early-onset dementia in Mar del Plata. Neurologia 2015 ; 30 (2) : 77-82.
 
33) 東京都健康長寿医療センター. 認知症疾患医療センターに期待される役割に関する調査. 令和3年度老人保健推進費等補助金老人保健健康増進等事業「認知症疾患医療センター運営事業の事業評価のあり方に関する調査研究事業」報告書. 2022, pp167-273. https://www.tmghig.jp/research/info/archives/014345/
 
34) みずほリサーチ&テクノロジーズ. 若年性認知症における治療と仕事の両立に関する手引き. 2021年. https://www.mizuho-ir.co.jp/case/research/pdf/r03mhlw_kaigo2021_01.pdf
 
35) 川勝忍ほか. 行動症状が優勢な若年性認知症の治療と社会的支援-自立支援医療制度の問題点を含めて. 医学のあゆみ 2021 ; 278 (12) : 1029-1033.
Medical*Online
36) 東京都福祉保健局. 若年性認知症の本人の通いの場をつくるガイドブック. 2020年. https://www.fukushihoken.metro.tokyo.lg.jp/zaishien/ninchishou_navi/torikumi/manual_text/jakunen_guidebook/index.html
 
粟田主一 (編). 特集 若年性認知症-臨床・基礎・社会的支援のstate of arts. 医学のあゆみ 2021 ; 278 (12).
 
丹野智文. 認知症の私から見える社会. 講談社 ; 2021.
 
P.82 掲載の参考文献
1) 内閣府. 令和4年版高齢社会白書. https://www8.cao.go.jp/kourei/whitepaper/index-w.html
 
2) 国立社会保障・人口問題研究所. 日本の世帯数の将来推計 (全国推計) (2018 (平成30) 年推計). http://www.ipss.go.jp/pp-ajsetai/j/HPRJ2018/t-page.asp
 
3) 粟田圭一. 特集にあたって : 一人暮らし, 認知症, 社会的孤立. 老年精神医学雑誌 2020 ; 31 (5) : 451-459.
 
4) 川越雅弘, 南拓磨. 一人暮らしの認知症高齢者の出現率および生活状況の実態. 老年精神医学雑誌 2020 ; 31 : 460-466.
 
5) Clare L, et al. Living Alone with Mild-To-Moderate Dementia : Findings from the IDEAL Cohort. J Alzheimers Dis 2020 ; 78 (3) : 1207-1216.
PubMed
6) Rozzini R, et al. Social, functional and health status influences on mortality : Consideration of a multidimensional inquiry in a large elderly population. J Cross Cult Gerontol 1991 ; 6 (1) : 83-90.
 
7) Teguo MT, et al. Feelings of Loneliness and Living Alone as Predictors of Mortality in the Elderly : The PAQUID Study. Psychosom Med 2016 ; 78 (8) : 904-909.
 
8) Labos E, et al. Cognitive impairment during the COVID-19- social isolation period. Medicina (B Aires) 2021 ; 81 (5) : 722-734.
PubMed
9) Grande G, et al. Living Alone and Dementia Incidence : A Clinical-Based Study in People With Mild Cognitive Impairment. J Geriatr Psychiatry Neurol 2018 ; 31 (3) : 107-113.
PubMed
10) Kikuchi K, et al. Exploratory research on outcomes for individuals missing through dementia wandering in Japan. Geriatric Gerontology 2019 ; 19 (9) : 902-906.
 
11) Webber PA, et al. Living alone with Alzheimer's disease : Effects on health and social service utilization patterns. Gerontologist 1994 ; 34 (1) : 8-14.
PubMed
12) Murayama N, et al. Risk factors for delusion of theft in patients with Alzheimer's disease showing mild dementia in Japan. Aging Ment Health 2009 ; 13 (4) : 563-568.
PubMed
13) Wardian J, et al. Validation of the DSSI-10 to measure social support in a general population. Res Soc Work Pract 2013 ; 23 : 100-106.
 
14) Lubben JE. Assessing Social Networks Among elderly populations. Family & Community Health 1988 ; 11 : 42-52.
 
15) 栗本鮎美ほか. 日本語版 Lubben Social Network Scale 短縮版 (LSNS-6) の作成と信頼性および妥当性の検討. 日本老年医学会雑誌 2011 ; 48 (2) : 149-157.
 
16) Koizumi Y, et al. Association between social support and depression status in the elderly : Results of a 1-year community-based prospective cohort study in Japan. Psychiatry Clin Neurosci 2005 ; 59 : 563-569.
PubMed
17) Blazer DG. Social support and mortality in an elderly community population. Am J Epidemiol 1982 ; 115 : 633-802.
 
18) 池田学ほか. 令和2年度 厚生労働行政推進調査事業 費補金厚生労働科学特別研究事業. コロナ感染症蔓延下における精神科医を含む認知症初期集中支援チームの活動評価と有用性の研究. 2021.
 

2章 認知症の診断

P.91 掲載の参考文献
1) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
2) World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders : Clinical Description and Diagnostic Guidelines. WHO ; 1992/融道男ほか (監訳). ICD-10 精神および行動の障害-臨床記述と診断ガイドライン, 新訂版. 医学書院 ; 2005.
 
3) Akatsu H, et al. Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital. J Neurol Sci 2002 ; 196 : 63-69.
 
4) Ikejima C, et al. Multicentre population-based dementia prevalence survey in Japan : A preliminary report. Psychogeriatrics 2012 ; 12 : 120-123.
PubMed
5) Kitagaki H, et al. CSF space in idiopathic normal pressure hydrocephalus : Morphology and volumetry. AJNR Am J Neuroradiol 1998 ; 19 : 1277-1284.
 
6) Hashimoto M, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme : A prospective cohort study. Cerebrospinal Fluid Res 2010 ; 7 : 18.
PubMed
7) Awata S, et al. Prevalence and subtype distribution of early-onset dementia in Japan. Psychogeriatrics 2020 ; 20 : 817-823.
PubMed
8) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
9) Folstein MF, et al. "Mini-mental state" : A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 ; 12 : 189-198.
 
10) 杉下守弘. 精神状態短時間検査-日本版 (MMSE-J). 日本文化科学社 ; 2012.
 
11) 長谷川和夫ほか. 老人の認知症診査スケールの一検討. 精神医学 1974 ; 16 : 965-969.
 
12) 加藤伸司ほか. 改訂長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精医誌 1991 ; 2 : 647-655.
 
13) 杉下守弘. 日本版ウエクスラー記憶検査法 WMS-R. 日本文化科学社 ; 2001.
 
14) 綿森淑子ほか. 日本版RBMTリバーミード行動記憶検査. 千葉テストセンター ; 2002.
 
15) 数井裕光ほか. 日本版リバーミード行動記憶検査 (RBMT) の有用性の検討. 神経進歩 2002 ; 46 : 307-318.
 
16) Lezak MD, et al. Complex Figure Test : Recall Administration. In : Lezak MD et al (eds). Neuropsychological Assessment, 5th edition. Oxford University Press ; 2012, pp499-505.
 
17) 是木明宏. ROCFT. 青木省三ほか (編), 精神・心理機能評価ハンドブック. 中山書店 ; 2015, pp64-65.
 
18) 日本高次脳機能障害学会 (旧日本失語症学会) (編), 日本高次脳機能障害学会 (旧日本失語症学会) Brain Function Test委員会. 標準失語症検査マニュアル, 改訂第2版. 新興医学出版社 ; 2003.
 
19) WAB失語症検査 (日本語版) 作成委員会. WAB失語症検査 日本語版. 医学書院 ; 1986.
 
20) 日本高次脳機能障害学会 (旧日本失語症学会) (編), 日本高次脳機能障害学会 (旧日本失語症学会) Brain Function Test委員会. 標準高次視知覚検査, 改訂第1版. 新興医学出版社 ; 2003.
 
21) Dubois B, et al. The FAB : A frontal assessment battery at bedside. Neurology 2000 ; 55 : 1621-1626.
PubMed
22) 小野剛. 簡単な前頭葉機能テスト. 脳科学 2001 ; 23 : 478-493.
 
23) Lezak MD, et al. Trail Making Test (TMT). In : Lezak MD et al (eds). Neuropsychological Assessment, 5th edition. Oxford University Press ; 2012, pp422-425.
 
24) 森山泰. TMT. 青木省三ほか (編), 精神・心理機能評価ハンドブック. 中山書店 ; 2015, pp136-137.
 
25) 日本版 WAIS-IV刊行委員会. 日本版 WAIS-IV理論・解釈マニュアル. 日本文化科学社 ; 2018.
 
26) Cummings JL. The Neuropsychiatric Inventory : Assessing psychopathology in dementia patients. Neurology 1997 ; 48 (5 suppl 6) : S10-16.
 
27) 博野信次ほか. 日本語版 Neuropsychiatric Inventory-痴呆の精神症状評価法の有用性の検討. 脳と神経 1997 ; 49 : 266-271.
 
28) Shigenobu K, et al. The Stereotypy Rating Inventory for frontotemporal lobar degeneration. Psychiatry Res 2002 ; 110 : 175-187.
PubMed
29) 繁信和恵. 常同行動評価尺度 (SRI). 青木省三ほか (編), 精神・心理機能評価ハンドブック. 中山書店 ; 2015, pp458-461.
 
30) Lawton MP, Brody EM. Assessment of older people : Self-maintaining and instrumental activities of daily living. Gerontologist 1969 ; 9 : 179-186.
PubMed
31) 小森憲治郎ほか. ADL尺度. 青木省三ほか (編), 精神・心理機能評価ハンドブック. 中山書店 ; 2015, pp450-453.
 
32) Hughes CP, et al. A new clinical score for staging of dementia. Br J Psychiatry 1982 ; 140 : 566.
 
33) 目黒謙一. 認知症早期発見のためのCDR判定ハンドブック. 医学書院 ; 2008.
 
青木省三ほか (編). 精神・心理機能評価ハンドブック. 中山書店 ; 2015.
 
「特発性正常圧水頭症の診療ガイドライン作成に関する研究」班/日本正常圧水頭症学会 (監修). 特発性正常圧水頭症診療ガイドライン 第3版. メディカルレビュー社 ; 2020.
 
Lezak MD, et al (eds). Neuropsychological Assessment, 5th edition. Oxford University Press ; 2012.
 
P.101 掲載の参考文献
1) McKhann G, et al. Clinical diagnosis of Alzheimer's disease : Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 ; 34 (7) : 939-944.
PubMed
2) Petersen RC, et al. Mild cognitive impairment : Clinical characterization and outcome. Arch Neurol 1999 ; 56 (3) : 303-308.
PubMed
3) Dubois B, et al. Revising the definition of Alzheimer's disease : A new lexicon. Lancet Neurol 2010 ; 9 : 1118-1127.
PubMed
4) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
5) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修). 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
6) McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 263-269.
PubMed
7) Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 270-279.
PubMed
8) Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 280-292.
PubMed
9) Price JL, et al. Neuropathology of nondemented aging : Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009 ; 30 (7) : 1026-1036.
PubMed
10) Mintun MA, et al. [11C] PIB in a nondemented population : Potential antecedent marker of Alzheimer disease. Neurology 2006 ; 67 (3) : 446-452.
 
11) Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012 ; 367 (9) : 795-804.
PubMed
12) Rowe CC, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010 ; 31 (8) : 1275-1283.
PubMed
13) Jack CR Jr, et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018 ; 14 (4) : 535-562.
 
14) Farias ST, et al. The measurement of everyday cognition (ECog) : Scale development and psychometric properties. Neuropsychology 2008 ; 22 (4) : 531-544.
PubMed
15) 日本核医学会ほか (編). アミロイド PET イメージング剤の適正使用ガイドライン. 第2版. http://jsnm.org/wp_jsnm/wp-content/themes/theme_jsnm/doc/amyloid_pet_imaging_gl_2.pdf (2022年2月26日閲覧)
 
16) 日本認知症学会ほか (監修). 認知症に関する脳脊髄液・血液バイオマーカーの適正使用指針 (第1版). https://www.neurology-jp.org/guidelinem/pdf/dementia_biomarker.pdf (2022年2月26日閲覧)
 
Jack CR Jr, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 257-262.
 
Morris JC. The Clinical Dementia Rating (CDR) : Current version and scoring rules. Neurology 1993 ; 43 : 2412-2414.
PubMed
Xia C, et al. Association of In Vivo [18F] AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol 2017 ; 74 (4) : 427-436.
PubMed
Sperling RA, et al. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol 2020 ; 77 (6) : 735-745.
PubMed
P.111 掲載の参考文献
1) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
2) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
3) Chui HC, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992 ; 42 (3) : 473-480.
 
4) Roman GC, et al. Vascular dementia : Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 ; 43 (2) : 250-260.
 
5) Erkinjuntti T, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000 ; 59 : 23-30.
PubMed
6) Hachinski V, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006 ; 37 (9) : 2220-2241.
PubMed
7) Gorelick PB, et al. Vascular contributions to cognitive impairment and dementia : A statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011 ; 42 (9) : 2672-2713.
PubMed
8) Sachdev P, et al. Diagnostic criteria for vascular cognitive disorders : A VASCOG statement. Alzheimer Dis Assoc Disord 2014 ; 28 (3) : 206-218.
PubMed
9) Skrobot OA, et al. Progress toward standardized diagnosis of vascular cognitive impairment : Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement 2018 ; 14 (3) : 280-292.
PubMed
10) Ghafar M, et al. Cognitive screening instruments to identify vascular cognitive impairment : A systematic review. Int J Geriatr Psychiatry 2019 ; 34 (8) : 1114-1127.
PubMed
11) Frantellizzi V, et al. Neuroimaging in Vascular Cognitive Impairment and Dementia : A Systematic Review. J Alzheimers Dis 2020 ; 73 (4) : 1279-1294.
PubMed
12) Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013 ; 12 (8) : 822-838.
PubMed
13) Palesi F, et al. Specific Patterns of White Matter Alterations Help Distinguishing Alzheimer's and Vascular Dementia. Front Neurosci 2018 ; 12 : 274.
PubMed
14) Kim HJ, et al. Distinctive Resting State Network Disruptions Among Alzheimer's Disease, Subcortical Vascular Dementia, and Mixed Dementia Patients. J Alzheimers Dis 2016 ; 50 (3) : 709-718.
PubMed
15) Park SY, et al. Analysis of Cerebral Blood Flow with Single Photon Emission Computed Tomography in Mild Subcortical Ischemic Vascular Dementia. Nucl Med Mol Imaging 2014 ; 48 (4) : 272-277.
PubMed
16) Kim GH, et al. Seoul criteria for PiB (-) subcortical vascular dementia based on clinical and MRI variables. Neurology 2014 ; 82 (17) : 1529-1535.
PubMed
17) Hosoki S, et al. Diagnostic and prognostic blood biomarkers in vascular dementia : From the viewpoint of ischemic stroke. Neurochem Int 2021 ; 146 : 105015.
PubMed
18) Ohrfelt A, et al. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement Geriatr Cogn Disord Extra 2011 ; 1 (1) : 31-42.
 
19) Candelario-Jalil E, et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke 2011 ; 42 (5) : 1345-1350.
PubMed
20) Giau VV, et al. Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome. Int J Mol Sci 2019 ; 20 (17) : 4298.
PubMed
21) Hachinski VC, Bowler JV. Vascular dementia. Neurology 1993 ; 43 (10) : 2159-2160.
PubMed
22) Roman GC, et al. Vascular cognitive disorder : A new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004 ; 226 (1-2) : 81-87.
 
23) Pohjasvaara T, et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDSAIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke 2000 ; 31 (12) : 2952-2957.
 
24) Gold G, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 2002 ; 59 (1) : 82-87.
 
25) Sachdev PS, et al. The Vascular Behavioral and Cognitive Disorders criteria for vascular cognitive disorders : A validation study. Eur J Neurol 2019 ; 26 (9) : 1161-1167.
PubMed
26) Smith EE, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD) 5 : Guidelines for management of vascular cognitive impairment. Alzheimers Dement (N Y) 2020 ; 6 (1) : e12056.
PubMed
Kalaria RN. The pathology and pathophysiology of vascular dementia. Neuropharmacology 2018 ; 134 (Pt B) : 226-239.
 
Pantoni L. Cerebral small vessel disease : From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010 ; 9 (7) : 689-701.
PubMed
Carnevale L, Lembo G. Innovative MRI Techniques in Neuroimaging Approaches for Cerebrovascular Diseases and Vascular Cognitive Impairment. Int J Mol Sci 2019 ; 20 (11) : 2656.
PubMed
P.120 掲載の参考文献
1) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Publishing ; 2013.
 
2) McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies : Third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-1872.
PubMed
3) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
4) McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB consortium. Neurology 2017 ; 89 : 88-100.
PubMed
5) Boeve BF, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013 ; 14 : 754-762.
PubMed
6) Ferman TJ, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011 ; 77 : 875-882.
PubMed
7) McKeith IG, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020 ; 94 : 1-13.
PubMed
8) Nelson PT, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurology 2010 ; 257 : 359-366.
 
9) Ferman TJ, et al. Pathology and temporal onset of visual hallucinations, misperceptions and family mis-identification distinguishes dementia with Lewy bodies from Alzheimer's disease. Parkinsonism Relat Disord 2013 ; 19 : 227-231.
 
10) 藤城弘樹. 2017年レヴィ小体型認知症臨床診断基準-レム期睡眠行動異常症と指標的バイオマーカー. BRAIN and NERVE 2018 ; 70 : 869-887.
 
11) Louis ED, et al. Association between mild parkinsonian signs and mild cognitive impairment in a community. Neurology 2005 ; 64 : 1157-1161.
 
12) Fujishiro H, et al. Prodromal dementia with Lewy bodies. Geriatr Gerontol Int 2015 ; 15 : 817-826.
PubMed
13) Fujishiro H, et al. Dementia with Lewy bodies : Early diagnostic challenges. Psychogeriatrics 2013 ; 13 : 128-138.
PubMed
14) Jack CR Jr, et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018 ; 14 : 535-562.
 
15) Berg D, et al. MDS Research criteria for prodromall Parkinson's disease. Mov Disord 2015 ; 30 : 1600-1611.
PubMed
16) Oudiette D, et al. Nonviolent elaborate behaviors may also occur in REM sleep behavior disorder. Neurology 2009 ; 72 : 551-557.
PubMed
17) 米国睡眠医学会 (著), 日本睡眠学会診断分類委員会 (訳). 睡眠障害国際分類 第3版. ライフ・サイエンス ; 2018.
 
18) Hogl B, et al. Idiopathic REM sleep behavior disorder and neurodegeneration-An update. Nat Rev Neurol 2018 ; 14 : 40-55.
PubMed
19) Haba-Rubio J, et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep 2018 ; 41 : zsx197.
PubMed
20) Bjornara KA, et al. REM sleep behavior disorder in Parkinson's disease - Is there a gender difference? Parkinsonism Relat Disord 2013 ; 19 : 120-122.
 
21) Bugallo P, Salavisa M. Factors Influencing the Presentation of REM Sleep Behavior Disorder : The Relative Importance of Sex, Associated Neurological Disorder, and Context of Referral to Polysomnography. J Clin Sleep Med 2019 ; 15 : 1789-1798.
 
22) Fujishiro H, et al. Early diagnosis of prodromal dementia with Lewy bodies using clinical history of probable REM sleep behavior disorder and cardiac 123I-MIBG scintigraphy in memory clinics. Psychogeriatrics 2021 ; 21 : 288-295.
 
23) Fernandez-Arcos A, et al. The Clinical Phenotype of Idiopathic Rapid Eye Movement Sleep Behavior Disorder at Presentation : A Study in 203 Consecutive Patients. Sleep 2016 ; 39 : 121-132.
PubMed
24) Frauscher B, et al. REM sleep behavior disorder in 703 sleep-disorder patients : The importance of eliciting a comprehensive sleep history. Sleep Med 2010 ; 11 : 167-171.
 
25) Miyamoto T, Miyamoto M. Phenoconversion from Idiopathic Rapid Eye Movement Sleep Behavior Disorder to Lewy Body Disease. Mov Disord Clin Pract 2018 ; 5 : 506-511.
PubMed
26) Chiba Y, et al. Retrospective survey of prodromal symptoms in dementia with Lewy bodies : Comparison with Alzheimer's disease. Dement Geriatr Cogn Disord 2012 ; 33 : 273-281.
PubMed
27) Shinagawa S, et al. Characteristics of eating and swallowing problems in patients who have dementia with Lewy bodies. Int Psychogeriatr 2009 ; 21 : 520-525.
PubMed
28) Naismith H, et al. Suicidal ideation in dementia : Associations with neuropsychiatric symptoms and subtype diagnosis. Int Psychogeriatr ; 2022 Mar 25 ; 1-8 (Online ahead of print.).
 
29) Van Assche L, et al. The Neuropsychological Profile and Phenomenology of Late Onset Psychosis : A Cross-sectional Study on the Differential Diagnosis of Very-Late-Onset Schizophrenia-Like Psychosis, Dementia with Lewy Bodies and Alzheimer's Type Dementia with Psychosis. Arch Clin Neuropsychol 2019 ; 34 (2) : 183-199.
PubMed
30) Frauscher B, et al. Comorbidity and medication in REM sleep behavior disorder : A multicenter casecontrol study. Neurology 2014 ; 82 : 1076-1079.
PubMed
31) Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978 ; 3 : 129-133.
PubMed
32) Fumimura Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol 2007 ; 66 : 354-362.
PubMed
33) Wang J, et al. Prevalence and correlates of REM sleep behavior disorder in patients with major depressive disorder : A two-phase study. J Neurol Neurosurg Psychiatry 2022 ; 93 : 1010-1017.
PubMed
34) Kazmi H, et al. Late onset depression : Dopaminergic deficit and clinical features of prodromal Parkinson's disease : A cross-sectional study. J Neurol Neurosurg Psychiatry 2021 ; 92 : 158-164.
PubMed
小阪憲司ほか. "Lewy小体病" の臨床神経病理学的研究. 精神経誌 1980 ; 82 : 292-311.
 
Fujishiro H, Kosaka K. When does cerebral β-amyloid deposition begin in Lewy body dementia? Neurol Clin Neurosci 2020 ; 8 : 362-371.
 
竹田和弘ほか. レビー小体病の臨床病理学的概念とレビー小体型認知症診断基準の変遷. 老年精神医学雑誌 2021 ; 32 : 1058-1067.
Medical*Online
Gore RL, et al. Delirium and dementia with Lewy bodies : Distinct diagnoses or part of the same spectrum? J Neurol Neurosurg Psychiatry 2015 ; 86 : 50-59.
PubMed
P.132 掲載の参考文献
1) The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994 ; 54 : 416-418.
 
2) Neary D, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998 ; 51 : 1546-1554.
PubMed
3) McKhann GM, et al. Clinical and pathological diagnosis of frontotemporal dementia. Arch Neurol 2001 ; 58 : 1803-1809.
PubMed
4) Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain 2011 ; 134 : 2456-2477.
PubMed
5) Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 ; 76 : 1006-1014.
PubMed
6) Karageorgiou E, et al. Frontotemporal lobar degeneration : A clinical approach. Semin Neurol 2014 ; 34 : 189-201.
PubMed
7) Bergeron D, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Ann Neurol 2018 ; 84 : 729-740.
 
8) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
9) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014, p606-609.
 
10) Hoglinger GU, et al. Clinical Diagnosis of Progressive Supranuclear Palsy : The Movement Disorder Society Criteria. Mov Disord 2017 ; 32 (6) : 853-864.
PubMed
11) Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
12) Strong MJ, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009 ; 10 (3) : 131-146.
PubMed
13) 厚生労働省. 指定難病127 前頭側頭葉変性症. http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000085357.pdf
 
14) 祖父江元ほか (監修). 前頭側頭葉変性症の療養の手引き. https://plaza.umin.ac.jp/neuro2/ftld.pdf
 
15) 池田学ほか. 進行性失語の概念と診断. 高次脳機能研究 2013 ; 33 (3) : 304-309.
 
16) Chan E, et al. The clinical profile of right temporal lobe atrophy. Brain 2009 ; 132 : 1287-1298.
 
17) Ducharme S, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 2020 ; 143 : 1632-1650.
PubMed
18) Perry DC, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain 2017 ; 140 : 3329-3345.
PubMed
19) Kobayashi R, et al. Dopamine transporter imaging for frontotemporal lobar degeneration with motor neuron disease. Front Neurosci 2022 ; 16 : 755211. doi : 10.3389/fnins.2022.755211.
 
20) 川勝忍ほか. 前頭側頭葉変性症の臨床. 日本臨牀 2018 ; 76 (増刊号 1) : 137-142.
 
21) Ossenkoppele R, et al. Prevalence of Amyloid PET Positivity in Dementia Syndromes : A Meta-analysis. JAMA 2015 ; 313 (19) : 1939-1949.
 
22) Seo SW, et al. Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology 2018 ; 90 : e1047-1056.
PubMed
Boeve BF, et al. Advances and controversies in frontotemporal dementia : Diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol 2022 ; 21 : 258-272.
PubMed
川勝忍ほか. 前頭側頭葉変性症概念の歴史的変遷. BRAIN and NERVE 2020 ; 72 (6) : 361-573.
 
P.141 掲載の参考文献
1) Shaw LM, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement 2018 ; 14 (11) : 1505-1521.
PubMed
2) Lim X, et al. The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies-A systematic review and meta-analysis. Parkinsonism Relat Disord 2013 ; 19 (10) : 851-858.
 
3) McKhann G, et al. Clinical diagnosis of Alzheimer's disease : Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 ; 34 : 939-944.
PubMed
4) Beach TG, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012 ; 71 (4) : 266-273.
PubMed
5) Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. Bapineuzumab 301 and 302 Clinical Trial Investigators. N Engl J Med 2014 ; 370 (4) : 322-333.
 
6) McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 26326-26329.
 
7) Jack CR Jr, et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018 : 14 (4) : 535-562.
 
8) Dubois B, et al. Clinical diagnosis of Alzheimer's disease : Recommendations of the International Working Group. Lancet Neurol 2021 ; 20 (6) : 484-496.
 
9) Jack CR Jr, et al. Suspected non-Alzheimer disease pathophysiology--concept and controversy. Nat Rev Neurol 2016 ; 12 (2) : 117-124.
PubMed
10) Wisse LEM, et al. Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology. Alzheimers Res Ther 2021 ; 13 (1) : 100.
PubMed
11) Crary JF, et al. Primary age-related tauopathy (PART) : A common pathology associated with human aging. Acta Neuropathol 2014 ; 128 (6) : 755-766.
 
12) Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE) : Consensus working group report. Brain 2019 ; 142 (6) : 1503-1527.
 
13) Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 2802-2892.
 
14) Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012 ; 367 (9) : 795-804.
PubMed
15) Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006 ; 59 (3) : 512-519.
PubMed
16) Cummings J, et al. Aducanumab : Appropriate use recommendations. J Prev Alzheimers Dis 2021 ; 8 (4) : 398-410.
PubMed
17) Nakamura A, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 2018 ; 554 (7691) : 249-254.
 
18) Kirmess KM, et al. The PrecivityAD(TM) test : Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta 2021 ; 519 : 267-275.
 
19) Palmqvist S, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurology 2019 ; 76 : 1060-1069.
 
20) Janelidze S, et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurol 2021 ; 78 (11) : 1375-1382.
 
21) Pannee J, et al. The global Alzheimer's Association round robin study on plasma amyloid β methods. Alzheimers Dement (Amst) 2021 ; 13 (1) : e12242.
 
22) Tatebe H, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology : Pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener 2017 ; 12 (1) : 63.
 
23) Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease : A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020 ; 19 (5) : 422-433.
 
24) Sato C, et al. Tau kinetics in neurons and the human central nervous system. Neuron 2018 ; 98 (4) : 861-864.
PubMed
25) Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020 ; 324 (8) : 772-781.
PubMed
26) Mattsson-Carlgren N, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain 2020 ; 143 (11) : 3234-3241.
PubMed
27) Palmqvist S, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 2021 ; 27 (6) : 1034-1042.
PubMed
日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院 ; 2017.
 
厚生労働省科学研究費 研究班作成「認知症に関する脳脊髄液・血液バイオマーカーの適正使用指針」. https://www.neurology-jp.org/guidelinem/pdf/dementia_biomarker.pdf
 
Hampel H, et al. State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimers Dement 2022 ; 18 (1) : 159-177.
PubMed
Delay C, et al. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease : An international overview. Alzheimers Dement 2022 ; 18 (10) : 1868-1879.
 
Hansson O, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement ; 2022. 7. 31 (online ahead of print).
 
P.150 掲載の参考文献
1) Matsuda H, et al. Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease. AJNR Am J Neuroradiol 2012 ; 33 (6) : 1109-1114.
PubMed
2) Matsuda H. Voxel-based Morphometry of Brain MRI in Normal Aging and Alzheimer's Disease. Aging Dis 2013 ; 4 (1) : 29-37.
PubMed
3) Fujishima M, et al. Mild cognitive impairment, poor episodic memory, and late-life depression are associated with cerebral cortical thinning and increased white matter hyperintensities. Front Aging Neurosci 2014 ; 6 : 306.
PubMed
4) Fujishima M, et al. Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. J Alzheimers Dis 2017 ; 56 (1) : 75-88.
PubMed
5) Franke K, Gaser C. Ten Years of BrainAGE as a neuroimaging biomarker of brain aging : What insights have we gained? Front Neurol 2019 ; 10 : 789.
PubMed
6) Beheshti I, et al. The association between "Brain-Age Score" (BAS) and traditional neuropsychological screening tools in Alzheimer's disease. Brain Behav 2018 ; 8 (8) : e01020.
PubMed
7) Beheshti I, et al. T1-weighted MRI-driven Brain Age Estimation in Alzheimer's Disease and Parkinson's Disease. Aging Dis 2020 ; 11 (3) : 618-628.
PubMed
8) Sone D, et al. Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer's disease : A combined positron emission tomography/magnetic resonance imaging study. Alzheimers Dement (Amst) 2017 ; 9 : 35-40.
PubMed
9) Yushkevich PA, et al. Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Hum Brain Mapp 2015 ; 36 (1) : 258-287.
PubMed
10) Hata K, et al. Automated Volumetry of Medial Temporal Lobe Subregions in Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Dis Assoc Disord 2019 ; 33 (3) : 206-211.
PubMed
11) Ogawa M, et al. Association between subfield volumes of the medial temporal lobe and cognitive assessments. Heliyon 2019 ; 5 (6) : e01828.
PubMed
12) Hosseini SM, et al. GAT : A graph-theoretical analysis toolbox for analyzing between-group differences in large-scale structural and functional brain networks. PLoS One 2012 ; 7 (7) : e40709.
 
13) Matsuda H. MRI morphometry in Alzheimer's disease. Ageing Res Rev 2016 ; 30 : 17-24.
PubMed
14) Tijms BM, et al. Similarity-based extraction of individual networks from gray matter MRI scans. Cereb Cortex 2012 ; 22 (7) : 1530-1541.
PubMed
15) Tijms BM, et al. Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiol Aging 2016 ; 37 : 154-160.
PubMed
16) Shigemoto Y, et al. Voxel-based correlation of 18F-THK5351 accumulation with gray matter structural networks in cognitively normal older adults. eNeurologicalSci 2021 ; 23 : 100343.
 
17) Tijms BM, et al. Single-subject grey matter graphs in Alzheimer's disease. PLoS One 2013 ; 8 (3) : e58921.
PubMed
18) Dicks E, et al. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiol Aging 2020 ; 94 : 71-80.
PubMed
19) Shigemoto Y, et al. Gray matter structural networks related to 18F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients. eNeurologicalSci 2021 ; 22 : 100309.
 
20) Raichle ME. The brain's dark energy. Sci Am 2010 ; 302 (3) : 44-49.
 
Sporns O. Graph theory methods : Applications in brain networks. Dialogues Clin Neurosci 2018 ; 20 (2) : 111-121.
PubMed
Wang J, et al. Gray Matter Age Prediction as a Biomarker for Risk of Dementia. Proc Natl Acad Sci U S A 2019 ; 116 (42) : 21213-21218.
PubMed
Damoiseaux JS. Effects of aging on functional and structural brain connectivity. Neuroimage 2017 ; 160 : 32-40.
PubMed
P.158 掲載の参考文献
1) Higuchi M, et al. In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis : Insights from neuroimaging research in humans and rodent models. Biochim Biophys Acta 2010 ; 1802 : 373-388.
PubMed
2) Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004 ; 55 : 306-319.
PubMed
3) Villemagne VL, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease : A prospective cohort study. Lancet Neurol 2013 ; 12 : 357-367.
 
4) Weiner MW, et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative : A review of papers published since its inception. Alzheimers Dement. Alzheimers Dement 2015 ; 11 : e1-120.
 
5) Giacobini E, Gold G. Alzheimer disease therapy--Moving from amyloid-β to tau. Nat Rev Neurol 2013 ; 9 : 677-686.
 
6) Higuchi M, et al. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002 ; 2 : 131-150.
PubMed
7) Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016 ; 79 : 110-119.
PubMed
8) Harada R, et al. 18F-THK5351 : A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med 2016 ; 57 : 208-214.
PubMed
9) Maruyama M, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013 ; 79 : 1094-1108.
 
10) Tagai K, et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. Neuron 2021 ; 109 : 42-58.
PubMed
11) Matsuoka K, et al. High-contrast imaging of α-synuclein pathologies in living patients with multiple system atrophy. Mov Disord, in press.
 
12) Capotosti F, et al. The development of [18F] ACI-12589, a high affinity and selective alpha-synuclein radiotracer, as a biomarker for Parkinson's disease and other synucleinopathies. Alzheimers Dement 2021 ; 17 (Suppl. 5) : e053943.
 
13) Arseni D, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 2022 ; 601 : 139-143.
PubMed
14) Mecca AP, et al. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimers Dement 2020 ; 16 : 974-982.
PubMed
15) Jack CR Jr, et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018 ; 14 : 535-562.
 
16) Spina S, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain 2021 ; 144 : 2186-2198.
PubMed
Hameed S, et al. Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. J Alzheimer Dis Rep 2020 ; 4 (1) : 21-37.
PubMed
Cummings J, et al. The Role of Biomarkers in Alzheimer's Disease Drug Development. Adv Exp Med Biol 2019 ; 1118 : 29-61.
PubMed
P.163 掲載の参考文献
1) McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
2) McKeith I, et al. Sensitivity and specificity of dopamine transporter imaging with 123IFP-CIT SPECT in dementia with Lewy bodies : A phase III, multicentre study. Lancet Neurol 2007 ; 6 : 305-313.
 
3) Colloby SJ, et al. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012 ; 135 : 2798-2808.
PubMed
4) Lloyd JJ, et al. A new visual rating scale for Ioflupane imaging in Lewy body disease. Neuroimage Clinical 2018 ; 20 : 823-829.
PubMed
5) Kasanuki K, et al. 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 2017 ; 44 : 358-365.
PubMed
6) Orimo S, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005 ; 109 : 583-588.
PubMed
7) Yoshita M, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies : A multicenter study. PLoS One 2015 ; 10 : e0120540.
PubMed
8) Matsubara T, et al. Autopsy validation of the diagnostic accuracy of 123I-metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease. Neurology 2022 ; 98 : e1648-e1659.
 
9) Ferman TJ, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011 ; 77 : 875-882.
PubMed
10) Harper L, et al. MRI visual rating scales in the diagnosis of dementia : Evaluation in 184 post-mortem confirmed cases. Brain 2016 ; 139 : 1211-1225.
PubMed
11) Higuchi M, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000 ; 162 : 247-256.
PubMed
12) Minoshima S, et al. Alzheimer's disease versus dementia with Lewy bodies : Cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001 ; 50 : 358-365.
PubMed
13) Kasanuki K, et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci 2012 ; 314 : 111-119.
PubMed
14) Graff-Radford J, et al. Dementia with Lewy bodies basis of cingulate island sign. Neurology 2014 ; 83 : 801-809.
PubMed
15) Franciotti R, et al. Anterior EEG slowing in dementia with Lewy bodies : A multicenter European cohort study. Neurobiol Aging 2020 ; 93 : 55-60.
PubMed
16) Rossi M, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 2020 ; 140 : 49-62.
PubMed
17) Ossenkoppele R, et al. Prevalence of amyloid PET positivity in dementia syndromes : A meta-analysis. JAMA 2015 ; 313 : 1939-1949.
PubMed
18) Ikonomovic MD, et al. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun 2016 ; 4 : 130.
 
19) Kantarci K, et al. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 2017 ; 81 : 58-67.
 
20) van Steenoven I, et al. Cerebrospinal fluid Alzheimer's disease biomarkers across the spectrum of Lewy body diseases ; results from a large multicenter cohort. J Alzheimers Dis 2016 ; 54 : 287-295.
PubMed
21) Gonzalez MC, et al. Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia Lewy bodies. JAMA Neurol 2022 ; 79 : 32-37.
PubMed
22) Bridel C, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology ; a systematic review and meta-analysis. JAMA Neurol 2019 ; 76 : 1035-1048.
 
P.167 掲載の参考文献
1) van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med 2023 ; 388 (1) : 9-21.
PubMed
2) Heppner FL, et al. Immune attack : The role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015 ; 16 (6) : 358-372.
 
3) McGeer PL, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibilty glycoprotein HLA-DR. Neuroci Lett 1987 ; 79 : 195-200.
 
4) Lue L-F, et al. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol 2010 ; 41 : 115-128.
PubMed
5) Bianchin MM, et al. Nasu-Hakola disease and primary microglial dysfunction. Nat Rev Neurol 2010 ; 6 (9) : 2 p following 523.
PubMed
6) Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013 ; 368 (2) : 107-116.
PubMed
7) Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015 ; 160 (6) : 1061-1071.
 
8) Suarez-Calvet M, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 2016 ; 8 (5) : 466-476.
PubMed
9) Orihuela R, et al. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol 2016 ; 173 (4) : 649-665.
PubMed
10) Heneka MT, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013 ; 493 (7434) : 674-678.
PubMed
11) Santos LE, et al. Microglial dysfunction connects depression and Alzheimer's disease. Brain Behav Immun 2016 ; 55 : 151-165.
PubMed
12) 門司晃. うつ病と炎症. 日本臨牀 2017 ; 75 : 1497-1501.
Medical*Online
13) Tai LM, et al. APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease : Current landscape, novel data, and future perspective. J Neurochem 2015 ; 133 (4) : 465-488.
 
14) Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016 ; 352 (6286) : 712-716.
PubMed
15) Marsh SE, et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A 2016 ; 113 (9) : E1316-E1325.
PubMed
16) Fan Z, et al. An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain 2017 ; 140 (3) : 792-803.
PubMed
17) Wang Q, et al. Microglia Polarization in Alzheimer's Disease : Mechanisms and a Potential Therapeutic Target. Front Aging Neurosci 2021 ; 13 : 772717.
 
18) Surendranathan A, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain 2018 ; 141 (12) : 3415-3427.
PubMed
19) Bevan-Jones WR, et al. Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain 2020 ; 143 (3) : 1010-1026.
PubMed
20) Stokholm MG, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder : A case-control study. Lancet Neurol 2017 ; 16 (10) : 789-796.
PubMed
21) Stokholm MG, et al. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiol Dis 2018 ; 115 : 9-16.
PubMed
22) Konishi H, Kiyama H. Microglial TREM2/DAP12 Signaling : A Double-Edged Sword in Neural Diseases. Front Cell Neurosci 2018 ; 12 : 206.
PubMed
23) Morenas-Rodriguez E, et al. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Sci Rep 2019 ; 9 (1) : 7803.
PubMed
P.173 掲載の参考文献
1) Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 2016 ; 131 : 267-280.
PubMed
2) Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 2017 ; 547 : 185-190.
PubMed
3) Zhang W, et al. Novel tau filament fold in corticobasal degeneration. Nature 2020 ; 580 : 283-287.
PubMed
4) Shi Y, et al. Structure-based classification of tauopathies. Nature 2021 ; 598 : 359-363.
PubMed
5) Tarutani A, et al. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification. Brain 2021 ; 144 : 2333-2348.
PubMed
6) Hosokawa M, et al. Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms. Brain 2021 ; awab289.
 

3章 認知症の症候学

P.184 掲載の参考文献
1) McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 : 263-269.
PubMed
2) 今村徹. アルツハイマー病, MCI. 河村満 (編), <アクチュアル 脳・神経疾患の臨床> 認知症-神経心理学的アプローチ. 中山書店 ; 2012, pp199-210.
 
3) 伊原武志ほか. 物忘れ外来のための日常記憶課題の検討. 神経心理学 2011 ; 27 : 160-166.
 
4) 音山若穂ほか. Clinical Dementia Rating (CDR) 日本語版の評価者間信頼性の検討. 老年精神医学雑誌 2000 ; 11 : 521-527.
Medical*Online
5) 高橋雅延ほか (編). <現代の認知心理学> 2. 記憶と日常. 北大路書房 ; 2011, pp208-241.
 
6) 下條由衣ほか. 日常記憶課題と一般的近時記憶課題の成績に乖離が見られる認知症症例の検討. 神経心理学 2012 ; 28 : 66-72.
 
7) 今村徹. 神経心理検査バッテリー : 結果の解釈と落とし穴. 老年精神医学雑誌 2020 ; 31 : 561-569.
Medical*Online
8) 鈴木千裕ほか. MMSEの3単語再生課題への補助再生と再認再生の導入の試み-中等度の認知機能障害を呈するアルツハイマー病患者における床効果の検討. 神経心理学 2013 ; 29 : 71-77.
 
9) 今村徹. 記憶障害. 松田実 (編著), 初学者のための神経心理学入門. 新興医学出版社 ; 2022, pp141-169.
 
10) 工藤由理ほか. アルツハイマー病患者の注意障害 Mini-Mental State Examination (MMSE) のSerial 7'sに影響を与える要因の検討. 老年精神医学雑誌 2011 ; 22 : 1055-1061.
Medical*Online
11) 佐藤厚ほか. アルツハイマー病患者における書字障害 書き取り課題における誤反応タイプと注意障害との関係. 神経心理学 2012 ; 28 : 266-273.
 
12) Chen P, et al. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 2000 ; 55 : 1847-1853.
PubMed
13) Cerhan JH, et al. Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease. Clin Neuropsychol 2002 ; 16 : 35-42.
PubMed
14) Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 ; 76 : 1006-1014.
PubMed
15) Crutch SJ, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement 2017 ; 13 : 870-884.
PubMed
16) Imamura T, et al. Age at onset and language disturbances in Alzheimer's disease. Neuropsychologia 1998 ; 36 : 945-949.
PubMed
17) Fujimori M, et al. Age at onset and visuocognitive disturbances in Alzheimer disease. Alzheimer Dis Assoc Disord 1998 ; 12 : 163-166.
PubMed
18) Le Heron C, et al. The anatomy of apathy : A neurocognitive framework for amotivated behaviour. Neuropsychologia 2018 ; 118 : 54-67.
 
19) 本間千尋ほか. アルツハイマー病患者における興奮と易刺激性 Neuropsychiatric Inventory (NPI) を用いた検討. 精神医学 2017 ; 59 : 661-669.
 
20) Senanarong V, et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord 2004 ; 17 : 14-20.
PubMed
21) 松本直美ほか. 日本語版NPI-DとNPI-Qの妥当性と信頼性の検討. 脳と神経 2006 ; 58 : 785-790.
 
22) 森悦朗. 認知症の症候学総論. 老年精神医学雑誌 2010 ; 21 (増刊I) : 74-78.
 
23) 福原竜治, 池田学. 物盗られ妄想. 神経心理学 2013 ; 29 : 257-265.
 
24) 鈴木夏美ほか. 生活上の出来事全体を忘れるアルツハイマー病患者の検討. 神経心理学 2019 ; 35 : 36-43.
 
25) 鷹橋鈴香ほか. 認知症の全般重症度が軽度 (CDR 1) から中等度 (CDR 2) に低下したアルツハイマー病の検討. 老年精神医学雑誌 2018 ; 29 : 1191-1208.
Medical*Online
26) 船山道隆. アルツハイマー病の意味記憶障害. 神経心理学 2020 ; 36 : 178-188.
 
Mendez M, Cummings JL. Dementia : A Clinical Approach, 3rd edition. Butterworth-Heinemann ; 2003.
 
Lezak MD, et al. Neuropsychological Assessment, 5th edition. Oxford University Press ; 2012.
 
P.192 掲載の参考文献
1) Mori E. Functional brain imaging. In : Erkinjuntti T, et al (eds). Vascular Cognitive Impairment, Martin Dunitz Publisher ; 2002, pp417-432.
 
2) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013, pp621-624.
 
3) Benson DF, Cummings JL. Angular gyrus syndrome simulating Alzheimer's Disease. Arch Neurol 1982 ; 38 : 616-620.
 
4) 森悦朗. 神経心理学の基礎 ; 臨床と基礎 (1) 前大脳動脈領域と後大脳動脈領域. 神経心理学 1999 ; 15 : 150-154.
 
5) Mori E, Yamadori A. Acute confusional state and acute agitated delirium : Occurrence after infarction in the right middle cerebral artery territory. Arch Neurol 1987 ; 44 : 1139-1143.
PubMed
6) 森悦朗. Confusional stateの神経心理. 脳と精神の医学 1993 ; 4 : 425-430.
 
7) Tatemichi TK, et al. Confusion and memory loss from capsular genu infarction : A thalamocortical disconnection syndrome? Neurology 1992 ; 42 : 1966-1979.
PubMed
8) Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993 ; 50 : 873-880.
PubMed
9) 森悦朗. 皮質-皮質下回路の損傷と認知・行動障害. 運動障害 2001 ; 11 : 111-118.
Medical*Online
10) Nishio Y, et al. Striatal infarcts mimicking frontotemporal dementia : A case report. Eur J Neurol 2003 ; 10 : 457-460.
PubMed
11) Ghika J. Mood and behavior in disorders of the basal ganglia. In : Bogousslavsky J, et al (eds). Behavior and Mood Disorders in Focal Brain Lesions, Cambridge University Press ; 2000, pp122-201.
 
12) Mori E, et al. Role of functional brain imaging in the evaluation of vascular dementia. Alzheimer Dis Assoc Disord 1999 ; 13 (Suppl 3) : S91-101.
 
13) 森悦朗. 間脳病変と記憶障害. 神経研究の進歩 2001 ; 45 : 198-208.
 
14) Erkinjuntti T. Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm 2002 ; Suppl 63 : 91-109.
 
15) Tierney MC, et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch Neurol 2001 ; 58 : 1654-1659.
PubMed
16) Debette S, et al. Clinical significance of magnetic resonance imaging markers of vascular brain injury : A systematic review and meta-analysis. JAMA Neurol 2000 ; 76 : 81-94.
 
17) Ding J, et al. Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology 2017 ; 88 : 2089-2097.
PubMed
18) Cipriano L, et al. Systematic review on the role of lobar cerebral microbleeds in cognition. J Alzheimers Dis 2022 ; 86 : 1025-1035.
PubMed
19) Charidimou A, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain 2017 ; 140 : 1829-1850.
PubMed
20) Greenberg SM, Charidimou A. Diagnosis of Cerebral Amyloid Angiopathy : Evolution of the Boston Criteria. Stroke 2018 ; 49 : 491-497.
PubMed
21) Auriel E, et al. Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA Neurol 2016 ; 73 : 197-202.
PubMed
22) Wu JJ, et al. Cerebral amyloid angiopathy-related inflammation : Current status and future implications. Chin Med J (Engl) 2021 ; 134 : 646-654.
PubMed
23) Uehara T, et al. Risk factors for silent cerebral infarcts in subcortical white matter and basal ganglia. Stroke 1999 ; 30 : 378-382.
PubMed
24) Schmidt R, et al. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke 1996 ; 27 : 2043-2047.
PubMed
25) Fein G, et al. Hippoc-ampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000 ; 12 : 1626-1635.
 
26) Hirono N, et al. Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. Stroke 2000 ; 31 : 1263-1268.
PubMed
O'Brien JT, Thomas A. Vascular dementia. Lancet 2015 ; 386 : 1698-1706.
 
Weaver NA, et al. Strategic infarct locations for post-stroke cognitive impairment : A pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts. Lancet Neurol 2021 ; 20 : 448-459.
PubMed
P.203 掲載の参考文献
1) McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
2) Breitve MH, et al. A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. Alzheimers Res Ther 2014 ; 6 (5-8) : 53.
 
3) Mueller C, et al. Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis : A meta-analysis of longitudinal studies. Ageing Res Rev 2019 ; 50 : 72-80.
PubMed
4) Hashimoto M, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies : A volumetric MRI study. Neurology 1998 ; 51 : 357-362.
PubMed
5) Matsushita M, et al. Are saving appearance responses typical communication patterns in Alzheimer's disease? PLoS One 2018 ; 13 (5) : e0197468.
PubMed
6) Calderon J, et al. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001 ; 70 : 157-164.
PubMed
7) Noe E, et al. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Movement Disorders 2003 ; 19 : 60-67.
 
8) Perry EK, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994 ; 5 : 747-749.
PubMed
9) Mori E, et al. Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies : A randomized, placebo-controlled trial. Ann Neurol 2012 ; 72 : 41-52.
 
10) Johns EK, et al. Executive functions in frontotemporal dementia and Lewy body dementia. Neuropsychology 2009 ; 23 : 765-777.
PubMed
11) Breitve MH, et al. A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer's Disease. Front Neurol 2018 ; 9 : 124.
PubMed
12) Mori E, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 2000 ; 57 : 489-493.
PubMed
13) Kakinuma K, et al. Logopenic aphasia due to Lewy body disease dramatically improved with donepezil. eNeurological Sci 2020 ; 19 : 100241.
 
14) Watanabe H, et al. Primary Progressive Aphasia as a Prodromal State of Dementia with Lewy Bodies : A Case Report. Front Neurol 2020 ; 11 : 49.
PubMed
15) McKeith IG, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020 ; 94 : 743-755.
PubMed
16) Ferman TJ, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 2013 ; 81 : 2032-2038.
PubMed
17) Kazui H, et al. Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias. PLoS One 2016 ; 11 (8) : e0161092.
PubMed
18) Aarsland D, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001 ; 16 : 528-536.
PubMed
19) Mamiya Y, et al. The Pareidolia Test : A Simple Neuropsychological Test Measuring Visual Hallucination-Like Illusions. PLoS One 2016 ; 11 (5) : e0154713.
 
20) Tsunoda N, et al. Clinical features of auditory hallucinations in patients with DLB : A soundtrack of visual hallucinations. J Clin Psychiatry 2018 ; 9 (3) : 17m11623.
PubMed
21) Ballard C, et al. Psychiatric morbidity in dementia with Lewy bodies : A prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999 ; 156 : 1039-1045.
PubMed
22) Hashimoto M, et al. Clinical features of delusional jealousy in elderly patients with dementia. J Clin Psychiatry 2015 ; 76 : 691-695.
PubMed
23) 今井正城, 橋本衛. うつ病とレビ－小体型認知症. 老年精神医学雑誌 2018 ; 29 : 267-273.
Medical*Online
24) Samuels S, et al. Depression in autopsy-comfirmed dementia with Lewy bodies and Alzheimer's disease. Mt Sinai J Med 2004 ; 71 : 55-62.
 
25) Chiu PY, et al. Depression in dementia with Lewy bodies : A comparison with Alzheimer's disease. PLoS One 2017 ; 12 (6) : e0179399.
PubMed
26) Breitve MH, et al. Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimers Res Ther 2018 ; 10 (1) : 83.
PubMed
27) Seignourel PJ, et al. Anxiety in dementia : A critical review. Clin Psychol Rev 2008 ; 28 ; 1071-1082.
PubMed
28) Thaipisuttikul P, et al. Capgras syndrome in Dementia with Lewy Bodies. Int Psychogeriatr 2012 ; 5 : 1-7.
 
29) Mosimann UP, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry 2006 ; 14 : 153-160.
PubMed
30) Honda K, et al. The usefulness of monitoring sleep talking for the diagnosis of dementia with Lewy bodies. Int Psychogeriatr 2013 ; 25 : 851-858.
PubMed
31) FitzGerald JM, et al. The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis : Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. J Am Med Dir Assoc 2019 ; 20 : 604-609.
PubMed
32) Vardy E, et al. History of a Suspected Delirium Is More Common in Dementia with Lewy Bodies Than Alzheimer's Disease : A Retrospective Study. Int J Geriatr Psychiatry 2014 ; 29 : 178-181.
PubMed
33) Aarsland D, et al. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001 ; 13 : 374-379.
PubMed
34) Imamura T, et al. Fall-related injuries in dementia with Lewy bodies (DLB) and Alzheimer's disease. Eur J Neurol 2000 ; 7 : 77-79.
PubMed
35) Horimoto Y, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol 2003 ; 250 : 530-533.
PubMed
36) Allan LM, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007 ; 78 : 671-677.
PubMed
37) Sonnesyn H, et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord 2009 ; 28 : 307-313.
PubMed
38) Stubendorff K, et al. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One 2012 ; 7 (10) : e45451.
PubMed
39) Yoo HS, et al. Olfactory dysfunction in Alzheimer's disease- and Lewy body-related cognitive impairment. Alzheimers Dement 2018 ; 14 : 1243-1252.
PubMed
40) Ala TA, et al. The Mini-Mental State exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2002 ; 17 : 503-509.
PubMed
41) Hashimoto M, et al. Relationship between dementia severity and behavioral and psychological symptoms of dementia in dementia with Lewy bodies and Alzheimer's disease patients. Dementia Geriatr Cogn Disord EXTRA 2015 ; 5 : 244-252.
 
42) Watanabe H, et al. Negative mood invites psychotic false perception in dementia. PLoS One 2018 ; 13 (6) : e0197968.
PubMed
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
小阪憲司, 池田学. 神経心理学コレクション レビー小体型認知症の臨床. 医学書院 ; 2010.
 
P.212 掲載の参考文献
1) The Lund and Manchester Group. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994 ; 57 : 416-418.
PubMed
2) Neary D, et al. Frontotemporal lobar degeneration : A consensus on clinical diagnostic criteria. Neurology 1998 ; 51 : 1546-1554.
PubMed
3) Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 ; 134 : 2456-2477.
PubMed
4) Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 ; 76 : 1006-1014.
PubMed
5) Shinagawa S, et al. When a Little Knowledge Can Be Dangerous : False-Positive Diagnosis of Behavioral Variant Frontotemporal Dementia among Community Clinicians. Dement Geriatr Cogn Disord 2016 ; 41 : 99-108.
PubMed
6) Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry : An update. J Psychosom Res 2002 ; 53 : 647-654.
PubMed
7) Kim EJ, et al. Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. Cerebral Cortex 2012 ; 22 : 251-259.
PubMed
8) Shinagawa S, et al. Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer's disease. Dement Geriatr Cogn Disord 2006 ; 21 : 74-80.
PubMed
9) Piguet O, et al. Behavioural-variant frontotemporal dementia : Diagnosis, clinical staging, and management. Lancet Neurol 2011 ; 10 : 162-172.
PubMed
10) Zamboni G, et al. Anosognosia for behavioral disturbances in frontotemporal dementia and corticobasal syndrome : A voxel-based morphometry study. Dement Geriatr Cogn Disord 2010 ; 29 : 88-96.
PubMed
11) Munoz-Neira C, et al. Neural correlates of altered insight in frontotemporal dementia : A systematic review. Neuroimage Clin 2019 ; 24 : 102066.
PubMed
12) Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neuro 1993 ; 50 : 873-880.
PubMed
13) Rankin KP, et al. Structural anatomy of empathy in neurodegenerative disease. Brain 2006 ; 129 : 2945-2956.
PubMed
14) Sollberger M, et al. Neural basis of interpersonal traits in neurodegenerative diseases. Neuropsychologia 2008 ; 47 : 2812-2827.
 
15) Bora E, et al. Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease : A meta-analysis. J Neurol Neurosurg Psychiatry 2015 ; 86 : 714-719.
PubMed
16) Kringelbach ML, Rolls ET. The functional neuroanatomy of the human orbitofrontal cortex : Evidence from neuroimaging and neuropsychology. Prog Neurobiol 2004 ; 72 : 341-372.
PubMed
17) Shinagawa S, et al. Violation of Laws in Frontotemporal Dementia : A Multicenter Study in Japan. J Alzheimers 2017 ; 57 : 1221-1227.
PubMed
18) Shinagawa S, et al. Characteristics of abnormal eating behaviours in frontotemporal lobar degeneration : A cross-cultural survey. J Neurol Neurosurg Psychiatry 2009 ; 80 : 1413-1414.
PubMed
19) Ikeda M, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002 ; 73 (4) : 371-376.
PubMed
20) Piguet O. Eating disturbance in behavioural-variant frontotemporal dementia. J Mol Neurosci 2011 ; 45 : 589-593.
PubMed
21) Prioni S, et al. Stereotypic behaviors in degenerative dementias. J Neurol 2012 ; 259 : 2452-2459.
PubMed
22) Shigenobu K, et al. The Stereotypy Rating Inventory for frontotemporal lobar degeneration. Psychiatry Res 2002 ; 110 (2) : 175-187.
PubMed
23) Lhermitte F. Human autonomy and the frontal lobes. Part II : Patient behavior in complex and social situations : The "environmental dependency syndrome". Ann Neurol 1986 ; 19 : 335-343.
 
24) Ghosh A, et al. Environmental dependency behaviours in frontotemporal dementia : Have we been underrating them? J Neurol 2013 ; 260 : 861-868.
 
25) Shimomura T, Mori E. Obstinate imitation behaviour in differentiation of frontotemporal dementia from Alzheimer's disease. Lancet 1998 ; 352 (9128) : 623-624.
PubMed
26) Mesulam M. Primary progressive aphasia. Ann Neurol 2001 ; 49 : 425-432.
PubMed
27) Hodges JR, Patterson K. Semantic memory disorders. Trends Cogn Sci 1997 ; 1 : 68-72.
PubMed
28) Hodges JR, et al. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992 ; 115 : 1783-1806.
PubMed
29) Tanabe H. The uniqueness of Gogi aphasia owing to temporal lobar atrophy. Alzheimer Dis Assoc Disord 2007 ; 21 : S12-S13.
PubMed
30) Kashibayashi T, et al. Transition of Distinctive Symptoms of Semantic Dementia during Longitudinal Clinical Observation. Dement Geriatr Cogn Disord 2010 ; 29 : 224-232.
PubMed
31) Ulugut Erkoyun H, et al. A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain 2020 ; 143 : 2831-2843.
PubMed
32) Thompson SA, et al. Left/right asymmetry of atrophy in semantic dementia : Behavioral-cognitive implications. Neurology 2003 ; 61 : 1196-1203.
PubMed
33) Lambon Ralph MA, Patterson K. Generalization and differentiation in semantic memory : Insights from semantic dementia. Ann N Y Acad Sci 2008 ; 1124 : 61-76.
PubMed
34) Bozeat S, et al. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000 ; 69 : 178-186.
PubMed
35) Kertesz A, et al. What is semantic dementia? : A cohort study of diagnostic features and clinical boundaries. Arch Neurol 2010 ; 67 : 483-489.
PubMed
36) Sato S, et al. Characteristics of behavioral symptoms in right-sided predominant semantic dementia and their impact on caregiver burden : A cross-sectional study. Alzheimers Res Ther 2021 ; 13 : 166.
PubMed
37) Otsuki M. [Classification and Diagnosis of Primary Progressive Aphasia]. Brain Nerve 2020 ; 72 (6) : 611-621.
PubMed
池田学 (編著). 日常診療に必要な認知症症候学. 新興医学出版社 ; 2014.
 
日本高次脳機能障害学会 教育・研修委員会 (編). 進行性失語. 新興医学出版社 ; 2014.
 
P.219 掲載の参考文献
1) Topiwala A, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline : Longitudinal cohort study. BMJ 2017 ; 357 : j2353. doi : 10.1136/bmj.j2353.
 
2) Schwarzinger M, et al. Contribution of alcohol use disorders to the burden of dementia in France 2008-13 : A nationwide retrospective cohort study. Lancet Public Health 2018 ; 3 : e124-e132.
 
3) Cheng C, et al. Alcohol-Related Dementia : A Systemic Review of Epidemiological Studies. Psychosomatics 2017 ; 58 : 331-342.
PubMed
4) Draper B, et al. Alcohol-related cognitive impairment in New South Wales hospital patients aged 50 years and over. Aust N Z J Psychiatry 2011 ; 45 : 985-992. doi : 10.3109/00048674.2011.61029.
 
5) Kelly S, et al. Alcohol and older people : A systematic review of barriers, facilitators and context of drinking in older people and implications for intervention design. PLos One 2018 ; 13 : e0191189.
PubMed
6) Livingston G, et al. Dementia prevention, intervention, and care : 2020 report of the Lancet Commission. Lancet 2020 ; 396 : 413-446.
PubMed
7) Visontay R, et al. Alcohol use and dementia : new research directions. Curr Opin Psychiatry 2021 ; 34 : 165-170. doi : 10.1097/YCO.0000000000000679.
 
8) Harper CG, et al. Clinical signs in the Wernicke-Korsakoff complex : A retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry 1986 ; 49 : 341-345.
PubMed
9) Galvin R, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol 2010 ; 17 : 1408-1418. doi : 10.1111/j.1468-1331.2010.03153.x.
 
10) Sechi GP, Serra A. Wernicke's encephalopathy : New clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007 ; 6 : 442-455. doi : 10.1016/S1474-4422 (07) 70104-7.
 
11) Oslin D, et al. Alcohol related dementia : Proposed clinical criteria. Int J Geriatr Psychiatry 1998 ; 13 : 203-212.
PubMed
12) Sachdeva A. Alcohol-Related Dementia and Neurocognitive Impairment : A Review Study. Int J High Risk Behav Addict 2016 ; 5 : e27976. doi : 10.5812/ijhrba.27976.
 
13) 木村充. 高齢者と飲酒問題-アルコール関連認知症を合併したアルコール依存症. 医学のあゆみ 2020 ; 274 : 117-120.
Medical*Online
14) Topiwala A, Ebmeier KP. Effects of drinking on late-life brain and cognition. Evid Based Ment Health 2018 ; 21 : 12-15. doi : 10.1136/eb-2017-102820.
 
15) Bates ME, et al. Neurocognitive impairment associated with alcohol use disorders : implications for treatment. Exp Clin Psychopharmacol 2002 ; 10 : 193-212. doi : 10.1037//1064-1297.10.3.193.
 
16) Nixon SJ, Lewis B. Clarifying the neurobehavioral sequelae of moderate drinking lifestyles and acute alcohol effects with aging. Int Rev Neurobiol 2019 ; 148 : 39-78. doi : 10.1016/bs.irn.2019.10.016.
 
17) Bartsch AJ. Manifestations of early brain recovery associated with abstinence from alcoholism. Brain 2007 ; 130 : 36-47. doi : 10.1093/brain/awl303.
 
18) Immonen S, et al. Moderate alcohol use is associated with decreased brain volume in early middle age in both sexes. Sci Rep 2020 ; 10 : 13998.
PubMed
19) Islam M, et al. Benzodiazepine Use and Risk of Dementia in the Elderly Population : A Systematic Review and Meta-Analysis. Neuroepidemiology 2016 ; 47 : 181-191. doi : 10.1159/000454881.
 
20) Penninkilampi R, Eslick GD. A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias. CNS Drugs 2018 ; 32 : 485-497.
PubMed
21) He Q, et al. Risk of Dementia in Long-Term Benzodiazepine Users : Evidence from a Meta-Analysis of Observational Studies. J Clin Neurol 2019 ; 15 : 9-19.
PubMed
22) Jacqmin-Gadda H, et al. Impact of benzodiazepine consumption reduction on future burden of dementia. Sci Rep 2020 ; 10 : 14666.
PubMed
23) Grossi CM, et al. Anticholinergic and benzodiazepine medication use and risk of incident dementia : A UK cohort study. BMC Geriatr 2019 ; 19 : 276.
 
24) Richardson K, et al. History of Benzodiazepine Prescriptions and Risk of Dementia : Possible Bias Due to Prevalent Users and Covariate Measurement Timing in a Nested Case-Control Study. Am J Epidemiol 2019 ; 188 : 1228-1236. doi : 10.1093/aje/kwz073.
 
25) Nafti M, et al. Is Benzodiazepine Use Associated With the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging. Ann Pharmacother 2019 ; 54 : 219-255.
PubMed
26) Hafdi M, et al. Association of Benzodiazepine and Anticholinergic Drug Usage With Incident Dementia : A Prospective Cohort Study of Community-Dwelling Older Adults. J Am Med Dir Assoc 2020 ; 21 : 188-193.
PubMed
27) Baek YH, et al. Uncertain Association Between Benzodiazepine Use and the Risk of Dementia : A Cohort Study. J Am Med Dir Assoc 2020 ; 21 : 201-211.
PubMed
28) Torres-Bondia F, et al. Benzodiazepine and Z-drug Use and the Risk of Developing Dementia. Int J Neuropsychopharmacol 2022 ; 25 : 261-268.
PubMed
29) Aldaz P, et al. Association between benzodiazepine use and development of dementia. Med Clin (Barc) 2021 ; 156 : 107-111. doi : 10.1016/j-medcli.2020.92.006.
 
Ridley N J, et al. Alcohol-related dementia : An update of the evidence. Alzheimers Res Ther 2013 ; 5 : 3.
PubMed
吉永清宏ほか. ベンゾジアゼピン系薬は認知症の発症リスクを高めるか? 臨床精神薬理 2015 ; 18 : 585-587.
 
松下幸生, 樋口進. アルコールと認知症リスク. BRAIN and NERVE 2016 ; 68 : 819-827.
 
P.229 掲載の参考文献
1) GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016 : A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018 ; 17 : 939-953.
PubMed
2) 厚生労働省. 令和元年度衛生行政報告例の概況. https://www.mhlw.go.jp/toukei/saikin/hw/eisei_houkoku/19/
 
3) Kalia LV, Lang AE. Parkinson's disease. Lancet 2015 ; 386 : 896-912.
PubMed
4) Emre M, et al. Clinical Diagnostic Criteria for dementia Associated with Parkinson's Disease. Mov Disord 2007 ; 22 : 1689-1707.
PubMed
5) Litvan I, et al. Diagnostic Criteria for Mild Cognitive Impairment in Parkinson's Disease : Movement Disorder Society Task Force Guidelines. Mov Disord 2012 ; 27 : 349-356.
PubMed
6) McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies : Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
7) Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia : Current concepts and controversies. J Neural Transm 2018 ; 125 : 615-650.
PubMed
8) Pedersen KF, et al. Natural course of mild cognitive impairment in Parkinson disease : A 5-year population-based study. Neurology 2017 ; 88 : 767-774.
PubMed
9) Jones JD, et al. Reverters from PD-MCI to Cognitively Intact are at Risk for Future Cognitive Impairment : Analysis of the PPIM Cohort. Parkinsonism Relat Disord 2018 ; 47 : 3-7.
 
10) Aarsland D, et al. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005 ; 20 : 1255-1263.
PubMed
11) Williams-Gray CH, et al. The distinct cognitive syndromes of Parkinson's disease : 5 year follow-up of the CamPalGN cohort. Brain 2009 ; 132 : 2958-2969.
PubMed
12) Williams-Gray CH, et al. The CamPalGN study of Parkinson's disease : 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013 ; 84 : 1258-1264.
 
13) Hely MA, et al. The Sydney multicenter study of Parkinson's disease : The inevitability of dementia at 20 years. Mov Disord 2008 ; 23 : 837-844.
PubMed
14) Marinus J, et al. Risk factors for non-motor symptoms in Parkinson's disease. Lancet Neurol 2018 ; 17 : 559-568.
PubMed
15) Noe E, et al. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004 ; 19 : 60-67.
 
16) Takemoto M, et al. Different Clinical and Neuroimaging Characteristics in Early Stage Parkinson's Disease with Dementia and Dementia with Lewy Bodies. J Alzheimers Dis 2016 ; 52 : 205-211.
PubMed
17) Rajput AH, et al. Course in Parkinson disease subtypes : A 39-year clinicopathologic study. Neurology 2009 ; 73 : 206-212.
PubMed
18) Aarsland D, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021 ; 7 : 47.
PubMed
19) Westbrook A, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science 2020 ; 367 : 1362-1366.
PubMed
20) Borodovitsyna O, et al. Noradrenergic modulation of cognition in health and disease. Neural Plast 2017 ; 2017 : 6031478.
PubMed
21) Ballinger EC, et al. Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron 2016 ; 91 : 1199-1218.
PubMed
22) Bohnen NI, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol 2015 ; 72 : 194-200.
PubMed
23) Fanciulli A, Wenning GK. Multiple-System Atrophy. N Engl J Med 2015 ; 372 : 249-263.
PubMed
24) Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-676.
PubMed
25) Stankovic I, et al. Cognitive impairment in multiple system atrophy : A position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014 ; 29 : 857-867.
 
26) Koga S, et al. Profile of Cognitive Impairment and Underlying Pathology in Multiple System Atrophy. Mov Disord 2017 ; 32 : 405-413.
PubMed
27) Diedrichsen J, et al. Universal Transform or Multiple Functionality? Understanding the Contribution of the Human Cerebellum across Task Domains. Neuron 2019 ; 102 : 918-928.
PubMed
28) Gilman S, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010 ; 74 : 1416-1423.
PubMed
日本神経学会 (監修), 「パーキンソン病診療ガイドライン」作成委員会 (編). パーキンソン病診療ガイドライン 2018. 医学書院 ; 2018.
 
日本神経学会 (監修), 「脊髄小脳変性症・多系統萎縮症診療ガイドライン」作成委員会 (編). 脊髄小脳変性症・多系統萎縮症診療ガイドライン 2018. 医学書院 ; 2018.
 
Kandel ER, et al (eds). Principles of Neural Science, sixth edition. McGraw Hill ; 2021.
 
P.237 掲載の参考文献
1) 中村雅之, 佐野輝. 精神症状を伴う神経変性疾患. 臨床精神医学 2019 ; 48 (1) : 75-81.
Medical*Online
2) 日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院 ; 2017.
 
3) Respondek G, et al. The phenotypic spectrum of progressive supranuclear palsy : A retrospective multicenter study of 100 definite cases. Mov Disord 2014 ; 2 (914) : 1758-1766.
 
4) Steele JC, et al. Progressive supranuclear palsy : A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobullbar palsy, nuchal dystonia and dementia. Arch Neurol 1964 ; 10 (4) : 333-359.
 
5) Litvan I, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : Report of the NINDS-SPSP international workshop. Neurology 1996 ; 47 (1) : 1-9.
PubMed
6) Hoglinger GU, et al. Movement Disorder Society-endorsed PSP Study Group : Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 (6) : 853-864.
 
7) Boxer AL, et al. Advances in progressive supranuclear palsy : New diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 2017 ; 16 : 552-563.
PubMed
8) Litvan I, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival : A clinicopathological study. J Neurol Neurosurg Psychiatry 1996 ; 61 (6) : 615-620.
 
9) 廣瀬源二郎. エキスパートに聞く (1) 眼球運動の診察. 老年精神医学雑誌 2021 ; 32 : 349-355.
Medical*Online
10) 饗場郁子. 進行性核上性麻痺の診察のポイント. 老年精神医学雑誌 2021 ; 32 : 1100-1109.
Medical*Online
11) Wenning GK, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999 ; 14 : 947-950.
PubMed
12) 饗場郁子ほか. 進行性核上性麻痺と自律神経障害. 神経内科 2015 ; 83 : 44-53.
 
13) 江面道典, 菊池昭夫. Parkinson症候群のイメージング. 脳神経内科 2021 ; 95 (6) : 788-796.
 
14) Quattrone A, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008 ; 246 : 214-221.
PubMed
15) Smith R, et al. Increased basal ganglia binding of 18F-AV1451 in patients with progressive supranuclear palsy. Mov Disord 2017 ; 32 : 108-114.
 
16) Tagai K, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. Neuron 2021 ; 109 : 42-58.e8.
 
17) 星山晋太郎, 山本賢司. 65. 進行性核上性麻痺. 精神科治療学 2019 ; 34 (増刊号) : 202-204.
 
18) 勝瀬大海. 進行性核上性麻痺および大脳皮質基底核変性症における精神症状. 老年精神医学雑誌 2016 ; 27 : 42-50.
Medical*Online
19) 水澤英洋ほか. 神経変性疾患ハンドブック-神経難病へのエキスパート・アプローチ. 南江堂 ; 2018.
 
20) Yatabe Y, et al. Neuropsychiatric symptoms of Progressive supranuclear palsy in a dementia clinic. Psychogeriatrics 2011 ; 11 : 54-59.
 
21) Golbe LI, et al. A clinical rating scale for progressive supranuclear palsy. Brain 2007 ; 130 : 1552-1565.
PubMed
22) Martin WRW, et al. Is Levodopa Response a Valid Indicator of Parkinson's Disease? Mov Disord 2021 ; 36 (4) : 948-954.
PubMed
23) 池田佳生. PSPとCBDの診断. 老年内科 2021 ; 3 (6) : 716-724.
 
24) Rebeiz JJ, et al. Cortico-dentatonigral degeneration with neuronal achromasia. Arch Neurol 1968 ; 18 : 20-33.
 
25) Gibb WR, et al. Corticobasal degeneration. Brain 1989 ; 112 (Pt 5) : 1171-1192.
 
26) 長谷川一子. 大脳皮質基底核症候群を呈するCBD以外の疾患-CBDの鑑別疾患. Clinical Neuroscience 2017 ; 35 (3) : 317-321.
 
27) Boeve BF, et al. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003 ; 54 (Suppl 5) : S15-S19.
 
28) 下畑享良ほか. 大脳皮質基底核症候群と大脳皮質基底核変性症の診断. 臨床神経 2016 ; 56 : 149-157.
 
29) Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
30) 富樫尚彦, 長谷川一子. 大脳皮質基底核症候群. 老年精神医学雑誌 2021 ; 32 : 1214-1225.
 
31) Mathew R, et al. Diagnostic criteria for corticobasal syndrome : A comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-410.
PubMed
32) Lang AE, et al. The Cortical Basal ganglia Functional Scale (CBFS) : Development and preliminary validation. Parkinsonism Relat Disord 2020 ; 79 : 121-126.
PubMed
33) 徳丸阿耶ほか. 画像検査. Clinical Neuroscience 2017 ; 35 (3) : 306-309.
 
34) Smith R, et al. In vivo retention of 18F-AV1451 in corticobasal syndrome. Neurology 2017 ; 89 : 845-853.
 
35) Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol 2014 ; 16 (3) : 282.
PubMed
Steele JC, et al. Progressive supranuclear palsy : A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobullbar palsy, nuchal dystonia and dementia. Arch Neurol 1964 ; 10 (4) : 333-359.
 
Litvan I, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : Report of the NINDS-SPSP international workshop. Neurology 1996 ; 47 (1) : 1-9.
PubMed
Hoglinger GU, et al. Movement Disorder Society-endorsed PSP Study Group : Clinical diagnosis of progressive supranuclear palsy : The movement disorder society criteria. Mov Disord 2017 ; 32 (6) : 853-864.
 
P.245 掲載の参考文献
1) 加藤賢嗣, 村井俊哉. ヒト免疫不全ウイルスによる認知症. 精神科治療学 2021 ; 36 (増) : 232-233.
 
2) Antinori A, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007 ; 69 : 1789-1799.
PubMed
3) Heaton RK, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy : CHARTER Study. Neurology 2010 ; 75 (23) : 2087-2096.
PubMed
4) Goodkin K, et al. A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. Neuropsychiatry (London) 2011 ; 1 (5) : 431-440.
PubMed
5) 岡慎一ほか. HAND研究は今後どう進むのか-J-HAND研究を終えて. HIV感染症とAIDSの治療 2016 ; 7 (2) : 6-12.
Medical*Online
6) Kinai E, et al. Association of age and time of disease with HIV-associated neurocognitive disorders : A Japanese nationwide multicenter study. J Neurovirol 2017 ; 23 (6) : 864-874.
PubMed
7) 国立感染症研究所. HIV/AIDS 2019年 (IASR Vol.41 p175-176 : 2020年10月号). https://www.niid.go.jp/niid/ja/aids-m/aids-iasrtpc/9921-488t.html
 
8) Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 2015 ; 45 : 1-12.
PubMed
9) Hazleton JE, et al. Novel mechanisms of central nervous system damage in HIV infection. HIV/AIDS (Auckl) 2010 ; 2 : 39-49.
PubMed
10) Saylor D, et al. HIV-associated neurocognitive disorder--Pathogenesis and prospects for treatment. Nat Rev Neurol 2016 ; 12 (4) : 234-248.
PubMed
11) Heaton RK, et al. The HNRC 500--Neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995 ; 1 (3) : 231-251.
 
12) Devlin KN, Giovannetti T. Heterogeneity of Neuropsychological Impairment in HIV Infection : Contributions from Mild Cognitive Impairment. Neuropsychol Rev 2017 ; 27 (2) : 101-123.
PubMed
13) Masters MC, Ances BM. Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol 2014 ; 34 (1) : 89-102.
PubMed
14) Klunder AD, et al. Mapping cerebellar degeneration in HIV/AIDS. Neuroreport 2008 ; 19 (17) : 1655-1659.
 
15) Kato T, et al. Neurocognitive impairment and gray matter volume reduction in HIV-infected patients. J Neurovirol 2020 ; 26 (4) : 590-601.
PubMed
16) Yoshihara Y, et al. Altered white matter microstructure and neurocognitive function of HIV-infected patients with low nadir CD4. J Neurovirol 2022 ; 28 (3) : 355-366.
PubMed
17) Chan P, et al. Cognitive Impairment and Persistent CNS Injury in Treated HIV. Curr HIV/AIDS Rep 2016 ; 13 (4) : 209-217.
PubMed
18) Anthony IC, et al. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005 ; 64 (6) : 529-536.
PubMed
19) Omeragic A, et al. Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders. Fluids Barriers CNS 2020 ; 17 (1) : 42.
PubMed
20) Schifitto G, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol 2009 ; 15 (2) : 176-186.
PubMed
21) Livelli A, et al. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders : Efficacy and Stability Over Time. Front Behav Neurosci 2015 ; 9 : 306.
PubMed
22) Golden MR, et al. Update on syphilis : Resurgence of an old problem. JAMA 2003 ; 290 (11) : 1510-1514.
PubMed
23) 国立感染症研究所. 日本の梅毒症例の動向について (2022年1月7日現在). https://www.niid.go.jp/niid/ja/syphilis-m-3/syphilis-idwrs/7816-syphilis-data-20180105.html
 
24) Radolf JD, et al. Syphilis (Treponema Pallidum). In : Bennett JE, et al (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th edition. Elsevier ; 2019, pp2865-2892.
 
25) 加藤博子, 安藤哲朗. 神経梅毒と認知症. BRAIN and NERVE 2016 ; 68 (4) : 309-316.
 
26) 青木眞. 梅毒 (syphilis : Treponema pallidum). 青木眞, レジデントのための感染症診療マニュアル, 第4版. 医学書院 ; 2020, pp1055-1069.
 
27) Nagappa M, et al. Neurosyphilis : MRI features and their phenotypic correlation in a cohort of 35 patients from a tertiary care university hospital. Neuroradiology 2013 ; 55 (4) : 379-388.
 
28) Gurses C, et al. Clinical and magnetic resonance imaging findings of HIV-negative patients with neurosyphilis. J Neurol 2007 ; 254 (3) : 368-374.
PubMed
29) Gray F, Keohane C. Spirochetal Infections of the CNS. In : Chretien F, et al (eds). Infections of the Central Nervous System : Pathology and Genetics. Wiley-Blackwell ; 2020, pp363-377.
 
30) Funnye AS, Akhtar AJ. Syphilis and human immunodeficiency virus co-infection. J Natl Med Assoc 2003 ; 95 (5) : 363-382.
PubMed
Woods SP, et al. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009 ; 19 (2) : 152-168.
 
Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 2015 ; 45 : 1-12.
PubMed
P.252 掲載の参考文献
1) Gennarelli, TA. Cerebral concussion and diffuse brain injuries. In : Cooper PR (ed). Head Injury, 3rd edition. Williams & Wilkins ; 1993, pp137-158.
 
2) Cicerone KD, et al. Evidence-based cognitive rehabilitation : Updated review of literature from 2009 through 2014. Arch Phys Med Rehabil 2019 ; 100 : 1515-1533.
PubMed
3) Cicerone KD, et al. Evidence-based cognitive rehabilitation : Updated review of literature 1988 through 2002. Arch Phys Med Rehabil 2005 ; 86 : 1681-1692.
 
4) Cicerone KD, et al. Evidence-based cognitive rehabilitation : Updated review of literature from 2003 through 2008. Arch Phys Med Rehabil 2011 ; 92 : 519-530.
PubMed
5) von Holst H, Cassidy JD. Mandate of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004 ; Suppl 43 : 8-10.
 
6) Carroll LJ, et al. Systematic Search and review procedures : Results of the who collaborating centre task force on mild traumatic brain injury. J Rehabil Med 2004 ; Suppl 43 : 11-14.
 
7) Mayer AR, et al. The spectrum of mild traumatic brain injury. Neurology 2017 ; 89 : 623-632.
PubMed
8) Karr JE, et al. The neuropsychological outcomes of concussion : A systematic review of meta-analysis on the cognitive sequelae of mild traumatic brain injury. Neuropsychology 2014 ; 28 : 321-336.
PubMed
9) Ponsford J, et al. Long-term outcomes after uncomplicated mild traumatic brain injury : A comparison with trauma contrls. J Neurotrauma 2011 : 28 : 937-946.
 
Mayer AR, et al. The spectrum of mild traumatic brain injury : A review. Neurology 2017 ; 89 : 623-632.
PubMed
von Holst H, et al. J Rehabil Med 2004 ; Suppl 43 : 4-144.
 
高畑圭輔. 頭部外傷による遅発性脳障害 : 慢性外傷性脳症 (CTE) のタウイメージング. Annual Review 神経 2021 ; 227-236.
Medical*Online
中島八十一. 高次脳機能障害の勃興と将来展望. 新興医学出版社 ; 2023.
 
P.258 掲載の参考文献
1) Kudo H, et al. Chronic subdual hematoma in elderly people : Present status on Awaji Island and epidemiological prospect. Neurol Med Chir (Tokyo) 1992 ; 32 : 207-209.
 
2) Santarius T, Hutchinson PJ. Chronic subdual haematoma : Time to rationalize treatment? Br J Neurosurg 2004 ; 18 : 328-332.
 
3) Rust T, et al. Chronic subdual haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci 2006 ; 13 : 823-827.
PubMed
4) Kotwica Z, et al. Chronic subdual hematoma (CSH) is still an important clinical problem, Analysis of 700 consecutive patients. Transl Neurosci 2019 ; 10 : 260-263.
 
5) Adhiyaman V, et al. Chronic subdural haematoma in the elderly. Postgrad Med J 2002 ; 78 (916) : 71-75.
PubMed
6) Beck J, et al. Spinal cerebrospinal fluid leak as the cause of chronic subdual hematomas in nongeriatric patients. J Neurosug 2014 ; 121 : 1380-1387.
 
7) 渡邉潤ほか. 【慢性硬膜下血腫の治療・手術 私の工夫】慢性硬膜下血腫と鑑別を要する疾患. 脳神経外科速報 2016 ; 26 : 1186-1192.
 
8) Wang X, et al. Pharmacological treatment in the management of chronic subdural hematoma. Front Aging Neurosci 2021 ; 13 : 68450. doi : 10.3389/fnagi.2021.684501
 
9) 厚生労働科学研究費補助金難治性疾患政策研究事業「特発性正常圧水頭症の診療ガイドライン作成に関する研究」班. 日本正常圧水頭症学会 (監修). 特発性正常圧水頭症診療ガイドライン 第3版. メディカルレビュー社 ; 2020.
 
10) Kito Y, et al. Neuropsychiatric symptoms in patients with idiopathic normal pressure hydrocephalus. Behav Neurol 2009 ; 21 (3) : 165-174.
PubMed
11) Saito M, et al. Cognitive profile of idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Dis Extra 2011 ; 1 (1) : 202-211.
PubMed
12) Kubo Y, et al. Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. Dement Geriatr Cogn Disord 2008 ; 25 (1) : 37-45.
PubMed
13) Hashimoto M, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme : A prospective cohort study. Cerebrospinal Fluid Res 2010 ; 7 : 18.
PubMed
14) Kazui H, et al. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2) : An open-label randomised trial. Lancet Neurol 2015 ; 14 (6) : 585-594.
PubMed
15) 吉山顕次ほか. 認知症疾患医療センターにおける特発性正常圧水頭症の現状. BRAIN and NERVE 2015 ; 67 (9) : 1139-1145.
 
日本脳神経外科学会/日本脳神経外傷学会 (監修), 頭部外傷治療・管理のガイドライン作成委員会 (編). 頭部外傷治療・管理のガイドライン 第4版. 医学書院 ; 2019.
 
鐘本英輝. 特発性正常圧水頭症の臨床症状と評価方法の最近の進歩-『特発性正常圧水頭症診療ガイドライン 第3版』にみる, 精神科での診療ポイント. 老年精神医学雑誌 2021 ; 32 (3) : 284-292.
Medical*Online
宮崎晃一, 石井一成. 特発性正常圧水頭症の神経画像の最新知見. 老年精神医学雑誌 2021 ; 32 (3) : 293-303.
Medical*Online
P.264 掲載の参考文献
1) 環境省環境再生・資源循環局 廃棄物適正処理推進課. 平成29年度「ごみ屋敷」に関する調査報告書. 平成30年3月. http://www.rilg.or.jp/htdocs/img/reiki/PDF/%EF%BC%91%EF%BC%94/h30-18.pdf
 
2) Macmillan D, Shaw P. Senile breakdown in standards of personal and environmental cleanliness. Br Med J 1966 ; 2 (5521) : 1032-1037.
PubMed
3) Clark AN, et al. Diogenes syndrome. A clinical study of gross neglect in old age. Lancet 1975 ; 1 (7903) : 366-368.
PubMed
4) Halliday G, et al. Community study of people who live in squalor. Lancet 2000 ; 355 (9207) : 882-886.
PubMed
5) Assal F. Diogenes Syndrome. Front Neurol Neurosci 2018 ; 41 : 90-97.
PubMed
6) Finney CM, Mendez MF. Diogenes Syndrome in Frontotemporal Dementia. Am J Alzheimers Dis Other Demen 2017 ; 32 (7) : 438-443.
PubMed
7) Sacchi L, et al. Diogenes syndrome in dementia : A case report. BJPsych Open 2021 ; 7 (2) : e43.
PubMed
8) 大西陽之ほか. 行動異常型前頭側頭型認知症によるDiogenes症候群の1例. 精神神経学雑誌 2022 ; 124 (6) : 373-381.
 
9) 野村祥平ほか. 高齢者のセルフ・ネグレクトの理論的な概念と実証研究の課題に関する考察. 高齢者虐待防止研究 2014 ; 10 (1) : 175-187.
 
10) 岸恵美子 (編集代表), 滝沢香ほか (編). セルフ・ネグレクトの人への支援. 中央法規 ; 2015.
 
11) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders : DSM-5, Vol. 10. American Psychiatric Association ; 2013.
PubMed
12) Dozier ME, et al. Age of onset and progression of hoarding symptoms in older adults with hoarding disorder. Aging Ment Health 2016 ; 20 (7) : 736-742.
PubMed
13) 池田学ほか. 令和3年度厚生労働科学特別研究事業「認知症初期集中支援チームが直面している地域における認知症者にかかる困難事例の類型化とその対応のあり方に関する調査研究事業」.
 
14) Ito K, et al. Diogenes syndrome in a 10-year retrospective observational study : An elderly case series in Tokyo. Int J Geriatr Psychiatry 2022 ; 37 (1).
 
15) Frost RO, et al. Development and Validation of the Clutter Image Rating. J Psychopathol Behav Assess 2008 ; 30 (3) : 193-203.
 
16) Halliday G, Snowdon J. The Environmental Cleanliness and Clutter Scale (ECCS). Int Psychogeriatr 2009 ; 21 (6) : 1041-1050.
PubMed
17) Finney CM, Mendez MF. Diogenes Syndrome in Frontotemporal Dementia. Am J Alzheimers Dis Other Demen 2017 ; 32 (7) : 438-443.
PubMed

4章 認知症の鑑別診断

P.272 掲載の参考文献
1) Mendez MF, et al. Neuropathologically confirmed Alzheimer's disease : Clinical diagnosis in 394 cases. J Geriatr psychiatry Neurol 1991 ; 4 : 26-29.
 
2) 馬場元. 高齢者の気分障害. 日本老年精神医学会 (編), 改訂・老年精神医学講座 ; 各論. ワールドプランニング ; 2009.
 
3) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
4) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostical Guidelines. WHO ; 1992/融道男ほか (監訳). ICD-10 精神および行動の障害-臨床記述と診断ガイドライン, 新訂版. 医学書院 ; 2005.
 
5) World Health Organization. ICD-11 Browser. https://icd.who.int/browse11/l-m/en <Version : 02/2022>
 
6) 本村啓介ほか. 各論 (4) 気分症群. ICD-11「精神, 行動, 神経発達の疾患」分類と病名の解説シリーズ. 精神経誌 2021 ; 123 (8) : 506-514.
 
7) 馬場元. 老年期の抑うつ症候群. 精神医学症候群 (第2版) I-発達障害・統合失調症・双極性障害・抑うつ障害. IV. 抑うつ障害群 8. 抑うつ症候群の病型. 日本臨牀 別冊 精神医学症候群 (第2版) I 2017 ; 540-545.
 
8) 三村將ほか (編). 老年期うつ病ハンドブック. 診断と治療社 ; 2009.
 
9) 馬場元. 高齢者特有の症状に対応する-老年症候群 抑うつ. 内科 2011 ; 108 (6) : 994-998.
 
10) 馬場元. 老年期のうつ病診療. 高齢者診療Up To Date No. 5. 新薬と臨牀 2021 ; 70 (10) : 1295-1301.
 
11) Hegeman JM, et al. Phenomenology of depression in older compared with younger adults : Meta-analysis. Br J Psychiatry 2012 ; 200 : 275-281.
PubMed
12) Gournellis R, et al. Guilt Delusional Beliefs Increase the Risk of Suicidal Attempt in Elderly Unipolar Psychotic Depressives. J Nerv Ment Dis 2019 ; 207 : 29-33.
PubMed
13) Maj M, et al. Phenomenology and prognostic significance of delusions in major depressive disorder : A 10-year prospective follow-up study. J Clin Psychiatry 2007 ; 68 : 1411-1417.
PubMed
14) Robert P, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009 ; 24 : 98-104.
PubMed
15) 楯林義孝. 認知症とうつ病. 老年精神医学雑誌 2008 ; 19 (4) : 414-419.
Medical*Online
16) Lee SI, Keltner NL. Antidepressant apathy syndrome. Perspect Psychiatr Care 2005 ; 41 (4) : 188-192.
PubMed
17) 前嶋仁, 馬場元. うつ病と認知症の関係. 最新医学 2016 ; 71 (増刊) : 1441-1446.
 
18) Kazui H, et al. Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias. PLoS One 2016 ; 11 (8) : e0161092.
PubMed
19) Steinberg M, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia : the Cache County Study. Int J Geriatr Psychiatry 2008 ; 23 (2) : 170-177.
PubMed
20) Lyketsos CG, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 2011 ; 7 (5) : 532-539.
PubMed
21) McKeith IG, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020 ; 94 (17) : 743-755.
PubMed
22) Utsumi K, et al. Psychotic Features Among Patients in the Prodromal Stage of Dementia with Lewy Bodies During Longitudinal Observation. J Alzheimers Dis 2021 ; 83 (4) : 1917-1927.
PubMed
23) 岡田和悟. 血管性痴呆の前駆症状. 老年精神医学雑誌 2005 ; 16 (3) : 322-328.
Medical*Online
24) Shinagawa S, et al. Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer's disease. Dement Geriatr Cogn Disord 2006 ; 21 (2) : 74-80.
PubMed
25) Lyketsos CG, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment : Results from the cardiovascular health study. JAMA 2002 ; 288 (12) : 1475-1483.
PubMed
26) Geda YE, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment : A prospective cohort study. Arch Neurol 2006 ; 63 (3) : 435-440.
PubMed
27) Geerlings MI, et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 2008 ; 70 (15) : 1258-1264.
PubMed
28) Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol 2011 ; 7 (6) : 323-331.
PubMed
29) Semkovska M, et al. Cognitive function following a major depressive episode : A systematic review and meta-analysis. Lancet Psychiatry 2019 ; 6 (10) : 851-861.
 
30) Dotson VM, et al. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010 ; 75 (1) : 27-34.
PubMed
31) Morimoto SS, et al. Alexopoulos, Diagnosis and treatment of depression and cognitive impairment in late life. Ann N Y Acad Sci 2015 ; 1345 (1) : 36-46.
PubMed
32) 前嶋仁, 馬場元. 高齢者気分障害における認知機能障害. 臨床精神薬理 2019 ; 22 (1) : 31-35.
 
33) Bora E, et al. Cognitive impairment in euthymic major depressive disorder : A meta-analysis. Psychol Med 2013 ; 43 : 2017-2026.
PubMed
34) Herrmann LL, et al. The cognitive neuropsychology of depression in the elderly. Psychol Med 2007 ; 37 : 1693-1702.
PubMed
35) Krishnan KR, et al. MRI-defined vascular depression. Am J Psychiatry 1997 ; 154 : 497-501.
PubMed
36) Fujikawa T, et al. Incidence of silent cerebral infarction in patients with major depression. Stroke 1993 ; 24 : 1631-1634.
PubMed
37) Hashem AH, et al. Late versus Early Onset Depression in Elderly Patients : Vascular Risk and Cognitive Impairment. Curr Aging Sci 2017 ; 10 : 211-216.
PubMed
38) 松田実. 精神6 認知症 代表疾患 1. アルツハイマー病. 三村將 (編), 新しい診断と治療のABC 66 (別冊) 2010 ; 61-71.
 
39) Alexopoulos GS, et al. The course of geriatric depression with "reversible dementia" : A controlled study. Am J Psychiatry 1993 ; 150 : 1693-1699.
PubMed
40) Reynolds CF 3rd, et al. Two-year follow-up of elderly patients with mixed depression and dementia. Clinical and electroencephalographic sleep findings. J Am Geriatr Soc 1986 ; 34 : 793-799.
PubMed
41) Small GW, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for geriatric psychiatry, the Alzheimer's association, and the American geriatric society. JAMA 1997 ; 278 : 1363-1371.
 
42) Greene RD, et al. Neurological Changes and Depression : 2020 Update. Clin Geriatr Med 2020 ; 36 : 297-313.
PubMed
Watt JA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia : systematic review and network meta-analysis. BMJ 2021 ; 372 : n532.
PubMed
Ma L. Depression, Anxiety, and Apathy in Mild Cognitive Impairment : Current Perspectives. Front Aging Neurosci 2020 ; 12 : 9.
PubMed
Kok RM, Reynolds CF 3rd. Management of Depression in Older Adults : A Review. JAMA 2017 ; 317 (20) : 2114-2122.
PubMed
P.280 掲載の参考文献
1) Roth M. The natural history of mental disorders in old age. J Ment Sci 1955 ; 101 : 281-301.
 
2) 古茶大樹. 高齢発症の精神病の歴史と精神病理学総論からみたその疾病分類学的問題点. 老年精神医学雑誌 2021 ; 32 : 603-610.
Medical*Online
3) Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr 1907 ; 64 : 146-148.
 
4) Kay DW, Roth M. Environmental and hereditary factors in the schizophrenias of age ("late paraphrenia") and their bearing on the general problem of causation in schizophrenia. J Ment Sci 1961 ; 107 : 649-686.
PubMed
5) Janzarik W. Uber das Kontaktmangelparanoid des hoheren Alters und den Syndromcharakter schizophrenen Krankseins. Nervenarzt 1973 ; 44 : 515-526.
 
6) Howard R, et al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis : An international consensus. The International Late-Onset Schizophrenia Group. Am J psychiatry 2000 ; 157 : 172-178.
 
7) Howard R, et al. ATLAS Trialists Group. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS) : A randomised, controlled, double-blind trial. Lancet Psychiatry 2018 ; 5 (7) : 553-563.
 
8) 佐竹祐人, 池田学. 老年期のサイコーシス. 老年精神医学雑誌 2022 ; 33 : 786-792.
Medical*Online
9) 古茶大樹. 遅発性パラフレニーと接触欠損パラノイド. 鹿島晴雄ほか (編). 妄想の臨床. 新興医学出版社 ; 2013, pp370-377.
 
10) Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010 ; 9 (1) : 119-128.
PubMed
11) Brodaty H, et al. Long-term outcome of late-onset schizophrenia : 5-year follow-up study. Br J psychiatry 2003 ; 183 : 213-219.
PubMed
12) Kodesh A, et al. Risk of dementia and death in very-late-onset schizophrenia-like psychosis : A national cohort study. Schizophr Res 2020 ; 223 : 220-226.
PubMed
13) Stafford J, et al. Association between risk of dementia and very late-onset schizophrenia-like psychosis : A Swedish population-based cohort study. Psychol Med 2021 ; 53 : 1-9.
 
14) Liew TM. Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia. Alzheimers Res Ther 2020 ; 12 (1) : 35.
PubMed
15) Utsumi K, et al. Psychotic Features Among Patients in the Prodromal Stage of Dementia with Lewy Bodies During Longitudinal Observation. J Alzheimers Dis 2021 ; 83 (4) : 1917-1927.
PubMed
16) Van Assche L, et al. The Neuropsychological Profile and Phenomenology of Late Onset Psychosis : A Cross-sectional Study on the Differential Diagnosis of Very-Late-Onset Schizophrenia-Like Psychosis, Dementia with Lewy Bodies and Alzheimer's Type Dementia with Psychosis. Arch Clin Neuropsychol 2019 ; 34 : 183-199.
PubMed
17) 數井裕光 (研究代表). BPSD出現予測マップとBPSD予防マニュアル BPSD出現予測マップ. 平成25-26年度 厚生労働科学研究費補助金 認知症対策総合研究事業, 平成27年 日本医療研究開発機構 (AMED) 研究費 認知症研究開発事業. https://www.bpsd-map.com/
 
18) Kazui H, et al. Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias. PLoS One 2016 ; 11 : e0161092.
PubMed
19) Ikeda M, et al. Delusions of Japanese patients with Alzheimer's disease. Int J Geriatr Psychiatry 2003 ; 18 : 527-532.
PubMed
20) Satake Y, et al. Characteristics of very late-onset schizophrenia-like psychosis classified with the biomarkers for Alzheimer's disease : A retrospective cross-sectional study. Int Psychogeriatr 2023 ; 30 : 1-14.
 
21) Tsunoda N, et al. Clinical Features of Auditory Hallucinations in Patients With Dementia With Lewy Bodies : A Soundtrack of Visual Hallucinations. J Clin Psychiatry 2018 ; 79 : 17m11623.
PubMed
22) Nagahama Y, et al. Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry 2007 ; 15 : 961-967.
PubMed
23) Suehiro T, et al. Case Report : De Clerambault's Syndrome in Dementia With Lewy Bodies. Front Psychiatry 2021 ; 12 : 665868.
PubMed
24) Taomoto D, et al. Case report : Delusional infestation in dementia with Lewy bodies. Front Psychiatry 2022 ; 13 : 1051067.
PubMed
25) Mori K, Ikeda M. Biological basis and psychiatric symptoms in frontotemporal dementia. Psychiatry Clin Neurosci 2022 ; 76 : 351-360.
PubMed
26) Sha SJ, et al. Frontotemporal dementia due to C9ORF72 mutations : Clinical and imaging features. Neurology 2012 ; 79 : 1002-1011.
PubMed
27) Naasan G, et al. Psychosis in neurodegenerative disease : Differential patterns of hallucination and delusion symptoms. Brain 2021 ; 144 : 999-1012.
PubMed
28) 大西陽之ほか. 行動異常型前頭側頭型認知症によるDiogenes症候群の1例. 精神神経学雑誌 2022 ; 124 : 373-381.
 
29) Nagao S, et al. Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. Eur Arch Psychiatry Clin Neurosci 2014 ; 264 : 317-331.
PubMed
30) Ismail Z, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia : Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2016 ; 12 : 195-202.
PubMed
31) Matsuoka T, et al. Prevalence of Mild Behavioral Impairment and Risk of Dementia in a Psychiatric Outpatient Clinic. J Alzheimers Dis 2019 ; 70 : 505-513.
 
32) Taragano FE, et al. Risk of Conversion to Dementia in a Mild Behavioral Impairment Group Compared to a Psychiatric Group and to a Mild Cognitive Impairment Group. J Alzheimers Dis 2018 ; 62 : 227-238.
 
33) Orso B, et al. Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia. Am J Geriatr Psychiatry 2020 ; 28 : 755-763.
PubMed
34) McKeith IG, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020 ; 94 : 543-755.
 
35) Kanemoto H, et al. Characteristics of very late-onset schizophrenia-like psychosis as prodromal dementia with Lewy bodies : A cross-sectional study. Alzheimers Res Ther 2022 ; 14 : 137.
PubMed
36) Satake Y, et al. Case Report : Usefulness of Biomarkers for Alzheimer's Disease in Two Cases With Very-Late-Onset Schizophrenia-Like Psychosis. Front Psychiatry 2021 ; 12 : 742659.
PubMed
37) De Simone MS, et al. Different deficit patterns on word lists and short stories predict conversion to Alzheimer's disease in patients with amnestic mild cognitive impairment. J Neurol 2017 ; 264 : 2258-2267.
PubMed
38) Stafford J, et al. Psychiatric disorders and risk of subsequent dementia : Systematic review and meta-analysis of longitudinal studies. Int J Geriatr Psychiatry 2022 ; 37 (5) : 10.1002/gps.5711.
 
特集 老年期の幻覚・妄想と神経心理学. 老年精神医学雑誌 2021 ; 33 (6).
 
P.288 掲載の参考文献
1) 吉野相英. てんかんを併発しやすい精神疾患. 吉野相英 (編), てんかん診療スキルアップ. 医学書院 ; 2014, pp149-174.
 
2) Amatniek JC, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006 ; 47 (5) : 867-872.
PubMed
3) Samson WN, et al. Clinical features and mortality in patients with early-onset Alzheimer's disease. Eur Neurol 1996 ; 36 (2) : 103-106.
PubMed
4) Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989 ; 46 (8) : 849-853.
PubMed
5) Shea YF, et al. A systematic review of familial Alzheimer's disease : Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Formos Med Assoc 2016 ; 115 (2) : 67-75.
PubMed
6) Vossel KA, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 2013 : 1158-1166.
PubMed
7) Cretin B, et al. Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases : Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant? J Alzheimers Dis 2016 ; 52 (3) : 1125-1133.
 
8) Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav 2010 ; 17 (4) : 461-466.
PubMed
9) Liedorp M, et al. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord 2010 ; 29 (5) : 432-437.
 
10) Vossel KA, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol 2016 ; 80 (6) : 858-870.
PubMed
11) Lam AD, et al. Association of epileptiform abnormalities and seizures in Alzheimer disease. Neurology 2020 ; 95 (16) : e2259-e2270.
PubMed
12) Lam AD, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nat Med 2017 ; 23 (6) : 678-680.
PubMed
13) Volicer L, et al. Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995 ; 6 (5) : 258-263.
PubMed
14) Horvath AA, et al. Subclinical epileptiform activity accelerates the progression of Alzheimer's disease : A long-term EEG study. Clin Neurophysiol 2021 ; 132 (8) : 1982-1989.
PubMed
15) Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007 ; 55 (5) : 697-711.
PubMed
16) Sanchez PE, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 2012 ; 109 (42) : E2895-2903.
 
17) Huijbers W, et al. Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain 2015 ; 138 (Pt 4) : 1023-1035.
 
18) Bakker A, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012 ; 74 (3) : 467-474.
PubMed
19) Vossel K, et al. Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity : A Randomized Clinical Trial. JAMA Neurol 2021 ; 78 (11) : 1345-1354.
PubMed
20) Butler C, Zeman A. Transient Global Amnesia. In : Reuber M, et al (eds). Borderland of Epilepsy Revisited. Oxford University Press ; 2013, pp114-126/吉野相英 (監訳). てんかんとその境界領域. 医学書院 ; 2017, pp107-118.
 
21) Hodges JR, Warlow CP. Syndromes of transient amnesia : Towards a classification. A study of 153 cases. J Neurol Neurosurg Psychiatry 1990 ; 53 (10) : 834-843.
 
22) Butler CR, et al. The syndrome of transient epileptic amnesia. Ann Neurol 2007 ; 61 (6) : 587-598.
PubMed
23) Zeman AZ, et al. Transient epileptic amnesia : A description of the clinical and neuropsychological features in 10 cases and a review of the literature. J Neurol Neurosurg Psychiatry 1998 ; 64 (4) : 435-443.
 
24) Vuilleumier P, et al. Failure to recall (but not to remember) : Pure transient amnesia during nonconvulsive status epilepticus. Neurology 1996 ; 46 (4) : 1036-1039.
PubMed
25) Jack CR, Jr., et al. NIA-AA Research Framework : Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018 ; 14 (4) : 535-562.
 
Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci 2016 ; 17 (12) : 777-792.
PubMed
Vossel KA, et al. Epileptic activity in Alzheimer's disease : Causes and clinical relevance. Lancet Neurol 2017 ; 16 (4) : 311-322.
PubMed
P.296 掲載の参考文献
1) Midorikawa A, Kawamura M. The relationship between subclinical Asperger's syndrome and frontotemporal lobar degeneration. Dement Geriatr Cogn Dis Extra 2012 ; 2 (1) : 180-186.
PubMed
2) 山縣文. この症例をどう診るか nonprogressive bvFTDと自閉症スペクトラム障害. 老年精医誌 2017 ; 28 (増刊I) : 85-90.
 
3) Okumura T, et al. A case of adult asperger's syndrome previously diagnosed as frontotemporal dementia. Prim Care Companion CNS Disord 2011 ; 13 (5) : PCC.11l01167.
 
4) Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 ; 134 (9) : 2456-2477.
 
5) Gregory C, et al. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease : theoretical and practical implications. Brain 2002 ; 125 (4) : 752-764.
 
6) Tanabe H, et al. Behavioral symptomatology and care of patients with Frontal Lobar Degeneration-based on the aspects of the phylogenetic and ontogenetic processes. Dement Geriatr Cong Disord 1999 ; 10 (Suppl 1) : 50-54.
 
7) Ikeda M, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cong Disord 2004 ; 17 (3) : 117-121.
 
8) 松下正明, 田邉敬貴. ピック病-二人のアウグスト. 医学書院 ; 2008.
 
9) Kipps CM, et al. Nonprogressive behavioural frontotemporal dementia : recent developments and clinical implications of the 'bvFTD phenocopy syndrome'. Curr Opin Neurol 2010 ; 23 (6) : 628-632.
PubMed
10) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5). American Psychiatric Publishing ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
11) 本田秀夫. 大人になった発達障害. 認知神経科学 2017 ; 19 (1) : 33-39.
 
12) 加藤秀一, 尾崎紀夫. 自閉スペクトラム症-診断上の留意点と, 発症メカニズムの最近の知見について. 臨床神経学 2019 ; 59 (1) : 13-20.
 
13) 宮岡等. 成人後に発達障害が疑われた事例への対応. 精神医学 2020 ; 62 (7) : 1011-1017.
 
14) 佐久田静, 橋本衛. 行動障害型前頭側頭型認知症と自閉スペクトラム症との鑑別. 精神医学 2020 ; 62 (2) : 151-161.
 
15) 神尾陽子ほか (監). Q&Aシリーズ 発達障害 ASD編. お茶の水女子大学 ヒューマンライフイノベーション開発研究機構 (人間発達教育科学研究所) ; 2021.
 
16) Filipek PA, et al. Practice parameter : Screening and diagnosis of autism. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000 ; 55 (4) : 468-479.
 
17) Folstein MF, et al. "Mini-Mental State" : A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 ; 12 (3) : 189-198.
 
18) 加藤伸司ほか. 改訂長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精医誌 1991 ; 2 (11) : 1339-1347.
Medical*Online
19) Dubois B, et al. The FAB : A frontal assessment battery at bedside. Neurology 2000 ; 55 (11) : 1621-1626.
PubMed
20) 山縣文. 発達障害と認知症を鑑別するための臨床的特徴. 精神医学 2020 ; 62 (7) : 985-999.
 
21) 田邉敬貴. 痴呆の症候学. 医学書院 ; 2000.
 
22) 田邉敬貴. ピック病の位置づけ-前頭側頭型認知症との関連. 老年精医誌 2000 ; 18 (6) : 585-590.
 
23) Whitwell JL, Josephs KA. Recent advances in the imaging of frontotemporal dementia. Curr Neurol Neurosci Rep 2012 ; 12 (6) : 715-723.
PubMed
24) Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Neuropsychology Press ; 1985.
 
25) Hirono N, et al. Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci 1999 ; 11 (4) : 498-503.
PubMed
26) Sakuta S, et al. Clinical features of behavioral symptoms in patients with semantic dementia : Does semantic dementia cause autistic traits? PLoS ONE 2021 ; 16 (2) : e0247184.
PubMed
池田学. 認知症-専門医が語る診断・治療・ケア (中公新書). 中央公論新社 ; 2010.
 
本田秀夫. 自閉スペクトラム症の理解と支援-子どもから大人までの発達障害の臨床経験から. 星和書店 ; 2017
 
P.302 掲載の参考文献
1) Larson EB, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987 ; 107 : 169-173.
PubMed
2) 杉山博通ほか. Treatable dementia-正常圧水頭症, 慢性硬膜下血腫, 薬剤性認知症の診断と治療. 総合臨牀 2011 ; 60 (9) : 1869-1874.
 
3) 日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院 ; 2017.
 
4) Moore AR, O'Keeffe ST. Drug-induced cognitive impairement in the elderly. Drug Aging 1999 ; 15 (1) : 15-18.
PubMed
5) Barker MJ, et al. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use : A meta-analysis. Arch Clin Neuropsychol 2004 ; 19 : 437-454.
 
6) Keefe RS, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia : A review and meta-analysis. Schizophr Bull 1999 ; 25 (2) : 201-222.
PubMed
7) Eisendrath SJ, Sweeny MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987 ; 144 : 506-507.
 
8) Boston Collaborative Drug Surveillance Program. Acute adverse reaction to prednisone in reaction to dose. Clin Pharmacol Ther 1972 ; 13 : 694-698.
 
9) 上條由佳ほか. ビタミンD製剤等薬剤により高Ca血症をきたし腎機能低下を呈した12症例. 薬剤による水・電解質異常・酸塩基平衡 [XIV]. 臨床体液 2011 ; 38 : 73-77.
 
10) 吉田英統ほか. 薬剤性の認知症状態. 老年精神医学雑誌 2008 ; 19 : 988-995.
 
11) The 2019 American Geriatrics Society Beers Criteria Update Expert Panel "American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". J Am Geriatr Soc 2019 ; 67 (4) : 674-694.
 
12) 日本老年医学会. 高齢者が気を付けたい多すぎる薬と副作用. https://www.jpn-geriat-soc.or.jp/info/topics/pdf/20161117_01_01.pdf
 
Barker MJ, et al. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use : A meta-analysis. Arch Clin Neuropsychol 2004 ; 19 : 437-454.
 
The 2019 American Geriatrics Society Beers Criteria Update Expert Panel "American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". J Am Geriatr Soc 2019 ; 67 (4) : 674-694.
 
P.308 掲載の参考文献
1) Ninomiya T. Diabetes mellitus and dementia. Curr Diab Rep 2014 ; 14 : 487.
PubMed
2) Kimura N, et al. Diabetes mellitus induces Alzheimer's disease pathology : Histopathological evidence from animal models. Int J Mol Sci 2016 ; 17 : 503.
PubMed
3) 羽生春夫. 糖尿病性認知症-病態・診断から治療・ケアまで. 医学と看護社 ; 2019.
 
4) Longo M, et al. Diabetes and aging from treatment goals to pharmacologic therapy. Front Endocrinol (Lausanne) 2019 ; 10 : 45.
PubMed
5) Hanyu H, et al. Discrepancy between cognitive test and brain imaging results in Alzheimer's disease associated with diabetes. Curr Alzheimer Res 2022 ; 19 : 95-103.
 

5章 認知症の治療

P.317 掲載の参考文献
1) 日本神経学会 (監修), 「認知症疾患治療ガイドライン」作成合同委員会 (編). 認知症疾患治療ガイドライン 2010. 医学書院 ; 2010.
 
2) 日本神経学会 (監修), 「認知症疾患治療ガイドライン」作成合同委員会 (編). 認知症疾患治療ガイドライン 2010 コンパクト版 2012. 医学書院 ; 2012.
 
3) 日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院 ; 2017.
 
4) 和田健二, 中島健二. 認知症の概念・定義. 日本認知症学会 (編), 認知症テキストブック. 中外医学社 ; 2008, pp8-14.
 
5) McKhann GM, et al. The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011 ; 7 (3) : 263-269.
PubMed
6) 玉岡晃. アルツハイマー病による認知症の診断-米国国立老化研究所/アルツハイマー病協会よりの推奨. Cognition Dementia 2012 ; 11 : 192-202.
Medical*Online
7) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
8) Dubois B, et al. Advancing research diagnostic criteria for Alzheimer's disease : The IWG-2 criteria. Lancet Neurol 2014 ; 13 (6) : 614-629. Erratum in : Lancet Neurol 2014 ; 13 (8) : 757.
 
9) 厚生労働省ほか. 認知症施策推進総合戦略 (新オレンジプラン) ～認知症高齢者等にやさしい地域づくりに向けて～. 平成29 (2017) 年7月改訂版. https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/kaitei_orangeplan.pdf
 
10) McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of the DLB Consortium. Neurology 2017 ; 89 : 88-100.
PubMed
11) 難病情報センター. 127 前頭側頭葉変性症. https://www.nanbyou.or.jp/wp-content/uploads/upload_files/File/127-201704-kijyun.pdf
 
12) 難病情報センター. 5 進行性核上性麻痺. https://www.nanbyou.or.jp/wp-content/uploads/upload_files/File/005-201704-kijyun.pdf
 
13) 難病情報センター. 7 大脳皮質基底核変性症. https://www.nanbyou.or.jp/wp-content/uploads/upload_files/File/007-201704-kijyun.pdf
 
14) Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 ; 134 : 2456-2477.
PubMed
15) Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 ; 76 : 1006-1014.
PubMed
16) 進行性核上性麻痺 (PSP) 診療ガイドライン2020作成委員会 (編). 進行性核上性麻痺 (PSP) 診療ガイドライン 2020. 神経治療 2020 ; 37 : 435-493.
 
17) Gorelick PB, et al. Vascular Contributions to Cognitive Impairment and Dementia : A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011 ; 42 : 2672-2713.
PubMed
P.327 掲載の参考文献
1) 理学療法士及び作業療法士法 (法律第百三十七号). https://www.mhlw.go.jp/web/t_doc?dataId=80038000&dataType=0&pageNo=1 (2022年2月22日閲覧)
 
2) 医政局長通知 (平成22年4月30日医政発0430第1号) 「医療スタッフの協働・連携によるチーム医療の推進について (通知) 」. https://www.mhlw.go.jp/topics/2013/02/dl/tp0215-01-09d.pdf (2022年2月25日閲覧)
 
3) 村井千賀. 私たちの仕事 (4) 作業療法士-作業をすることで人は元気になれる. 老年精神神経医学会誌 2011 ; 22 (11) : 1323-1326.
 
4) 福井圀彦ほか. 老人のリハビリテーション 第4版. 医学書院 ; 1998, p172.
 
5) 村井千賀, 北村立. 認知症患者の作業療法におけるICFの活用事例. 総合リハビリテーション 2018 ; 46 (1) : 31-36.
 
6) 鈴木みずえほか. 認知症高齢者における疼痛の有病率と疼痛が認知症の行動・心理症状に及ぼす影響. 老年看護学 2014 ; 19 (1) : 25-33.
 
7) 世界保健機関 (WHO) /障害者福祉研究会 (編). 国際生活機能分類 (ICF) -国際障害分類 改定版. 中央法規出版 ; 2002.
 
8) 村井千賀, 北村立. 認知症高齢者のリハビリテーション. 精神科救急 2010 ; 13 (8) : 64-68.
 
9) 山根寛著. ひとと作業・作業活動-作業の知をとき技を育む 新版. 三輪書店 ; 2015.
 
10) 村井千賀, 北村立. 老年期の精神医療における多職種協働の実践例報告-社会参加の再開により娘に対する被害妄想が消失した一例. 老年精神医学雑誌 2015 ; 26 (1) ; 84-88.
 
11) 日本作業療法士協会. 作業療法マニュアル 66 生活行為向上マネジメント 改訂第3版. 日本作業療法士協会 ; 2018.
 
12) Schreiner AS, et al. Positive affect among nursing home residents with Alzheimer's dementia : The effect of recreational activity. Aging Ment Health 2005 ; 9 (2) ; 129-134.
PubMed
13) Kolanowski AM, et al. Efficacy of theory-based activities for behavioral symptoms of dementia. Nurs Res 2005 ; 54 (4) : 219-228.
PubMed
14) 椛島敬行ほか. 総合病院入院中にせん妄を併発した患者に対するリエゾンチームによる精神科作業療法. 作業療法 2021 ; 40 : 721-729.
Medical*Online
15) 村井千賀ほか. 対象者理解を深める-ICFを利用した対象者理解. 作業療法ジャーナル 2010 ; 44 (5) : 374-382.
 
16) 村井千賀. ICFと作業療法における活用, 作業療法ジャーナル 2020 ; 54 (11) : 1176-1180.
 
17) 村井千賀, 新美芳樹. ADL (activities of daily living) と認知症. 老年精神医学雑誌 2017 ; 28 (9) : 959-964.
Medical*Online
18) 池田学 (監修), 村井千賀 (編). 認知障害作業療法ケースブック. MEDICAL VIEW ; 2020, pp38-42.
 
19) 村井千賀ほか. こだわりや常同行動を日常ケアに利用することで生活が安定した前頭側頭型認知症の事例. 認知症ケア事例ジャーナル 2009 ; 2 (1) : 79-85.
 
20) 厚生労働省. 認知症施策推進総合戦略 (新オレンジプラン) ～認知症高齢者等にやさしい地域づくりに向けて～. https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/nop1-2_3.pdf#search=%27%E6%96%B0%E3%82%AA%E3%83%AC%E3%83%B3%E3%82%B8%E3%83%97%E3%83%A9%E3%83%B3%27 (2022年2月24日閲覧)
 
池田学 (監修), 村井千賀 (編). 認知障害作業療法ケースブック-疾患別にみる認知症と作業療法 AD, DLB, FTLDを中心に. MEDICAL VIEW ; 2020.
 
池田学 (監修), 村井千賀 (編). 認知障害作業療法ケースブック-重度別の認知症と作業療法 ADL/IADL能力の獲得に向けて. MEDICAL VIEW ; 2020.
 
P.337 掲載の参考文献
1) Ueda T, et al. Effects of music therapy on behavioral and psychological symptoms of dementia : A systematic review and meta-analysis. Ageing Res Rev 2013 ; 12 : 628-641.
PubMed
2) McDermott O, et al. Music therapy in dementia : A narrative synthesis systematic review. Int J Geriatr Psychiatry 2013 ; 28 : 781-794.
PubMed
3) Pedersen SKA, et al. Effects of music on agitation in dementia : A meta-analysis. Front Psychol 2017 ; 8 : 742. doi : 10.3389/fpsyg.2017.00742.
 
4) Zhang Y, et al. Does music therapy enhance behavioral and cognitive function in elderly dementia patients? A systematic review and meta-analysis. Ageing Res Rev 2017 ; 35 : 1-11.
PubMed
5) Leggieru M, et al. Music intervention approaches for Alzheimer's disease : A review of the literature. Front Neurosci 2019 ; 13 : 132. doi : 10.3389/fnins.2019.00132.
 
6) Moreno-Morales C, et al. Music therapy in the treatment of dementia : A systematic review and metaanalysis. Front Med 2020. 19 ; 7 : 160. doi : 10.3389/fmed.2020.00160.
 
7) Dyer SM, et al. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr 2018 ; 30 : 295-309. doi : 10.1017/S1041610217002344.
 
8) Vasionyte I, Madison G. Musical intervention for patients with dementia : A meta-analysis. J Clin Nursing 2013 ; 22 : 1203-1216.
 
9) Moreno-Morales C, et al. Music therapy in the treatment of dementia : A systematic review and meta-analysis. Front Med 2020 ; 7 : 160. doi.org/10.3389/fmed.2020.00160.
 
10) Miyazaki A, et al. Drum communication program intervention in older adults with cognitive impairment and dementia at nursing home : Preliminary evidence from pilot randomized controlled trial. Front Aging Neurosci 2020 ; 12 : 142. doi.org/10.3389/fnagi.2020.00142.
 
11) Perez-Ros P, et al. Preferred music listening intervention in nursing home residents with cognitive impairment : A randomized intervention study. J Alzheimer Dis 2019 ; 70 : 433-442. doi : 10.3233/JAD-190361.
 
12) Garrido S, et al. Music playlists for people with dementia : Trialing a guide for caregivers. J Alzheimer Dis 2020 ; 77 : 219-226. doi : 10.3233/JAD-200457.
 
13) Bellelli G, et al. Music interventions against agitated behavior in elderly persons with dementia : A cost-effective perspective. Int J Geriatr Psychiatry 2012 ; 27 : 327.
PubMed
14) Lin Y, et al. Effectiveness of group music intervention against agitated behavior in elderly persons with dementia. Int J Geriatr Psychiatry 2011 ; 26 : 670-678.
PubMed
15) Livingston G, et al. Non-pharmacological interventions for agitation in dementia : Systematic review of randomized controlled trials. Br J Psychiatry 2014 ; 205 : 436-442.
PubMed
16) Raglio A, et al. Music, music therapy and dementia : A review of literature and the recommendations of the Italian Psychogeriatric Association. Maturitas 2012 ; 72 : 305-310.
PubMed
17) Abe M, et al. The assessments of music therapy for dementia based on the Cochrane review. Dement Geriatr Cogn Disord Extra 2022 ; 12 : 6-13. doi : 10.1159/000521231.
 
18) Chung JC, et al. Snoezelen for dementia. Cochrane Database Syst Rev 2002 ; 4 : Cd003152.
PubMed
19) Hermans DG, et al. Nonpharmacological interventions for wandering of people with dementia in the domestic setting. Cochrane Database Syst Rev 2007 ; 1 : Cd005994.
PubMed
20) Woods B, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev 2012 ; 2 : Cd005562.
PubMed
21) Woods B, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev 2018 ; 3 : Cd001120.
PubMed
22) van der Steen JT, et al. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev 2018 ; 7 : Cd003477.
PubMed
23) Abraha I, et al. Simulated presence therapy for dementia. Cochrane Database Syst Rev 2020 ; 4 : Cd011882.
PubMed
24) Orgeta V, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2020 ; 2 : Cd011961.
PubMed
25) Dodd S, et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol 2018 ; 96 : 84-92.
 
26) Satoh M, et al. The effects of physical exercise with music on cognitive function of elderly people : Mihama-Kiho project. PLoS One 2014 ; 9 (4) : e95230.
PubMed
27) Tabei K, et al. Physical Exercise with Music Reduces Gray and White Matter Loss in the Frontal Cortex of Elderly People : The Mihama-Kiho Scan Project. Front Aging Neurosci 2017 ; 9 : 174.
PubMed
28) Satoh M, et al. The Effects of a 5-Year Physical Exercise Intervention with Music in Community- Dwelling Normal Elderly People : The Mihama-Kiho Follow-Up Project. J Alzheimers Dis 2020 ; 78 (4) : 1493-1507.
PubMed
29) Satoh M, et al. Physical Exercise with Music Maintains Activities of Daily Living in Patients with Dementia : Mihama-Kiho Project Part 21. J Alzheimers Dis 2017 ; 57 (1) : 85-96.
PubMed
30) Tabei K, et al. Cognitive Function and Brain Atrophy Predict Non-pharmacological Efficacy in Dementia : The Mihama-Kiho Scan Project2. Front Aging Neurosci 2018 ; 10 : 87.
PubMed
佐藤正之. 音楽療法はどれだけ有効か-科学的根拠を検証する. 化学同人 ; 2017.
 
P.344 掲載の参考文献
1) Wimo A, et al. Global estimates of informal care. 2018. https://www.alzint.org/u/global-estimates-of-informal-care.pdf
 
2) Collins RN, Kishita N. Prevalence of depression and burden among informal caregivers of people with dementia : A meta-analysis. Ageing Soc 2020 ; 40 (11) : 2355-2392.
 
3) Kaddour L, Kishita N. Anxiety in informal dementia carers : A meta-analysis of prevalence. J Geriatr Psychiatry Neurol 2020 ; 33 (3) : 161-172.
PubMed
4) Charlson F, et al. New WHO prevalence estimates of mental disorders in conflict settings : A systematic review and meta-analysis. Lancet 2019 ; 394 (10194) : 240-248.
PubMed
5) Fridriksdottir N, et al. Family members of cancer patients : Needs, quality of life and symptoms of anxiety and depression. Acta Oncol 2011 ; 50 (2) : 252-258.
PubMed
6) Beck AT. Cognitive therapy of depression. Guilford Press ; 1979.
 
7) Losada A, et al. Explanation of caregivers distress from the cognitive model : The role of dysfunctional thoughts. Psicol Conductual 2006 ; 14 (1) : 115-128.
 
8) Montorio I, et al. Dysfunctional thoughts about caregiving questionnaire : Psychometric properties of a new measure. Int Psychogeriatr 2009 ; 21 (5) : 913-921.
PubMed
9) Livingston G, et al. Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia : Pragmatic randomised controlled trial. BMJ 2013 ; 347 : f6276.
PubMed
10) Hann KEJ, McCracken LM. A systematic review of randomized controlled trials of acceptance and commitment therapy for adults with chronic pain : Outcome domains, design quality, and efficacy. J Contextual Behav Sci 2014 ; 3 (4) : 217-227.
 
11) Kishita N, et al. A meta-analysis of third wave mindfulness-based cognitive behavioral therapies for older people. Int J Geriatr Psychiatry 2017 ; 32 (12) : 1352-1361.
PubMed
12) Losada A, et al. Cognitive-behavioral therapy (CBT) versus acceptance and commitment therapy (ACT) for dementia family caregivers with significant depressive symptoms : Results of a randomized clinical trial. J Consult Clin Psychol 2015 ; 83 (4) : 760-772.
PubMed
13) Kishita N, et al. Internet-delivered guided self-help acceptance and commitment therapy for family carers of people with dementia (iACT4CARERS) : A feasibility study. Aging Ment Health 2022 ; 26 (10) : 1933-1941.
PubMed
14) Kishita N, et al. Which interventions work for dementia family carers? : An updated systematic review of randomized controlled trials of carer interventions. Int Psychogeriatr 2018 ; 30 (11) : 1679-1696.
PubMed
15) Cheng ST, et al. The effectiveness of nonpharmacological interventions for informal dementia caregivers : An updated systematic review and meta-analysis. Psychol Aging 2020 ; 35 (1) : 55-77.
PubMed
16) Cheng ST, Zhang F. A comprehensive meta-review of systematic reviews and meta-analyses on nonpharmacological interventions for informal dementia caregivers. BMC Geriatr 2020 ; 20 : 137.
 
17) Kishita N, Laidlaw K. Cognitive behaviour therapy for generalized anxiety disorder : Is CBT equally efficacious in adults of working age and older adults? Clin Psychol Rev 2017 ; 52 : 124-136.
PubMed
18) Young HM, et al. Social determinants of health : Underreported heterogeneity in systematic reviews of caregiver interventions. Gerontologist 2020 ; 60 (Suppl 1) : S14-S28.
 
P.352 掲載の参考文献
1) Linnemann A, Fellgiebel A. Psychotherapie bei Leichter kognitiver Beeintrachtigung und Demenz. Nervenarzt 2017 ; 88 : 1240-1245.
PubMed
2) Steinberg M. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia : The Cache County Study. Int J Geriatr Psychiatry 2008 ; 23 (2) : 170-177. doi : 10.1002/gps.1858.
 
3) Hepple J. Psychotherapies with older people : an overview. Advances in Psychiatric Treatment 2004 ; 10 : 371-377.
 
4) Bonder BR. Psychotherapy for Individuals with Alzheimer Disease. Alzheimer Disease and Associated Disorders 1994 ; 8 (Suppl 3) : 75-81.
 
5) Burns A, et al. Brief psychotherapy in Alzheimer's disease : Randomised controlled trial. Br J Psychiatry 2005 ; 187 (2) : 143-147.
 
6) Douglas S, et.al. Non-pharmacological interventions in dementia. Advances in Psychiatric Treatment 2004 ; 10 : 171-179.
 
7) Sukhawathanakul P. Psychotherapeutic Interventions for Dementia : A Systematic Review. Can Geriatr J 2021 ; 24 (3) : 222-236.
PubMed
8) Hirakawa Y. Emotional and Spiritual Pain and Suffering of Older People with End-of-Life Dementia from the Perspective of Nurses and Care Workers : A Qualitative Study. J Nurs Care 2014 ; 3 : 6. doi : 10.4172/2167-1168.1000212.
 
9) 森田達也ほか. 終末期がん患者の霊的・実存的苦痛に対するケア-系統的レビューにもとづく統合化. 緩和医療学 2001 ; 3 (4) : 444-456.
Medical*Online
10) Murata H. Spiritual pain and its care in patients with terminal cancer : Construction of a conceptual framework by philosophical approach. Palliat Support Care 2003 ; 1 : 15-21.
PubMed
11) Kiosses DN, et al. Problem adaptation therapy for older adults with major depression and cognitive impairment : A randomized clinical trial. JAMA Psychiatry 2015 ; 72 : 22-30.
PubMed
12) Mackin RS, et al. Cognitive outcomes after psychotherapeutic interventions for major depression in older adults with executive dysfunction. Am J Geriatr Psychiatry 2014 ; 22 : 1496-1503.
PubMed
13) Finnema E, et al. The effects of emotion-oriented approaches in the care for persons suffering from dementia : A review of the literature. Int J Geriatr Psychiatry 2000 ; 15 (2) : 141-161. doi : 10.1002/(sici)1099-1166 (200002) 15 : 2 < 141 : : aid-gps92 > 3.0.co ; 2-5.
 
14) Mackinlay E, Trevitt C. Living in aged care : Using spiritual reminiscence to enhance meaning in life for those with dementia. Int J Ment Health Nurs 2010 ; 19 (6) : 394-401. doi : 10.1111/j.1447-0349.2010.00684.x.
 
15) Wu LF, Koo M. Randomized controlled trial of a six-week spiritual reminiscence intervention on hope,
PubMed
16) Carreira K, et al. A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function. Int J Geriatr Psychiatry 2008 ; 23 : 1110-1113.
PubMed
17) Bloch S. Supportive psychotherapy. In : Bolch S (ed). An Introduction to the Psychotherapies, 4th edition. Oxford University Press ; 2006.
 
18) Junaid O, Hegde S. Supportive psychotherapy in dementia. Advances in Psychiatric Treatment 2007 ; 13 : 17-23. doi : 10.1192/apt.bp.105.002030.
 
19) Berk L, et al. Mindfulness-based stress reduction in middle-aged and older adults with memory complaints : A mixed-methods study. Aging Ment Health 2018 ; 22 : 1107-1114. doi : 10.1080/13607863.2017.1347142.
 
20) Collins RN, et al. The evaluation of a compassion-focused therapy group for couples experiencing a dementia diagnosis. Clin Gerontol 2018 ; 41 (5) : 474-486.
PubMed
21) Snarski M, et al. The effects of behavioral activation therapy with inpatient geriatric psychiatry patients. Behav Ther 2011 ; 42 : 100-108.
PubMed
22) Weber K, et al. Longitudinal assessment of psychotherapeutic day hospital treatment for neuropsychiatric symptoms in dementia. Aging Ment Health 2009 ; 13 (1) : 92-98.
PubMed
23) Waldorff FB, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease : The multi-centre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). Br Med J 2012 ; 345 : e4693. doi : 10.1136/bmj.e4693.
 
24) Bakker T, et al. Integrative psychotherapeutic nursing home program to reduce multiple psychiatric symptoms of cognitively impaired patients and caregiver burden : Randomized controlled trial. Am J Geriatr Psychiatr 2011 ; 19 (6) : 507-520.
 
25) Jha A, et al. Effectiveness of a recovery-orientated psychiatric intervention package on the well-being of people with early dementia : A preliminary randomised controlled trial. Int J Geriatr Psychiatry 2013 ; 28 : 589-596.
PubMed
26) Hilgeman MM, et al. Preserving Identity and Planning for Advance Care (PIPAC) : Preliminary outcomes from a patient-centered intervention for individuals with mild dementia. Aging Ment Health 2014 ; 18 : 411-424.
PubMed
27) Lu YY-F, et al. Feasibility and Effect Sizes of the Revised Daily Engagement of Meaningful Activities Intervention for Individuals With Mild Cognitive Impairment and Their Caregivers. J Gerontol Nurs 2016 ; 42 (3) : 45-58. doi : 10.3928/00989134-20160212-08.
 
28) Cheston R, et al. Group psychotherapy and people with dementia. Aging Ment Health 2003 ; 7 (6) : 452-461.
PubMed
29) Logsdon RG, et al. Early-stage memory loss support groups : Outcomes from a randomized controlled clinical trial. J Gerontol B Psychol Sci Soc Sci 2010 ; 65B : 691-697.
 
30) Gaugler JE, et al. The memory club : Providing support to persons with early-stage dementia and their care partners. Am J Alzheimers Dis Other Demen 2011 ; 26 : 218-226.
PubMed
31) Marshall A, et al. A pilot randomized controlled trial to compare changes in quality of life for participants with early diagnosis dementia who attend a 'Living Well with Dementia' group compared to waiting-list control. Aging Ment Healzth 2015 ; 19 (6) : 526-535.
 
32) Tappen RM, Williams CL. Therapeutic conversation to improve mood in nursing home residents with Alzheimer's disease. Res Gerontol Nurs 2009 ; 2 : 267-275.
PubMed
33) Hirakazura A. Emotional therapy for patients with dementia. Geriatr Gerontl Int 2008 ; 8 : 303-306.
PubMed
34) Rockland LH. Supportive Therapy : A Psychodynamic Approach. Basic Books ; 1989.
 
35) Novalis P, et al. Clinical Manual of Supportive Psychotherapy. American Psychiatric Publishing ; 1993.
 
36) Robie KJ. An exploration of psychologists' perceptions of the process of psychotherapy for the treatment of psychological concerns and mental disorders in elders who have concomitant dementia. The University of ToledoProQuest Dissertations Publishing ; Degree Year 1998. 9908015.
 
37) Solomon K, Szwabo P. Psychotherapy for patients with dementia. In : Morley JE, et al (eds). Memory function and aging- related disorders. Springer Publishing Company ; 1992, pp295-319.
 
38) 繁田雅弘. 認知症の精神療法-アルツハイマー型認知症の人との対話. HOUSE出版 ; 2020.
 
39) 野村豊子. 第2章 コミュニケーションスキル. 日本認知症ケア学会 (編), 改訂・認知症ケアの実際 I : 総論. ワールドプランニング ; 2004, pp21-43.
 
40) 黒川由紀子. 老いの臨床心理-高齢者のこころのケアのために. 日本評論社 ; 1998.
 
黒川由紀子 (編). 認知症と回想法. 金剛出版 ; 2008.
 
ブノワ・ヴェルドン (著), 小倉拓也ほか (訳). こころの熟成-老いの精神分析. 白水社 ; 2021.
 
ヘンリー・ピンスカー (著), 秋田恭子ほか (訳). サポーティヴ・サイコセラピー入門. 岩崎学術出版社 ; 2011.
 
成田善弘. 精神療法家の仕事-面接と面接者. 金剛出版 ; 2003.
 
神田橋條治. 精神科診断面接のコツ. 岩崎学術出版社 ; 1984.
 
神田橋條治. 精神科講義. 創元社 ; 2012.
 
厚生労働省. 認知症の人の日常生活・社会生活における意思決定支援ガイドライン. 平成30年6月. https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/0000212396.pdf
 
繁田雅弘ほか. ケアラーへの情報提供-医療機関の情報提供に対する家族の満足度調査から. 老年精神医学雑誌 2014 ; 25 (9) : 984-992.
Medical*Online
繁田雅弘, 稲村圭亮. 軽度アルツハイマー型認知症および軽度認知障害への精神療法の試み-支持的精神療法と森田療法を用いて. 精神経誌 2020 ; 122 (7) : 499-508.
 
村瀬嘉代子, 青木省三. 心理療法の基本 [完全版]. 金剛出版 ; 2014.
 
P.361 掲載の参考文献
1) Lecun Y, et al. Deep learning. Nature 2015 ; 521 (7553) : 436-444.
PubMed
2) Juneja S, et al. A Perspective Roadmap for IoMT-Based Early Detection and Care of the Neural Disorder, Dementia. J Healthc Eng 2021 ; 2021 : 6712424.
 
3) Stavropoulos TG, et al. Wearable Devices for Assessing Function in Alzheimer's Disease : A European Public Involvement Activity About the Features and Preferences of Patients and Caregivers. Front Aging Neurosci 2021 ; 13 : 643135.
PubMed
4) Sharma S, et al. DeTrAs : Deep learning-based healthcare framework for IoT-based assistance of Alzheimer patients. Neural Comput Appl 2020 ; 1-13.
 
5) Ogawa M, et al. Current Status of Telemedicine for Parkinson's Disease in Japan : A Single-Center Cross-Sectional Questionnaire Survey. J Mov Disord 2022 ; 15 (1) : 58-61.
PubMed
6) Hall AO, et al. Using Tablet-Based Assessment to Characterize Speech for Individuals with Dementia and Mild Cognitive Impairment : Preliminary Results. AMIA Jt Summits Transl Sci Proc 2019 ; 2019 : 34-43.
PubMed
7) Ishikawa T, et al. Handwriting Features of Multiple Drawing Tests for Early Detection of Alzheimer's Disease : A Preliminary Result. Stud Health Technol Inform 2019 ; 264 : 168-172.
PubMed
8) Shinkawa K, et al. Multimodal Behavior Analysis Towards Detecting Mild Cognitive Impairment : Preliminary Results on Gait and Speech. Stud Health Technol Inform 2019 ; 264 : 343-347.
PubMed
9) Yamada Y, et al. Combining Multimodal Behavioral Data of Gait, Speech, and Drawing for Classification of Alzheimer's Disease and Mild Cognitive Impairment. J Alzheimers Dis 2021 ; 84 (1) : 315-327.
PubMed
10) Yoshii K, et al. A Study for Detecting Mild Cognitive Impairment by Analyzing Conversations with Humanoid Robots. IEEE Access 2021 ; 347-350.
 
11) Hao Kevin CHONG Z, et al. Predicting potential Alzheimer medical condition in elderly using IOT sensors-Case study. Institutional Knowledge at Singapore Management University ; 2017.
 
12) Ishii H, et al. An Early Detection System for Dementia Using the M2 M/IoT Platform. Procedia Comput Sci 2016 ; 96 : 1332-1340.
 
13) Tiersen F, et al. Smart Home Sensing and Monitoring in Households With Dementia : User-Centered Design Approach. JMIR Aging 2021 ; 4 (3) : e27047.
PubMed
14) Hung LP, et al. A Novel IoT Based Positioning and Shadowing System for Dementia Training. Int J Environ Res Public Health 2021 ; 18 (4) : 1-21.
 
15) Munoz-Montoya F, et al. Augmented Reality Based on SLAM to Assess Spatial Short-Term Memory. IEEE Access 2019 ; 7 : 2453-2466.
 
加藤浩晃. 医療 4.0 (第4次産業革命時代の医療). 日経BP ; 2018.
 
伊本貴士. IoTの全てを網羅した決定版IoTの教科書. 日経BP ; 2017.
 
P.367 掲載の参考文献
1) 杉下守弘ほか. MMSE-J (精神状態短時間検査-日本版) 原法の妥当性と信頼性. 認知神経科学 2018 ; 20 (2) : 91-110.
 
2) 加藤伸司ほか. 改訂長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精神医学雑誌 1991 ; 2 (11) : 1339-1347.
Medical*Online
3) Velayudhan L, et al. Review of brief cognitive tests for patients with suspected dementia. Int Psychogeriatr 2014 ; 26 (8) : 1247-1262.
PubMed
4) Fujiwara Y, et al. Brief screening tool for mild cognitive impairment in older Japanese : Validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 2010 ; 10 (3) : 225-232.
PubMed
5) Takenoshita S, et al. Validation of Addenbrooke's cognitive examination III for detecting mild cognitive impairment and dementia in Japan. BMC Geriatr 2019 ; 19 (1) : 123.
 
6) Peters F, et al. Abnormal temporal dynamics of visual attention in Alzheimer's disease and in dementia with Lewy bodies. Neurobiol Aging 2012 ; 33 (5) : 1012.
 
7) 鈴木匡子. 認知症の症候学的診断と認知機能評価. 日本臨牀 2018 ; 76 (増刊号 1) : 11-15.
 
8) Economou A, et al. Episodic memory in Alzheimer disease, frontotemporal dementia, and dementia with Lewy bodies/Parkinson disease dementia : Disentangling retrieval from onsolidation. Alzheimer Dis Assoc Disord 2016 ; 30 (1) : 47-52.
PubMed
9) Bergeron D, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Ann Neurol 2018 ; 84 (5) : 729-740.
 
10) Smirnov DS, et al. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2020 ; 94 : e2076-e2087.
PubMed
11) 日本神経心理学会, 日本高次脳機能障害学会. 臨床神経心理士制度規則. 2021年9月29日改訂. https://www.jccn.info/_files/ugd/52637e_9db0a694ba7d4ed58446303b6b495fc7.pdf
 
12) 日本老年精神医学会. 日本老年精神医学会認定専門心理士制度規則/日本老年精神医学会認定上級専門心理士制度規則. http://184.73.219.23/rounen/P_shinrishi/p-41.htm
 
13) 池田学. 認知機能評価の問題点と将来 臨床神経心理士ならびに専門心理士の学会認定制度について. Dementia Japan 2022 ; 36 (3) : 449-452.
 
P.374 掲載の参考文献
1) 中村祐, 吉山容正. 認知症治療薬によるカルシウム制御を介した神経障害抑制. CLINICAL CALCIUM 2015 ; 25 (2) : 263-273.
 
2) 日本神経学会 (監修), 「認知症疾患診療ガイドライン」作成委員会 (編). 認知症疾患診療ガイドライン 2017. 医学書院 ; 2017.
 
3) Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007 ; 120 (5) : 388-397.
PubMed
4) Burns A, et al. British Association for Psychopharmacology. Clinical practice with anti-dementia drugs : A consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006 ; 20 (6) : 732-755.
PubMed
5) Tariot PN, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil : A randomized controlled trial. JAMA 2004 ; 291 (3) : 317-324.
PubMed
6) 中村祐ほか. メマンチン塩酸塩のドネペジル塩酸塩併用時における中等度および高度アルツハイマー型認知症に対する有効性および安全性. Geriatr Med 2017 ; 54 (11) : 1147-1158.
 
7) 中村祐ほか. アルツハイマー型認知症に対するドネペジル塩酸塩, メマンチン製剤併用時の安全性及び有効性 (アリセプト特定使用成績調査). Geriatr Med 2017 ; 55 (1) : 87-100.
 
8) 平成27年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) 認知症に対するかかりつけ医の向精神薬使用の適正化に関する調査研究班作成. かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン (第2版). https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/0000140619.pdf
 
P.383 掲載の参考文献
1) Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010 ; 9 (1) : 119-128.
PubMed
2) Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 (3) : 280-292.
PubMed
3) Hardy JA, Higgins GA. Alzheimer's disease : The amyloid cascade hypothesis. Science 1992 ; 256 (5054) : 184-185.
PubMed
4) Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016 ; 8 (6) : 595-608.
PubMed
5) Schenk D, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 (6740) : 173-177.
PubMed
6) Nicoll JA, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide : A case report. Nat Med 2003 ; 9 (4) : 448-452.
PubMed
7) Salloway S, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014 ; 370 (4) : 322-333.
PubMed
8) Doody RS, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014 ; 370 (4) : 311-321.
PubMed
9) Honig LS, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med 2018 ; 378 (4) : 321-330.
PubMed
10) Ostrowitzki S, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther 2017 ; 9 (1) : 95.
PubMed
11) Salloway S, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med 2021 ; 27 (7) : 1187-1196.
 
12) Mintun MA, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med 2021 ; 384 (18) : 1691-1704.
PubMed
13) Salloway S, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease. JAMA Neurol 2022 ; 79 (1) : 13-21.
PubMed
14) Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 2021 ; 13 (1) : 80.
 
15) Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016 ; 537 (7618) : 50-56.
 
16) Cummings J, et al. Aducanumab : Appropriate Use Recommendations. J Prev Alzheimers Dis 2021 ; 8 (4) : 398-410.
PubMed
17) Cummings J, et al. Alzheimer's disease drug development pipeline : 2021. Alzheimers Dement (N Y) 2021 ; 7 (1) : e12179.
PubMed
18) Novak P, et al. ADAMANT : A placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging 2021 ; 1 : 521-534.
PubMed
19) Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease : A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 2016 ; 388 (10062) : 2873-2884.
PubMed
20) de Bruijn RF, et al. The potential for prevention of dementia across two decades : The prospective, population-based Rotterdam Study. BMC Med 2015 ; 13 : 132.
PubMed
21) van der Flier WM, et al. Vascular cognitive impairment. Nat Rev Dis Primers 2018 ; 4 : 18003.
PubMed
22) Satizabal CL, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. N Engl J Med 2016 ; 374 (6) : 523-532.
PubMed
23) Jacobs V, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm 2014 ; 11 (12) : 2206-2213.
PubMed
24) Jacobs V, et al. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared with Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. Am J Cardiol 2016 ; 118 (2) : 210-214.
PubMed
25) Douiri A, et al. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation 2013 ; 128 (12) : 1341-1348.
PubMed
26) Grosso Jasutkar H, et al. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacol Rev 2022 ; 74 (1) : 207-237.
 
27) Aarsland D, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021 ; 7 (1) : 47.
PubMed
28) Armstrong MJ. Advances in dementia with Lewy bodies. Ther Adv Neurol Disord 2021 ; 14 : 17562864211057666.
PubMed
29) Ikeda M, et al. Epidemiology of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2004 ; 17 (4) : 265-268.
PubMed
30) Panza F, et al. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol 2020 ; 16 (4) : 213-228.
PubMed
31) Rohrer JD, Boxer AL. The Frontotemporal Dementia Prevention Initiative : Linking Together Genetic Frontotemporal Dementia Cohort Studies. Adv Exp Med Biol 2021 ; 1281 : 113-121.
PubMed
32) Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement 2009 ; 5 (5) : 406-418.
PubMed
Cummings J, et al. Alzheimer's disease drug development pipeline : 2022. Alzheimers Dement (N Y) 2022 ; 8 (1) : e12295.
PubMed
van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med 2023 ; 388 (1) : 9-21.
PubMed
P.390 掲載の参考文献
1) Takahashi K, et al. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006 ; 126 (4) : 663-676.
PubMed
2) Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007 ; 131 (5) : 861-872.
PubMed
3) Shi Y, et al. Induced pluripotent stem cell technology : A decade of progress. Nat Rev Drug Discov 2017 ; 16 (2) : 115-130.
PubMed
4) Kondo T, et al. iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid beta Combination for Alzheimer's Disease. Cell Rep 2017 ; 21 (8) : 2304-2312.
PubMed
5) Kondo T, et al. Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study : Randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ Open 2021 ; 11 (6) : e051343.
 
6) Tran H, et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat Med 2022 ; 28 (1) : 117-124.
PubMed
7) Imamura K, et al. Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Sci Rep 2016 ; 6 : 34904.
PubMed
8) Frew J, et al. Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. Mol Neurodegener 2020 ; 15 (1) : 21.
PubMed
9) Wainger BJ, et al. Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons. Cell Rep 2014 ; 7 (1) : 1-11.
PubMed
10) Wainger BJ, et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis : A Randomized Clinical Trial. JAMA Neurol 2021 ; 78 (2) : 186-196.
PubMed
11) Egawa N, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012 ; 4 (145) : 145ra104.
PubMed
12) Fujimori K, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 2018 ; 24 (10) : 1579-1589.
PubMed
13) Morimoto S, et al. Ropinirole hydrochloride for amyotrophic lateral sclerosis : A single-center, randomized feasibility, double-blind, placebo-controlled trial. medRxiv doi : https://doi.org/10.1101/2021.12.05.21267266.
 
14) Imamura K, et al.The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 2017 ; 9 (391) : eaaf3962.
PubMed
15) Imamura K, et al. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study : Protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. BMJ Open 2019 ; 9 (12) : e033131.
PubMed
16) Imamura K, et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study) : A multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine 2022 ; 53 : 101707.
PubMed
P.397 掲載の参考文献
1) Vinasi R, et al. Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer's disease : A systematic review. Int Clin Psychopharmacol 2021 ; 36 (4) : 169-180.
PubMed
2) Schneider LS, et al ; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006 ; 355 (15) : 1525-1538. doi : 10.1056/NEJMoa061240.
 
3) Schneider LS, et al. Risk of death with atypical antipsychotic drug treatment for dementia : Meta-analysis of randomized placebo-controlled trials. JAMA 2005 ; 294 (15) : 1934-1943. doi : 10.1001/jama.294.15.1934.
 
4) FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients. FDA Talk paper 2005. 4. 11.
 
5) Arai H, et al ; J-CATIA Study Group. Mortality risk in current and new antipsychotic Alzheimer's disease users : Large scale Japanese study. Alzheimers Dement 2016 ; 12 (7) : 823-830.
 
6) 本間昭. 平成24年度厚生労働科学研究費補助金 厚生労働科学特別研究事業報告書「認知症, 特にBPSDへの適切な薬物使用に関するガイドライン作成に関する研究」.
 
7) American Psychiatric Association (著), 新井平伊 (監訳). アメリカ精神医学会 BPSDに対する抗精神病薬治療ガイドライン-認知症の焦燥や精神病症状に対して. ワールドプランニング ; 2017.
 
8) Tariot PN, et al. Trial of Pimavanserin in Dementia-Related Psychosis. N Engl J Med 2021 ; 385 : 309-319.
PubMed
9) Tariot PN, et al. Pimavanserin and dementia-related psychosis. Lancet Neurol 2022 ; 21 (2) : 114-115.
PubMed
Schneider LS, et al. Risk of death with atypical antipsychotic drug treatment for dementia : Meta-analysis of randomized placebo-controlled trials. JAMA 2005 ; 294 (15) : 1934-1943.
PubMed
American Psychiatric Association (著), 新井平伊 (監訳). アメリカ精神医学会 BPSDに対する抗精神病薬治療ガイドライン-認知症の焦燥や精神病症状に対して. ワールドプランニング ; 2017.
 
P.401 掲載の参考文献
1) 遠隔精神科手引書策定タスクフォース. 精神科領域における遠隔 (オンライン) 診療のための手引書, 2018. https://www.i2lab.info/tebikisho
 
2) World Health Organization. Telemedicine : opportunities and developments in Member States : report on the second global survey on eHealth 2009. http://www.who.int/goe/publications/goe_telemedicine_2010.pdf
 
3) Bestsennyy O, et al. Telehealth : A quarter-trillion-dollar post-COVID-19 reality? McKinsey & Company (Update : 2021. 7. 9). https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-aquarter-trillion-dollar-post-covid-19-reality (2022年11月11日閲覧)
 
4) 厚生省. 情報通信機器を用いた診療 (いわゆる「遠隔診療」) について (平成9年12月24日健政発第1075号厚生省健康政策局長通知). https://www.mhlw.go.jp/bunya/iryou/johoka/dl/tushinki01.pdf
 
5) 厚生労働省. 「情報通信機器を用いた診療 (いわゆる「遠隔診療」) について」の一部改正について (平成15年3月31日医政発第0331020号厚生労働省医政局長通知). https://www.mhlw.go.jp/bunya/iryou/johoka/dl/tushinki02.pdf
 
6) 厚生労働省. 情報通信機器を用いた診療 (いわゆる「遠隔診療」) について (平成27年8月10日厚生労働省医政局長事務連絡). https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000094452.pdf
 
7) 厚生労働省. オンライン診療の適切な実施に関する指針. 平成30年3月 (令和元年7月一部改訂). https://www.mhlw.go.jp/content/000534254.pdf
 
8) Kinoshita S, et al. Changes in telepsychiatry regulations during the COVID-19 pandemic : 17 countries and regions' approaches to an evolving healthcare landscape. Psychol Med 2022 ; 52 (13) : 2606-2613.
 
9) Brearly TW, et al. Neuropsychological test administration by videoconference : A systematic review and meta-analysis. Neuropsychol Rev 2017 ; 27 (2) : 174-186.
PubMed
10) 飯干紀代子ほか. ビデオ会議システムを用いて高齢者に行う神経心理検査. 認知神経科学 2020 ; 22 : 158-167.
 
11) 岸本泰士郎ほか. 高齢者に対するビデオ会議システムを用いた改訂長谷川式簡易知能評価スケールの信頼性試験. 日本遠隔医療学会雑誌 2016 ; 12 : 145-148.
 
12) 飯干紀代子ほか. テレビ会議システムを用いた時計描画検査の信頼性. 高次脳機能研究 2017 ; 37 : 64-71.
 
13) Iiboshi K, et al. A Validation Study of the Remotely Administered Montreal Cognitive Assessment Tool in the Elderly Japanese Population. Telemed J E Health 2020 ; 26 : 920-928.
PubMed
14) Yoshida K, et al. Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale : A validation study. J Telemed Telecare 2020 ; 26 : 482-487.
 
15) 内田直樹, 浦島創. 認知症診療とオンライン診療. 在宅新療 0-100 2018 ; 3 (9) : 846-850.
 
16) Poon P, et al. Cognitive intervention for community-dwelling older persons with memory problems : Telemedicine versus face-to-face treatment. Int J Geriatr Psychiatry 2005 ; 20 : 285-286.
PubMed
17) Mosca IE, et al. Analysis of Feasibility, Adherence, and Appreciation of a Newly Developed Tele-Rehabilitation Program for People With MCI and VCI. Front Neurol 2020 Nov 27 ; 11 : 583368. doi : 10.3389/fneur.2020.583368.
 

6章 認知症と社会

P.410 掲載の参考文献
1) 高木八尺ほか (編). 人権宣言集. 岩波文庫 ; 1946.
 
2) 中川剛. 基本的人権の考え方. 有斐閣 ; 1991.
 
3) 内閣法制局法令用語研究会 (編). 有斐閣法律用語辞典. 有斐閣 ; 1993.
 
4) 宮沢俊義. 憲法講話. 岩波新書 ; 1967.
 
5) 内閣府. 令和4年版 高齢者白書. https://www8.cao.go.jp/kourei/whitepaper/w-2022/zenbun/04pdf_index.html
 
6) 内閣府. 2016年度 高齢者の経済・生活環境に関する調査. https://www8.cao.go.jp/kourei/ishiki/h28/sougou/zentai/index.html
 
7) 高田創. 日本の格差に関する現状. みずほ総合研究所資料. 2015. http://www.cao.go.jp/zeicho/gijiroku/zeicho/2015/__icsFiles/afieldfile/2015/08/27/27zen17kai7.pdf
 
8) 国立社会保障・人口問題研究所. 「生活保護」に関する公的統計一覧. https://www.ipss.go.jp/s-info/j/seiho/seiho.asp
 
9) 小塩隆士ほか. 日本の社会保障政策-課題と改革. 東京大学出版会 ; 2014.
 
10) 藤森克彦. 低所得高齢者の実態と求められる所得補償制度 (2/3). みずほ情報総研 ; 2012. https://www.mizuho-r.co.jp/publication/contribution/2012/nenkintokeizai01_02.htm
 
11) 藤田孝典, 下流老人. 一億総老後崩壊の衝撃. 朝日新書 ; 2015.
 
12) 最高裁判所. 意思決定支援を踏まえた後見事務のガイドライン. 2020. https://www.courts.go.jp/vc-files/courts/2021/20201030guideline.pdf
 
13) 齋藤正彦. 成年後見制度の現状と課題. 法と精神医学 2011 ; 26 : 65-75.
 
14) 齋藤正彦. 高齢者の安全を守る成年後見制度等の活用について. 生存科学 2014 ; 24 : 61-70.
 
15) 齋藤正彦. 家族支援を期待できない低所所得高齢者世帯に対する社会政策. 老年精神医学雑誌 2017 ; 28 (3) : 227-237.
 
16) 最高裁判所. 令和3年成年後見関係事件の概況. https://www.courts.go.jp/vc-files/courts/2021/20220316koukengaikyou-r3.pdf
 
野崎泰伸. 「共倒れ」社会を超えて-生の無条件の肯定へ! 筑摩選書 ; 2015.
 
立岩真也. 唯の生. 筑摩書房 ; 2009.
 
齋藤正彦, 井藤佳恵 (編著). 私たちの医療倫理が試されるとき-自己決定・自己責任論を超えて. ワールドプランニング ; 2021.
 
P.419 掲載の参考文献
1) 松下正明. エイジズムから尊厳に満ちた地域社会へ-Butler RNの業績と3A (Ageism, Abuse, Annihilation) 現象. 老年精神医学雑誌 2017 ; 28 : 447-457.
Medical*Online
2) Achenbaum WA. Robert N. Butler, MD : Visionary of Healthy Aging. Columbia University Press ; 2013.
 
3) Butler RN. Age-ism : Another form of bigotry. Gerontologist 1969 ; 9 : 243-246.419
 
4) Butler RN. Why Survive? Being Old in America. Harper & Row ; 1975/内園耕二 (監訳), グレッグ・中村文子 (訳). 老後はなぜ悲劇なのか? アメリカの老人たちの生活. メヂカルフレンド社 ; 1991.
 
5) Palmore EB. Ageism. Negative and Positie, 2nd edition. Springer ; 1999/ (1990年の初版) 奥山正司ほか (訳). エイジズム. 優遇と偏見・差別. 法政大学出版局 ; 1995.
 
6) Butler RN. Ageism : A foreword. J Soc Issues 1980 ; 36 : 8-11.
 
7) Kagan SH. Ageism and the helping profession. In : Nelson TD (ed). Ageism. Stereotyping and Prejudice Against Older Persons, 2nd edition. MIT Press ; 2017.
 
8) Kagan SH, Melendez-Torres GJ. Ageism in nursing. J Nurs Manag 2015 ; 23 : 644-650.
PubMed
9) Kemper S. Elder speak : Speech accommodations to older adults. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 1994 ; 1 : 17-28.
 
10) Bugental DB, Hehman JA. The nature and effects of patronizing speech on older adults. In : Nelson TD (ed). Ageism. Stereotyping and Prejudice Against Older Persons, 2nd edition. MIT Press ; 2017.
 
11) Diehl M, et al. Subjective aging and awareness of aging. Toward a new understanding of the aging self. Annu Rev Gerontol Geriatr 2015 ; 35 : 1-28.
 
12) Levy B. Handwriting as a reflection of aging self-stereotypes. Journal of Geriatric Psychiatry 2000 ; 33 : 81-94.
 
13) Sue DW, et al. Racial microaggressions in everyday life : Implications for clinical practice. Am Psychol 2007 ; 62 : 271-286.
PubMed
14) Sue DW. Microaggressions in Every Life. Race, Gender & Sexual Orientation. Wiley ; 2010/デラルド・ウィン・スー (著), マイクロアグレッション研究会 (訳). 日常生活に埋め込まれたマイクロアグレッション. 明石書店 ; 2020.
 
15) Pierce C. Offensive mechanisms. In : Barbour F (ed). In the Black Seventies. Porter Sargent ; 1970.
 
16) Gendron TL, et al. The language of ageism : Why we need to use words carefully. Gerontologist 2015 ; 56 : 997-1006.
PubMed
17) Williams MT. Microaggressions : Clarification, evidence, and impact. Pespect Psychol Sci 2020 ; 15 : 3-26.
PubMed
18) Bytheway B. Ageism. Open University Press ; 1995.
 
19) Nelson TD (ed). Ageism. Stereotyping and Prejudice Against Older Persons, 2nd edition. MIT Press ; 2017.
 
20) Palmore EB, et al (eds). Encyclopedia of Ageism. The Haworth Press ; 2005.
 
21) Macnicol J. Age Discrimination. An Historical and Contemporary Analysis. Cambridge University Press ; 2006.
 
22) Butler RN. Ageism in America, International Longevity Center ; 2006.
 
23) 松下正明. 不老不死より健康長寿へ-さまざまな不幸のさなかにあって長寿をどう生き抜いていくのか. 老年精神医学雑誌 2001 ; 12 : 221-228.
 
24) Rowe JW, Kahn RL. Successful Aging. Dell Publishing ; 1998.
 
25) 金子善彦. 老人虐待. 星和書店 ; 1987.
 
26) 高齢者処遇研究会 (代表 田中荘司). 高齢者の福祉施設における人間関係の調査に係わる総合的研究. その2, わが国における4高齢者虐待の基礎研究. 月刊地域福祉情報 1995 ; 32 : 200-224.
 
27) 厚生労働省. 「高齢者虐待防止状況」. https://www.mhlw.go.jp/search.html?q=%E9%AB%98%E9%BD%A2%E8%80%85%E8%99%90%E5%BE%85%E9%98%B2%E6%AD%A2%E7%8A%B6%E6%B3%81&cx=005876357619168369638%3Aydrbkuj3fss&cof=FORID%3A9&ie=UTF-8&sa=
 
28) 厚生労働省. 令和2年度「高齢者虐待の防止, 高齢者の養護者に対する支援等に関する法律」に基づく対応状況等に関する考査結果, 資料1, 2. https://www.mhlw.go.jp/content/12304250/000871876.pdf https://www.mhlw.go.jp/content/12304250/000871877.pdf
 
29) 片多順. 長寿のシマ沖縄の高齢者たち. 青柳まちこ (編), 老いの人類学. 世界思想社 ; 2004.
 
Butler RN, Gleason HP (eds). Productive Aging : Enhancing Vitality in Later Life. Springer ; 1985.
 
Butler RN. The Longevity Prescription : The 8 Proven Keys to a Long, Healthy Life. Avery ; 2011.
 
P.424 掲載の参考文献
1) 日本総合研究所. 公的介護保険サービスにおける身許保証等に関する調査研究事業報告書. 2021. https://www.jri.co.jp/MediaLibrary/file/column/opinion/pdf/r1mimoto_report.pdf
 
2) Jeffrey DS. Decision making. Current Biology 2005 ; 15 (1) : 9-11.
 
3) 一般社団法人意思決定支援機構 (監修), 成元迅ほか (編). 実践! 認知症の人にやさしい金融ガイド. クリエイツかもがわ ; 2017.
 
4) Grisso T, Appelbaum PS Assessing Competence to Consent to Treatment ; A Guide for Physicians and Other Health Professionals. Oxford University Press ; 1998/北村總子, 北村俊則 (訳). 治療に同意する能力を測定する-医療・看護・介護・福祉のためのガイドライン. 日本評論社 ; 2000.
 
5) Jennifer M, et al. Neuropsychological Predictors of Decision-Making Capacity over 9 Months in Mild-to-Moderate Dementia. J Gen Intern Med 2006 ; 21 (1) : 78-83.
 
6) 加藤佑佳ほか. 認知機能障害により医療行為における同意能力が問題となった2例-MacCAT-Tを用いた医療同意能力の評価について. 老年精神医学雑誌 2013 ; 24 : 928-936.
Medical*Online
7) Carol AS, Erik JP. Categorization = Decision Making + Generalization. Neurosci Biobehav Rev 2013 ; 37 (7) : 1187-1200.
 
8) Kato Y, et al. Anxiety Impacts Consent Capacity to Treatment in Alzheimer's Disease. Front Psychol 2021 ; 12 : 685430-685430.
PubMed
9) 厚生労働省. 認知症の人の日常生活・社会生活における意思決定支援ガイドライン. 2018. https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/0000212396.pdf
 
10) 飯干紀代子. 1 高齢者のコミュニケーションの特徴. 成本迅ほか (編), 認知症と医療. 勁草書房 ; 2018, pp127-134.
 
成本迅. 認知症の人の医療選択と意思決定支援-本人の希望をかなえる「医療同意」を考える. クリエイツかもがわ ; 2016.
 
成本迅ほか (編). 認知症と医療. 勁草書房 ; 2018.
 
小賀野晶一 (編). 地域生活の支援と公私協働の社会システム. 勁草書房 ; 2022.
 
P.429 掲載の参考文献
1) WHO definition of palliative care. http://www.who.int/cancer/palliative/definition/en//「WHO (世界保健機関) による緩和ケアの定義 (2002) 」定訳 (日本緩和医療学会サイト内). https://www.jspm.ne.jp/proposal/proposal.html
 
2) 日本老年医学会. 高齢者ケアの意思決定プロセスに関するガイドライン-人工的水分・栄養補給の導入を中心として. 2012. https://www.jpn-geriat-soc.or.jp/proposal/pdf/jgs_ahn_gl_2012.pdf
 
3) 池田学. 認知症の症候学と食行動異常. 歯界展望特別号 2017「歯科医療 未来と夢 第23回日本歯科医学会総会」, 50-53.
 
4) American Geriatrics Society. Feeding Tubes in Advanced Dementia Position Statement. 2014. https://doi.org/10.1111/jgs.12924
 
5) Ahronheim JC. Nutrition and hydration in the terminal patient. Clin Geriatr Med 1996 ; 12 : 379-391.
PubMed
6) 日本老年医学会. ACP推進に関する提言. 2019. https://www.jpn-geriat-soc.or.jp/proposal/acp.html
 
7) 厚生労働省. 人生の最終段階における医療・ケアの決定プロセスに関するガイドライン. 2018. https://www.mhlw.go.jp/file/04-Houdouhappyou-10802000-Iseikyoku-Shidouka/0000197702.pdf
 
8) 会田薫子. 延命医療と臨床現場-人工呼吸器と胃ろうの医療倫理学. 東京大学出版会 ; 2011.
 
9) 日本老年医学会. 「高齢者の終末期の医療およびケア」に関する日本老年医学会の「立場表明」2012. 日老医誌 2012 ; 49 : 381-386.
 
10) 会田薫子. 長寿時代の医療・ケア-エンドオブライフの論理と倫理. 筑摩書房 ; 2019.
 
P.439 掲載の参考文献
1) 研究代表者朝田隆. 都市部における認知症有病率と認知症の生活機能障害への対応 (平成21～24年度 厚生労働科学研究費補助金認知症対策総合研究事業).
 
2) 研究代表者二宮利治. 日本における認知症の高齢者人口の将来推計に関する研究 (平成26年度 厚生労働科学研究費補助金特別研究事業).
 
3) 認知症施策推進関係閣僚会議. 令和元年6月18日. 認知症施策推進大綱. https://www.kantei.go.jp/jp/singi/ninchisho_kaigi/pdf/shisaku_taikou.pdf
 
4) 厚生労働省. 認知症ケアパス. https://www.mhlw.go.jp/content/000965198.pdf
 
5) 厚生労働省. 平成30年6月. 認知症の人の日常生活・社会生活における意思決定支援ガイドライン. https://www.city.tsuyama.lg.jp/common/photo/free/files/10931/gaidorain.pdf
 
6) Livingston G, et al. Dementia prevention, intervention, and care : 2020 report of the Lancet Commission. Lancet 2020 ; 396 : 413-446.
PubMed
7) 令和元年度 厚生労働省老人保健健康増進等事業「海外認知症予防ガイドラインの整理に関する調査研究事業」 WHOガイドライン『認知機能低下および認知症のリスク低減』邦訳検討委員会. 認知機能低下および認知症のリスク低減 WHOガイドライン. https://www.jri.co.jp/MediaLibrary/file/column/opinion/detail/20200410_theme_t22.pdf
 
8) 厚生労働省. 認知症施策関連ガイドライン (手引き等), 取組事例. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000167731_00001.html
 
9) 厚生労働省老健局老人保健課. 令和2年度 全国介護保険・高齢者保健福祉担当課長会議資料, p45. https://www.mhlw.go.jp/content/12300000/000750872.pdf
 
10) 厚生労働省. 認知症初期集中支援チーム. https://www.mhlw.go.jp/content/000839130.pdf
 
11) 厚生労働省. 認知症疾患医療センター. https://www.mhlw.go.jp/content/001004956.pdf
 
12) 厚生労働省. 認知症カフェ. https://www.mhlw.go.jp/content/000935275.pdf
 
13) 認知症官民協議会. https://ninchisho-kanmin.or.jp/
 
14) 東京都健康長寿医療センター研究所. <プレスリリース> 「わが国の若年性認知症の有病率と有病者数」. https://www.tmghig.jp/research/release/2020/0727-2.html
 
15) 令和3年度 厚生労働省 老人保健健康増進等事業. 若年性認知症における治療と仕事の両立に関する手引き. https://www.hyogos.johas.go.jp/sanpo/wp-content/uploads/2022/02/r03mhlw_kaigo2021_01.pdf
 
16) 日本医療研究開発機構. 認知症研究開発事業. https://www.amed.go.jp/program/list/14/03/001.html
 
17) J-MINT認知症予防を目指した多因子介入によるランダム化比較研究. https://j-mint.ncgg.go.jp/
 
18) 厚生労働省. 主な認知症施策. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000076236_00006.html#%E8%AA%8D%E7%9F%A5%E7%97%87%E3%82%AB%E3%83%95%E3%82%A7
 
プレス資料「わが国の若年性認知症の有病率と有病者数」. https://www.tmghig.jp/research/release/cms_upload/20200727.pdf
 
厚生労働省. 主な認知症施策. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000076236_00006.html#%E8%AA%8D%E7%9F%A5%E7%97%87%E3%82%AB%E3%83%95%E3%82%A7
 
P.446 掲載の参考文献
1) World Health Organization. Global status report on the public health response to dementia. https://www.who.int/publications/i/item/9789240033245
 
2) GOV.UK. Living Well With Dementia : a national dementia strategy. https://www.gov.uk/government/publications/living-well-with-dementia-a-national-dementia-strategy
 
3) Kmietowicz Z. Cameron launches challenge to end "national crisis" of poor dementia care. BMJ 2012 ; 344 : e2347.
PubMed
4) GOV.UK. Prime Minister's challenge on dementia. https://www.gov.uk/government/publications/prime-ministers-challenge-on-dementia
 
5) GOV.UK. Prime Minister's challenge on dementia 2020. https://www.gov.uk/government/publications/prime-ministers-challenge-on-dementia-2020
 
6) Federation des Centres Memoire. Le 1er plan Alzheimer : 2001-2004. https://www.centres-memoire.fr/le-premier-plan-alzheimer-2001-2004/
 
7) Le gouvernement francais. Plan maladie d'Alzheimer et maladies apparentees 2004-2007. https://solidarites-sante.gouv.fr/IMG/pdf/planalzheimer.pdf
 
8) Rocher P, Lavallart B. Le Plan Alzheimer 2008-2012. Gerontologie et societe 2009 ; 32 : 13-31.
 
9) Le gouvernement francais. Le plan contre les maladies neuro-degeneratives 2014-2019. https://www.gouvernement.fr/action/le-plan-contre-les-maladies-neuro-degeneratives-2014-2019
 
10) Office of the Assistant Secretary for Planning and Evaluation. National Plan to Address Alzheimer's Disease and Other NAPA Documents. https://aspe.hhs.gov/collaborations-committees-advisory-groups/napa/napa-documents
 
11) Howe AL. From states of confusion to a national action plan for dementia care : The development of policies for dementia care in Australia. Int J Geriatr Psychiatry 1997 ; 12 : 165-171.
PubMed
12) Australian Health Ministers' Conference. National Framework for Action on Dementia 2006-2010. https://www.dcnet.gr.jp/retrieve/kaigai/pdf/au09_02NationalFramework.pdf
 
13) Australian Government. National Framework for Action on Dementia 2015-2019. https://www.health.gov.au/resources/publications/national-framework-for-action-on-dementia-2015-2019
 
14) 厚生労働省. G8認知症サミットで宣言並びに共同声明に合意. https://www.mhlw.go.jp/stf/houdou/0000033640.html
 
15) 厚生労働省. 認知症サミット日本後継イベントについて. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000058871.html
 
16) 外務省. G20 OSAKA LEADERS' DECLARATION. https://www.mofa.go.jp/policy/economy/g20_summit/osaka19/en/documents/final_g20_osaka_leaders_declaration.html
 
17) World Health Organization. First WHO ministerial conference on global action against dementia : meeting report, WHO Headquarters, Geneva, Switzerland, 16-17 March 2015. https://apps.who.int/iris/handle/10665/179537
 
18) World Health Organization. Global action plan on the public health response to dementia 2017-2025. https://www.who.int/publications/i/item/global-action-plan-on-the-public-health-response-to-dementia-2017---2025
 
19) World Health Organization. The Global Dementia Observatory (GDO). https://globaldementia.org/en
 
20) World Health Organization. Global status report on the public health response to dementia. https://www.who.int/publications/i/item/9789240033245
 
P.453 掲載の参考文献
1) 渕野勝弘. 老人性認知症疾患センターの果たしてきた役割. 老年精神医学雑誌 2008 ; 19 : 22-28.
Medical*Online
2) 粟田主一. 令和元年度認知症疾患医療センター運営事業実績報告書. 令和2年度老人保健健康増進等事業「認知症疾患医療センターの事業評価および質の管理に関する調査研究事業」報告書. 2020, pp91-218.
 
3) Awata S, et al. Prevalence and subtype distribution of early-onset dementia in Japan. Psychogeriatrics 2020 ; 20 : 817-823.
PubMed
4) 粟田主一. 認知症疾患医療センター運営事業実績調査. 平成28年度老人保健健康増進等事業「認知症疾患医療センターの機能評価に関する調査研究事業」報告書. 2017, pp11-70.
 
5) 内海久美子, 柳渡彩香. 地方における認知症疾患医療センターの活動と課題-北海道認知症疾患医療センターとしての砂川市立病院の取組み. 老年精神医学雑誌 2019 ; 30 (12) : 1335-1343.
Medical*Online
6) 一般社団法人認知症疾患医療センター全国研究会ホームページ. https://dementia-center.info
 
P.459 掲載の参考文献
1) 粟田主一 (編著). 認知症初期集中支援チーム実践テキストブック-DASCによる認知症アセスメントと初期支援. 中央法規出版 ; 2015.
 
2) 厚生労働省. 地域支援事業実施要綱. https://www.mhlw.go.jp/content/12300000/000506705.pdf (accessed 2019-4-26).
 
3) Department of Health, GOV UK. Living Well With Dementia : A national dementia strategy, part of improving care for people with dementia. 2009, pp9-15. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/168220/dh_094051.pdf
 
4) 厚生労働省認知症施策検討プロジェクトチーム. 今後の認知症施策の方向性について. https://www.mhlw.go.jp/stf/shingi/2r9852000002fv2e-att/2r9852000002fv5j.pdf (accessed 2012-6-18).
 
5) 厚生労働省. 認知症施策推進総合戦略 (新オレンジプラン). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000064084.html (accessed 2015-1-15).
 
6) 国立長寿医療研究センター. 認知症初期集中支援チームにおける効果的な活動に関する調査研究事業 (研究代表者 : 鷲見幸彦). 令和2年度老人保健事業推進費等補助金 (老保健健康増進等事業分) 報告書. https://www.ncgg.go.jp/ncgg-kenkyu/documents/R2-3H.pdf
 
7) 鷲見幸彦. 認知症初期集中支援チームについて. 日老医誌 2015 ; 52 : 138-146.
 
8) 池田学 (研究代表者). コロナ感染症蔓延下における精神科医を含む認知症 初期集中支援チームの活動評価と有用性の研究 令和2年度 総括・分担研究報告書. 厚生労働行政推進調査事業費補金. 令和3年 (2021) 3月. https://www.med.osaka-u.ac.jp/pub/psy/news/4a6ed584c5e5b15f68f29b3d26051cdc2c5e2af6.pdf
 
9) 大阪大学大学院医学系研究科精神医学教室. 令和3年度 厚生労働省老健事業「認知症初期集中支援チームが直面している地域における 認知症者にかかる困難事例に関する事例集」. https://www.med.osaka-u.ac.jp/pub/psy/news/ea998a7fa25280ed6946db5d03e64df7456bf9ed.PDF
 
P.463 掲載の参考文献
1) 長谷川典子, 前田潔. 新型コロナウイルス感染症流行下における神戸市の認知症施策. 老年精神医学雑誌 2021 ; 32 (8) : 856-863.
Medical*Online
2) 前田潔, 長谷川典子. 認知症「神戸モデル」-神戸市における認知症ケア施策, 診断助成, 事故救済, 診断後支援. 老年精神医学雑誌 2019 ; 30 (6) : 691-696.
Medical*Online
3) 長谷川和夫, 加藤伸司. 「改訂長谷川式簡易知能評価スケール (HDS-R) 」の手引き-臨床現場における正しい使い方と活かし方. 中央法規出版 ; 2020, pp30-31.
 
4) 粟田主一 (編著). 認知症初期集中支援チーム実践テキストブック-DASCによる認知症アセスメントと初期支援. 中央法規出版 ; 2015, pp306.
 
5) 長谷川典子. 認知症神戸モデルにおける認知症初期集中支援チームの活動. 老年精神医学雑誌 2022 ; 33 (8) : 767-774.
Medical*Online
6) 池田学 (研究代表). コロナ感染症蔓延下における精神科医を含む認知症 初期集中支援チームの活動評価と有用性の研究 令和2年度 総括・分担研究報告書. 厚生労働行政推進調査事業費補金. 令和3年 (2021) 3月. https://www.med.osaka-u.ac.jp/pub/psy/news/4a6ed584c5e5b15f68f29b3d26051cdc2c5e2af6.pdf
 
P.470 掲載の参考文献
1) 道路交通法改正 (平成29年3月12日施行). 高齢運転者交通事故防止対策. https://www.npa.go.jp/koutsuu/kikaku/koureiunten/koureiunntennmatome.html
 
2) 令和2年警察白書 統計資料. https://www.npa.go.jp/hakusyo/r02/data.html
 
3) 平成30年度警察庁事業. 「高齢運転者交通事故防止対策に関する提言」の具体化に向けた調査研究に係る認知機能と安全運転の関係に関する調査研究. https://www.npa.go.jp/koutsuu/kikaku/koureiunten/menkyoseido-bunkakai/cognitivef/cognitivef_report.pdf
 
4) 全日本交通安全協会. 道路交通法の改正ポイント. https://www.jtsa.or.jp/new/koutsuhou-kaisei.html
 
5) 令和2年改正道交法に係る協力依頼について. http://www.yamaguchi.med.or.jp/wp-content/uploads/2021/08/2021ken2_161.pdf
 
6) 日本医師会. かかりつけ医向け認知症高齢者の運転免許更新に関する診断書作成の手引き. モデル診断書様式. http://dl.med.or.jp/dl-med/doctor/ninmen/20170301kaigo_tebiki.pdf, 2017
 
7) 警察庁. 運転免許証の自主返納制度について. https://www.npa.go.jp/policies/application/license_renewal/return_DL.html
 
8) 道路交通法の一部を改正する法律 令和2年法律第42号. https://www.npa.go.jp/laws/kaisei/houritsu/200610/01honnbunn.pdf
 
9) Reger MA. The relationship between neuropsychological functioning and driving ability in dementia : Meta-analysis. Neuropsychology 2004 ; 18 : 85-93.
PubMed
10) Hird MA. A Systematic Review and Meta-Analysis of On Road Simulator and Cognitive Driving Assessment in Alzheimer's Disease and Mild Cognitive Impairment. J Alzheimers Dis 2016 ; 53 : 713-729.
 
11) 上村直人. 痴呆患者の自動車運転の実態と医師の対応. 精神経誌 2005 ; 107 (12) : 1328-1334.
 
12) 上村直人ほか. 認知症医療における課題 11. 認知症の人にとっての運転をやめる難しさ, やめたあとの難しさ. Progress in Medicine 2016 ; 36 (8) : 1051-1057.
 
13) 上村直人ほか. 心理教育的アプローチにより運転中断に成功したアルツハイマー型痴呆患者の一例. 精神科治療学 2002 ; 17 (8) : 1033-1038.
 
14) Chihuri S, et al. Driving Cessation and Health Outcomes in Older Adults. J Am Geriatr Soc 2016 ; 64 (2) : 332-341.
PubMed
15) 警察庁. 改正道路交通法 (高齢運転者対策・第二種免許等の受験資格の見直し) の施行に向けた調査研究 調査研究報告書. 令和3年3月. https://www.npa.go.jp/koutsuu/menkyo/kaisei_doukouhou_r02/final_report.pdf
 
荒井由美子 (執筆代表者). 認知症高齢者の自動車運転を考える 家族介護者のための支援マニュアル 認知症高齢者の安全と安心のために [第二版]. https://www.ncgg.go.jp/ri/topics/documents/cgss5.pdf
 
Fujito R, et al. Comparing the driving behaviours of individuals with frontotemporal lobar degeneration and those with Alzheimer's disease. Psychogeriatrics 2016 ; 16 (1) : 27-33.
PubMed
池田学, 上村直人 (編著). 臨床医のための! 高齢者と認知症の自動車運転. 中外医学社 ; 2018.
 
P.475 掲載の参考文献
1) Etters L, et al. Caregiver burden among dementia patient caregivers : A review of the literature. J Am Acad Nurse Pract 2008 ; 20 (8) : 423-428.
PubMed
2) Cheng ST. Dementia Caregiver Burden : A Research Update and Critical Analysis. Curr Psychiatry Rep 2017 ; 19 (9) : 64.
 
3) Montgomery W, et al. Alzheimer's disease severity and its association with patient and caregiver quality of life in Japan : Results of a community-based survey. BMC Geriatr 2018 ; 18 (1) : 141.
PubMed
4) Schulz R, Beach SR. Caregiving as a risk factor for mortality : The Caregiver Health Effects Study. JAMA 1999 ; 282 (23) : 2215-2219.
PubMed
5) Sallim AB, et al. Prevalence of Mental Health Disorders Among Caregivers of Patients With Alzheimer Disease. J Am Med Dir Assoc 2015 ; 16 (12) : 1034-1041.
PubMed
6) van der Lee J, et al. Multivariate models of subjective caregiver burden in dementia : A systematic review. Ageing Res Rev 2014 ; 76-93.
PubMed
7) Soltys A, et al. The Moderating Effects of Personal Resources on Caregiver Burden in Carers of Alzheimer's Patients. Front Psychiatry 2021 ; 12 : 772050.
PubMed
8) Koyama A, et al. Caregiver Burden in Semantic Dementia with Right- and Left-Sided Predominant Cerebral Atrophy and in Behavioral-Variant Frontotemporal Dementia. Dement Geriatr Cogn Dis Extra 2018 ; 8 (1) : 128-137.
PubMed
9) Arai Y, et al. Reliability and validity of the Japanese version of the Zarit Caregiver Burden Interview. Psychiatry Clin Neurosciences 1997 ; 51 : 281-287.
 
10) 博野信次ほか. 痴呆患者の介護の負担-日本語版Zarit Caregiver Burden Interviewによる検討. 脳神経 1998 ; 50 : 561-567.
 
11) 荒井由美子ほか. Zarit 介護負担尺度日本語版の短縮版 (J-ZBI_8) の作成-その信頼性と妥当性に関する検討. 日本老年医学会雑誌 2003 ; 40 : 497-503.
 
12) Herbert R, et al. Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Canadian Journal on Aging 2000 ; 19 : 494-507.
 
13) 加藤伸司. 家族介護の視点から. 認知症の予防とケア. 長寿科学振興財団 ; 2019, pp295-303.
 
14) 敷井裕光ほか. BPSDケアの現状. 老年精神医学雑誌 2020 ; 31 (増刊号) : 78-83.
 
15) 敷井裕光. BPSDケアの課題と現状. 認知症の最新医療 2020 ; 10 (4) : 170-175.
 
16) Yu DSF, et al. Unravelling positive aspects of caregiving in dementia : An itegrative review of research literature. Int J Nurs Stud 2018 ; 79 : 1-26.
 
17) Tarlow BJ, et al. Positive Aspects of Caregiving : Contributions of the REACH Project to the Development of New Measures for Alzheimer's Caregiving. Res Aging 2004 ; 26 : 429-453.
 
Lawton MP, et al. Measuring caregiving appraisal. J Gerontol 1989 ; 44 (3) : 61-71. doi : 10.1093/geronj/44.3.p61.
 
色本涼ほか. 認知症家族介護者に対する集団認知行動療法-日本版START (家族のための戦略) プログラム. 老年精神医学雑誌 2020 ; 31 (4) : 346-353.
Medical*Online
扇澤史子, 黒川由紀子. 家族介護者の認知症を受け止める心理プロセスと介護負担感, 介護肯定感との関連性についての文献的考察. 上智大学心理学年報 2010 ; 34 : 73-87.
 
P.481 掲載の参考文献
1) 内海久美子. 認知症疾患医療センターにおける認知症診療. 精神医学 2021 ; 63 (8) : 1213-1220.
 
2) 多賀努. 若年性認知症の本人・家族の視点を政策に反映することの重要性と本人発意の政策形成の課題. 精神医学 2020 ; 62 (11) : 1517-1525.
 
3) クリスティ－ン・ボーデン (著), 檜垣陽子 (訳). 私は誰になっていくの? -アルツハイマー病者からみた世界. クリエイツかもがわ ; 2003.
 
4) 若年認知症家族会・彩星の会 (編), 宮永和夫 (編集代表). 若年性認知症-本人・家族が紡ぐ7つの物語. 中央法規 ; 2006.
 
5) 粟田主一. わが国における若年性認知症の有病率と生活実態調査. 精神医学 2020 ; 62 (11) : 1429-1444.
 
6) 私たちの日々をつづる. 北海道若年性認知症の人と家族の会 ; 2021.
 
7) 矢吹知之ほか (編). 認知症とともにあたりまえに生きていく. 中央法規 ; 2021.
 
8) 金圓景. 若年性認知症家族会の意義と課題. 日本認知症ケア学会誌 2020 ; 18 (4) : 820-829.
Medical*Online
9) 就労中に若年性認知症の診断をうけたら-若年性認知症の人の「はたらく」と「社会参加」を支えるために. 北海道若年性認知症の人と家族の会 ; 2022.
 
P.485 掲載の参考文献
1) DLBSNについて. レビー小体型認知症サポートネットワーク. http://dlbsn.org/aboutus.html 2022年3月30日アクセス
 
2) 認知症関係当事者・支援者連絡会議. https://ninchisho-renrakukai.com/ 2022年3月30日アクセス
 
3) Manabe Y, et al. Lewy body dementia in Japan. International Lewy Body Dementia Conference USA 2019. 6. 25.
 
P.490 掲載の参考文献
内閣官房 認知症施策推進関係閣僚会議「認知症施策推進大綱」 (2019). https://www.mhlw.go.jp/content/12300000/000519434.pdf
 
多世代・地域交流の図書館プロジェクト. https://www.facebook.com/dementia.friendly.libraries.in.kansai (2022年2月15日閲覧)
 
川崎市総務企画局「川崎市総合計画 第2期実施計画」 (2020). http://www.city.kawasaki.jp/170/cmsfiles/contents/0000096/96459/sokei2-0soron.pdf
 
P.502 掲載の参考文献
1) Schicktanz S. If dementia prevention is the answer, what was the question? : Observations from the German Alzheimer's debate. In : Leibing A, et al (eds). Preventing dementia? : Critical perspectives on the new paradigm of preparing for old age. Berghahn Books ; 2020, p66.
 
2) 北中淳子. 高齢者倫理 新健康主義 : 日本での認知症予防論争をめぐって. 現代思想 2019 ; 47 (12) : 151-160.
 
3) Leibing A. Situated Prevention : Framing the "New Dementia". J Law Med Ethics 2018 ; 46 (3) : 704-716.
PubMed
4) Cohen L. No aging in India : Alzheimer's, the Bad Family, and other modern things. University of California Press ; 2000.
 
5) Lupton D. Data selves : More-than-human perspectives. Polity Press ; 2020.
 
6) 木之下徹. 認知症の人が「さっきも言ったでしょ」と言われて怒る理由-5000人を診てわかったほんとうの話. 講談社 ; 2020.
 
7) ロック M (著), 坂川雅子 (訳). アルツハイマー病の謎-認知症と老化の絡まり合い. 名古屋大学出版会 ; 2018.
 
8) Leibing A. The turn towards prevention : Moral narratives and the vascularization of Alzheimer's disease. New Genet Soc 2020 ; 39 (1) : 31-51.
 
9) 松下正明. MCIとプレクリニカルAD概念の「いかがわしさ」. 老年精神医学雑誌 2016 ; 27 (6) : 660-665.
Medical*Online
10) Sivaramakrishnan K. As the world ages : Rethinking a demographic crisis. Harvard University Press ; 2018.
 
11) Schicktanz S. If dementia prevention is the answer, what was the question? : Observations from the German Alzheimer's debate. In : Leibing A, et al (eds). Preventing dementia? : Critical perspectives on the new paradigm of preparing for old age. Berghahn Books ; 2020, p76.
 
12) Schweda M, Pfaller L. Responsibilization of aging? : An ethical analysis of the moral economy of prevention. In : Leibing A, et al (eds). Preventing dementia? : Critical perspectives on the new paradigm of preparing for old age. Berghahn Books ; 2020, p193.
 
13) Moreira T. Revisiting MCI : On classificatory drift. In : Leibing A, et al (eds). Preventing dementia? : Critical perspectives on the new paradigm of preparing for old age. Berghahn Books ; 2020, pp146-147.
 
14) Schweda M, Pfaller L. Responsibilization of aging? : An ethical analysis of the moral economy of prevention. In : Leibing A, et al (eds). Preventing dementia? : Critical perspectives on the new paradigm of preparing for old age. Berghahn Books ; 2020, pp70-72.
 
15) Dutch euthanasia case : Doctor acted in interest of patient, court rules [Internet]. BBC ; 2019 Sept 11 [cited 2020 Dec 13]. Available from : https://www.bbc.com/news/world-europe-49660525
 
16) 北中淳子. 自殺の医療人類学-生きづらさへの文化的視点. 精神医学 2020 ; 63 (7) : 1063-1072.
 
17) 中島紀恵子. 新版, 認知症の人々の看護. 医歯薬出版 ; 2013.
 
18) ハッキング I (著), 出口康夫, 久米暁 (訳). 何が社会的に構成されるのか. 岩波書店 ; 2006.
 
19) McLean A. The person in dementia : A study in nursing home care in the US. Broadview Press ; 2007.
 
20) 生井久美子. ルポ 希望の人びと ここまできた認知症の当事者発信. 朝日選書 ; 2017.
 
21) 松田実. 認知症を関係性の障害という視点からどう語れるか. 木之下徹 (編), 認知症医療. 中山書店 ; 2014, p29.
 
22) 六車由実. 驚きの介護民俗学. 医学書院 ; 2012.
 
23) Leibing A, et al (eds). Thinking about dementia : Culture, loss, and the anthropology of senility. Rutgers University Press ; 2006.
 
24) 出口泰靖. なんてわかりやすい人たち (インタビュー) /具体の人, 小澤勲. 小澤勲 (編著), ケアってなんだろう. 医学書院 ; 2006, p179.
 
25) 丹野智文. 認知症の私から見える社会. 講談社 ; 2021.
 
26) Brijnath B. Unforgotten : Love and the culture of dementia care in India. Berghahn Books ; 2014.
 
27) 山崎英樹. 認知症の人の体験からみる症候学. 木之下徹 (編), 認知症医療. 中山書店 ; 2014, p5.
 
28) 鈴木大介. 「脳コワさん」支援ガイド. 医学書院 ; 2020.
 
29) Kitanaka J. In the mind of dementia : Neurobiological empathy, incommensurability, and the dementia tojisha movement in Japan. Med Anthropol Q 2020 ; 34 (1) : 119-135.
PubMed
30) Luhrmann T, et al. Differences in voice-hearing experiences of people with psychosis in the USA, India and Ghana : Interview-based study. Br J Psychiatry 2015 ; 206 (1) : 41-44.
PubMed
31) 真喜屋浩. 沖縄の一農村における精神疾患に関する疫学的研究. 慶應医学 1978 ; 5 (6) : 503-512.
 
32) 大井玄. 「痴呆老人」は何を見ているか. 新潮社 ; 2008.
 
33) 神庭重信. 精神科領域におけるギャップの克服をめざして. 精神神経学雑誌 2021 ; 123 (7) : 387-387.
 
34) 笠井清登 (代表). 文部科学省科学研究費補助金・学術変革領域研究「当事者化」人間行動科学 相互作用する個体脳⇔世界の法則性/物語性の理解. 2021.
 
35) 山崎英樹. 認知症ケアの知好楽-神経心理学からスピリチュアルケアまで. 雲母書房 ; 2011.
 
36) 池田学. 認知症者のコミュニケーション. 高次脳機能研究 2015 ; 35 (3) : 292-296.
 
37) ユクスキュル J, クリサート G (著), 日高敏隆, 羽田節子 (訳). 生物から見た世界. 岩波書店 ; 2005.
 
38) Ballenger JF. The biomedical deconstruction of senility and the persistent stigmatization of old age in the United States. In : Leibing A, et al (eds). Thinking about dementia. Rutgers University Press ; 2006.
 
39) Lemos Dekker N. Anticipating an unwanted future : Euthanasia and dementia in the Netherlands. J R Anthropol Inst 2021 ; 27 : 815-831.
 
ロック M (著), 坂川雅子 (訳). アルツハイマー病の謎-認知症と老化の絡まり合い. 名古屋大学出版会 ; 2018.
 
井口高志. 認知症社会の希望はいかにひらかれるのか-ケア実践と本人の声をめぐる社会学的探求. 晃洋書房 ; 2020.
 
筧裕介 (著), 認知症未来共創ハブほか (監修). 認知症世界の歩き方-認知症のある人の頭の中をのぞいてみたら? ライツ社 ; 2021.
 
熊谷晋一郎. 当事者研究-等身大の <わたし> の発見と回復. 岩波書店 ; 2020.
 

7章 ICD - 11における統合失調症以外の一次性精神症群

P.513 掲載の参考文献
1) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
2) Marneros A, Tsuang MT. Schizoaffective Disorders : Present level and future perspectives. In : Marneros A, et al (eds). Schizoaffective Psychoses. Springer ; 1986.
 
3) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
4) Pope HG, Lipinski JF. Diagnosis in schizophrenia and depressive illness. Arch Gen Psychiatry 1978 ; 35 : 811-828.
PubMed
5) Kendler KS. Mood-incongruent psychotic affective illness. Arch Gen Psychiatry 1991 ; 48 : 362-369.
PubMed
6) Kendell RE, Brockington IF. The identification of disease entities and the relationship between schizophrenic and affective psychoses. Br J Psychiatry 1980 ; 137 : 324-331.
PubMed
7) Marneros A. Schizoaffective disorder : Clinical aspects, differential diagnosis, and treatment. Curr Psychiatry Rep 2003 ; 5 : 202-205.
PubMed
8) Perris C, Brockington IF. Cycloid psychoses and their relation to the major psychoses. In : Perris C, et al (eds). Biological psychiatry. Elsevier ; 1981, pp447-450.
 
9) Pull CB, et al. Nosological position of schizo-affective psychosis in France. Psychiatr Clin (Basel) 1983 ; 16 : 141-148.
PubMed
10) Wimmer A. Psykogene Sindssygdomsformer. In Sct. Hans Hospital 1816-1915, Jubilaeums-skrift (Kobenhaven : Gad), 1916 ; 85-216 ; edited and translated by J. Schioldann as Psychogenic Psychoses (Burnside : Adelaide Academic Press, 2003).
 
11) 須賀英道. 非定型精神病の新しい診断基準-その意義と成立までの経過. 最新精神医学 2013 ; 18 : 301-305.
 
12) Spitzer RL, Williams JBW. Classification in psychiatry. In : Kaplan HI, et al (eds). Comprehensive Textbook of Psychiatry, 3rd edition. Williams & Wilkins ; 1980.
 
13) Tandon R, Maj M. Nosological status and definition of schizophrenia. Some considerations for DSM-V and ICD-11. Asian J Psychiatry 2008 ; 1 : 22-27.
 
14) Janzarik W. Die nosologishe Differenzierung der idiopathishen Psychosyndrome : Ein psychiatrisher Sisphus-Mythos. Nervenarzt 1989 ; 60 : 86-89.
PubMed
Angst J. The course of schizoaffective disorders. In : Marneros A, et al (eds). Schizoaffective Psychoses. Springer ; 1986.
 
P.520 掲載の参考文献
1) 浅井智久ほか. 統合失調症型パーソナリティと統合失調症の連続性. Japanese psychological Review 2010 ; 53 (2) : 240-261.
 
2) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text revision (DSM-IV-TR). APA ; 2000, pp697-701.
PubMed
3) Perris F, et al. Comorbidity of obsessive-compulsive disorder and schizotypal personality disorder : Clinical response and treatment resistance to pharmacotherapy in a 3-year follow-up naturalistic study. Front Psychiatry 2019 ; 10 : 386. doi : 10.3389/fpsyt.2019.00386.
 
4) Pulay AJ, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder : Results from the wave 2 national epidemiologic survey on alcohol and related conditions. Prim Care Companion J Clin Psychiatry 2009 ; 11 : 53-67.
PubMed
5) Reynolds K, et al. Prevalence of psychiatric disorders in U.S. older adults : Findings from a nationally representative survey. World Psychiatry 2015 ; 14 (1) : 74-81.
PubMed
6) Oltmanns TF, et al. Prevalence of personality disorders at midlife in a community sample : Disorders and symptoms reflected in interview, self, and informant reports. J Psychopathol Behav Assess 2014 ; 36 : 177-188.
 
7) Courtois R, et al. Exploratory study toward development of the French version of the questionnaire on personality traits (QPT/VKP-4) in an elderly population in comparison to young adults. Psychol Rep 2014 ; 115 (1) : 115-132.
 
8) Livesley WJ, et al. Dimentions of personality disorder. The DSM-III-R cluster A diagnoses. J Nerv Ment Dis 1990 ; 178 (10) : 627-635.
 
9) 杉原玄一. DSM-5の診断基準 第1章 概念と疫学. 最新医学 別冊 診断と治療のABC136 統合失調症. 最新医学社 ; 2018.
 
10) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. APA ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
11) Vaglum P, et al.Comparison between personality disorder diagnoses in DSM-III and DSM-III-R : Reliability, diagnostic overlap, predictive validity. Psychopathology 1989 ; 22 : 309-314.
PubMed
12) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
13) Rosell DR, et al. Schizotypal personality disorder : A current review. Curr Psychiatry Rep 2014 ; 16 (7) : 452.
PubMed
14) Sobin C, et al. Evidence of a schizotypy subtype in OCD. J Psychiatr Res 2000 ; 34 : 15-24.
PubMed
15) 加藤敏ほか (編). 現代精神医学事典. 弘文堂 ; 2011.
 
16) 宮岡等, 小川陽子. 教育講演 大人の発達障害と精神疾患の鑑別と合併-その意義. 心身医 2019 ; 59 (5) : 416-421.
 
17) Raine A. The SPQ : A scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991 ; 17 : 555-564.
PubMed
18) Raine A, et al. The SPQ-B : A brief screening instrument for schizotypal personality disorder. J Personal Disord 1995 ; 9 : 346-355.
 
19) 鈴木道雄ほか. 統合失調症-脳画像研究からみた発症脆弱性と統合失調症型障害における顕在発症防御機構. 臨床精神医学 2008 ; 37 (4) : 377-384.
 
20) Suzuki M. Differential contributions of prefrontal and temporolimbic pathology to mechanisms of psychosis. Brain 2005 ; 128 : 2109-2122.
PubMed
21) Takahashi T, et al. Morphologic alterations of the parcellated superior temporal gyrus in schizophrenia spectrum. Schizophr Res 2006 ; 83 : 131-143.
PubMed
22) 鈴木道雄. 脳画像からみた統合失調症の顕在発症防御機構. 加藤敏ほか (編). レジリアンス-現代精神医学の新しいパラダイム. 金原出版 ; 2009, pp165-185.
 
23) Takayanagi Y, et al. Reduced Cortical Thickness in Schizophrenia and Schizotypal Disorder. Schizophr Bull 2020 ; 46 (2) : 387-394.
PubMed
24) Koenigsberg HW, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003 ; 64 : 628-634.
PubMed
25) Rabella M, et al. Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. Neuroimage Clin 2016 ; 11 : 770-779.
PubMed
26) Rybakowski JK, et al. Low dose risperidone in the treatment of schizophrenia-like symptoms in high-risk subjects. J Clin Psychopharmacol 2003 ; 23 : 674-675.
PubMed
27) McClure MM, et al. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. J Clin Psychopharmacol 2009 ; 29 : 396-398.
PubMed
28) Keshavan M, et al. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 2004 ; 71 : 97-101.
PubMed
29) Di Lorenzo R, et al. Aripiprazole : Effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol 2007 ; 15 : 569-575.
PubMed
30) Baer L, et al. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1992 ; 49 : 862-866.
PubMed
31) Bogetto F, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD) : A 12-week open trial. Psychiatry Res 2000 ; 96 : 91-98.
PubMed
32) Poyurovsky M. Clozapine in treatment-refractory obsessive-compulsive disorder with comorbid schizotypal personality disorder. Isr J Psychiatry Relat Sci 2008 ; 45 : 219-220.
PubMed
33) Markovitz PJ, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991 ; 148 : 1064-1067.
PubMed
34) Gutkovich Z, et al. Transient psychosis with psycho- genic polydipsia in schizotypal patient taking fluoxetine. Psychosomatics 1998 ; 39 : 295-296.
 
35) Kirchner SK, et al. Diagnosis and treatment of schizotypal personality disorder : Evidence from a systematic review. PJ Schizophr 2018 ; 4 (1) : 20. doi : 10.1038/s41537-018-0062-8.
 
36) Karterud S, et al. Day hospital therapeutic community treatment for patients with personality disorders. An empirical evaluation of the containment function. J Nerv Ment Dis 1992 ; 180 : 238-243.
PubMed
37) McKay D, et al. Social skills training in a case of obsessive-compulsive disorder with schizotypal personality disorder. J Behav Ther Exp Psychiatry 1996 ; 27 : 189-194.
 
38) McGlashan TH, et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders : Toward a hybrid model of axis II disorders. Am J Psychiatry 12005 ; 62 : 883-889.
 
39) Nordentoft M, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006 ; 83 : 29-40.
 
40) Mehlum L, et al. Personality disorders 2-5 years after treatment : A prospective follow-up study. Acta Psychiatr Scand 1991 ; 84 : 72-77.
PubMed
41) Bender DS, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001 ; 158 : 295-302.
PubMed
42) Raine A. Schizotypal personality : Neurodevelopmental and psychosocial trajectories. Annu Rev Clin Psychol 2006 ; 2 : 291-326.
PubMed
43) Woods SW, et al. Validity of the prodromal risk syndrome for first psychosis : Findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009 ; 35 : 894-908.
PubMed
44) Debbane M, et al. Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull 2015 ; 41 (Suppl 2) : S396-S407.
 
45) Fenton WS, et al. Risk of schizophrenia in character disordered patients. Am J Psychiatry 1989 ; 146 : 1280-1284.
PubMed
46) Hjorthoj C, et al. Association of Substance Use Disorders With Conversion From Schizotypal Disorder to Schizophrenia. JAMA Psychiatry 2018 ; 75 (7) : 733-739.
PubMed
47) Carrion RE, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 2013 ; 70 : 1133-1142.
PubMed
48) Addington J, et al. At clinical high risk for psychosis : Outcome for nonconverters. Am J Psychiatry 2011 ; 168 : 800-805.
PubMed
49) Matsui M, et al. Schizotypal disorder and schizophrenia : A profile analysis of neuropsychological functioning in Japanese patients. J Int Neuropsychol Soc 2007 ; 13 (4) : 672-682.
PubMed
50) McClure MM, et al. Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. Schizophr Res 2013 ; 144 : 146-150.
PubMed
51) McGurk SR, et al. Vocational functioning in schizotypal and paranoid personality disorders. Psychiatry Res 2013 ; 210 : 498-504.
PubMed
52) Canal-Rivero M, et al. Understanding the Influence of Personality Traits on Risk of Suicidal Behaviour in Schizophrenia Spectrum Disorders : A Systematic Review. J Clin Med 2021 ; 10 (19) : 4604.
 
53) Sher L. Schizotypal personality disorder and suicide : Problems and perspectives. Acta Neuropsychiatrica 2021 ; 33 (5) : 280-282. doi : https://doi.org/10.1017/neu.2021.19
 
54) Burch GS, et al. Schizotypy and creativity in visual artists. Br J Psychiatry 2006 ; 97 : 177-190.
 
55) Segal DL, et al. The odd and eccentric (cluster A) personality disorders and aging. In : Personality Disorders and Older Adults : Diagnosis, Assessment, and Treatment. John Wiley & Sons ; 2006, pp23-54.
 
56) Clark AN, et al. Diogenes syndrome. A clinical study of gross neglect in old age. Lancet 1975 ; 1 (7903) : 366-368.
PubMed
57) Rosenthal M, et al. Diogenes syndrome and hoarding in the elderly : Case reports. Isr J Psychiatry Relat Sci 1999 ; 36 (1) : 29-34.
PubMed
Rosell DR, et al. Schizotypal personality disorder : A current review. Curr Psychiatry Rep 2014 ; 16 (7) : 452.
PubMed
Takayanagi Y, et al. Reduced Cortical Thickness in Schizophrenia and Schizotypal Disorder. Schizophr Bull 2020 ; 46 (2) : 387-394.
PubMed
P.531 掲載の参考文献
1) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
2) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostical Guidelines. World Health Organization, 1994/融道男ほか (監訳). ICD-10 精神および行動の障害-臨床記述と診断ガイドライン, 新訂版. 医学書院 ; 2005.
 
3) 針間博彦. Psychosis -「精神病」から「精神症」へ. 精神経誌 2021 ; 123 (5) : 294.
 
4) Pichot P. The Concept of 'Bouffee delirante' with Special Reference to the Scandinavian Concept of Reactive Psychosis. Psychopathology 1986 ; 19 : 35-43.
 
5) Leonhard K. Classification of endogenous psychoses and their differentiated etiology, 2nd, rev. and enlarged edition. Springer ; 1999.
 
6) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders ; Diagnostic criteria for research. World Health Organization ; 1993/中根允文ほか (訳). ICD-10 精神および行動の障害-DCR研究用診断基準, 新訂版. 医学書院 ; 2008.
 
7) Stromgren E. Reactive (psychogenic) psychoses and their relations to schizoaffective psychoses. In : Marneros A, et al (eds). Schizoaffective Psychoses. Springer ; 1986, pp260-271.
 
8) 林拓二 (編著). 非定型精神病-内因性精神病の分類と診断を考える. 新興医学出版社 ; 2008.
 
9) 厚生省精神保健医療研究「精神疾患の診断基準の作成に関する研究」班. JCM第5版. 1992.
 
10) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. American Psychiatric Association ; 2013.
 
11) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition. American Psychiatric Association ; 1980.
 
12) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Association ; 1994.
 
13) Langfeldt G. The Schizophreniform State. Munksgaad ; 1939.
 
Marneros M, Pillmann F. Acute and transient psychoses. Cambridge University Press ; 2004/米田博 (監訳). 急性一過性精神病. アルタ出版 ; 2012.
 
針間博彦. 急性一過性精神症. 精神科治療学 2021 ; 36 (増刊号) : 40-41.
 
P.537 掲載の参考文献
1) Winokur G. Delusional disorder (paranoia). Compr Psychiatry 1977 ; 18 (6) : 511-521.
PubMed
2) Gelder M, et al. Shorter Oxford Textbook of Psychiatry, 4th edition. Oxford University Press ; 2001.
 
3) Kraepelin E. Psychiatrie : ein Lehrbuch fur Studirende und Aerzte. J.A. Barth ; 1896/内沼幸雄ほか (訳). パラノイア論. 医学書院 ; 1976.
 
4) 濱田秀伯. 精神病理学臨床講義. 弘文堂 ; 2002.
 
5) Kraepelin E. Psychiatrie ; Ein Lehrbuch Fur Studierende und Arzte. 1913/内沼幸雄ほか (訳). パラノイア論. 医学書院 ; 1976.
 
6) Lange J. Die Paranoiafrage. Deuticke ; 1927/内沼幸雄ほか (訳). パラノイア論. 医学書院 ; 1976.
 
7) Lewis A. Paranoia and paranoid : A historical perspective. Psychol Med 1970 ; 1 (1) : 2-12.
PubMed
8) Munro A. Monosymptomatic hypochondriacal psychosis. Br J Psychiatry Suppl 1988 ; (2) : 37-40.
PubMed
9) Jaspers K. Allgemeine Psychopathologie, ein Leitfaden fur Studierende, Arzte und Psychologen. J. Springer ; 1913/西丸四方 (訳). 精神病理学原論. みすず書房 ; 1971.
 
10) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders : DSM-5. American Psychiatric Association ; 2013.
 
11) Verma R, et al. Neuroimaging Findings in US Government Personnel With Possible Exposure to Directional Phenomena in Havana, Cuba. JAMA 2019 ; 322 (4) : 336-347.
PubMed
12) Huq SF, et al. Probabilistic Judgements in Deluded and Non-Deluded Subjects. Q J Exp Psychol Sect A 1988 ; 40 (4) : 801-812.
 
13) Garety PA, et al. Reasoning in deluded schizophrenic and paranoid patients. Biases in performance on a probabilistic inference task. J Nerv Ment Dis 1991 ; 179 (4) : 194-201.
PubMed
14) World Health Organization. ICD-11 Browser <Version : 02/2022>. https://icd.who.int/browse11/l-m/en
 
15) Cermolacce M, et al. What is Bizarre in Bizarre Delusions? A Critical Review. Schizophr Bull 2010 ; 36 (4) : 667-679.
PubMed
16) Pryse-Phillips W. An Olfactory Reference Syndrome. Acta Psychiatr Scand 1971 ; 47 (4) : 484-509.
PubMed
17) Suzuki K, et al. Do olfactory reference syndrome and Jiko-shu-kyofu (a subtype of Taijin-kyofu) share a common entity? Acta Psychiatr Scand 2004 ; 109 (2) : 150-155.
 
18) Thomas E, et al. Olfactory Reference Disorder : Diagnosis, Epidemiology and Management. CNS Drugs 2015 ; 29 (12) : 999-1007.
PubMed
19) Begum M, McKenna PJ. Olfactory reference syndrome : A systematic review of the world literature. Psychol Med 2011 ; 41 (3) : 453-461.
PubMed
20) Krebs G, et al. Recent advances in understanding and managing body dysmorphic disorder. Evid Based Ment Health 2017 ; 20 (3) : 71-75.
PubMed
21) McPhie ML, Kirchhof MG. A systematic review of antipsychotic agents for primary delusional infestation. J Dermatol Treat 2022 ; 33 : 709-721.
 
22) Consortium TB, et al. Analysis of shared heritability in common disorders of the brain. Science 2018 ; 360 (6395) : eaap8757.
 
23) Insel TR, Cuthbert BN. Medicine. Brain disorders? Precisely. Science 2015 ; 348 (6234) : 499-500.
PubMed
24) Clementz BA, et al. Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers. Am J Psychiatry 2016 ; 173 (4) : 373-384.
PubMed
Huq SF, et al. Probabilistic Judgements in Deluded and Non-Deluded Subjects. Q J Exp Psychol A 1988 ; 40 (4) : 801-812.
PubMed
Garety PA, et al. Reasoning in deluded schizophrenic and paranoid patients. Biases in performance on a probabilistic inference task. J Nerv Ment Dis 1991 ; 179 (4) : 194-201.
PubMed
Phillips LD, Edwards W. Conservatism in a simple probability inference task. J Exp Psychol 1966 ; 72 (3) : 346.
 
Moritz S, Woodward TS. A generalized bias against disconfirmatory evidence in schizophrenia. Psychiatry Res 2006 ; 142 (2-3) : 157-165.
 
National Institute of Mental Health. RDoC Matrix. https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/constructs/rdoc-matrix
 
P.546 掲載の参考文献
1) Jesse S, et al. Alcohol withdrawal syndrome : Mechanisms, manifestations, and management. Acta Neurol Scand 2017 ; 135 : 4-16.
PubMed
2) 高橋宏. 症状 アルコール嗜癖・中毒. 懸田克躬ほか (編), <現代精神医学大系> 15B 薬物依存と中毒 II. 中山書店 ; 1977, pp71-89.
 
3) Srisurapanont M, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 2003 ; 6 (4) : 347-352.
PubMed
4) 加藤伸勝. 薬物依存-生物・心理・社会性障害の視点から. 新興医学出版社 ; 1993.
 
5) 小沼杏坪. 覚せい剤依存症の治療. 福居顯二 (責任編集), <専門医のための精神科臨床リュミエール> 26. 依存症・衝動制御障害の治療. 中山書店 ; 2011, pp98-110.
 
6) 覚せい剤中毒者対策に関する専門家会議 (座長 : 加藤伸勝) : 昭和60年度覚せい剤中毒者総合対策研究報告書. 1986.
 
7) Connell PH. Amphetamine Psychosis. Chapman and Hall Ltd ; 1958.
 
8) 田所作太郎ほか. 覚せい剤依存症. 中外医学社 ; 1983.
 
9) 立津政順ほか. 覚醒剤中毒者9人の30年後. 精神医学 1997 ; 39 : 1035-1043.
 
10) Guerin AA, et al. Cognition and Related Neural Findings on Methamphetamine Use Disorder : Insights and Treatment Implications From Schizophrenia Research. Front Psychiatry 2019 ; 10 : 880.
PubMed
11) Hedges DM, et al. Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway. Neuropsychopharmacology 2018 ; 43 : 1405-1414.
PubMed
12) Luby E, et al. Study of a new schizophrenomimetic drug-Sernyl. Arch Nerol Psychiat 1959 ; 81 : 363-369.
 
13) Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 1987 ; 9 : 12-35.
PubMed
14) 樹神学. Sernyl [1- (1-phenylcyclohexyl) piperidine・HCl] による実験的精神障碍の研究. 精神経誌 1964 ; 66 : 781-800.
 
15) Anis NA, et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983 ; 79 : 565-575.
 
16) 大月三郎. 総論 症状. 懸田克躬ほか (編), <現代精神医学大系> 14. 症状精神病. 中山書店 ; 1976, pp3-36.
 
17) 石田明史ほか. 器質性精神障害に関する臨床的課題. 京都市立病院紀要 2017 ; 37 (2) : 172-176.
 
18) 兼本浩祐, 長谷川裕記. 通過症候群. 臨床精神医学 2015 ; 44 (2) : 155-161.
Medical*Online
19) 池村義明. 原点に帰って原典を読む-症例を中心に 外因性精神病の成立 (その1) Karl Ludwig Bonhoeffer (1868-1948) による外因反応型 (Die exogenen Reaktionstypen) (1908, 1910, 1912) の記述-その後の症候性精神病 (symptomatische Psychosen) 概念の変遷と発展. 精神科治療学 2003 ; 18 (11) : 1347-1354.
 
20) Stauder KH. Die todliche Katatonie. Arch Psychiatr 1934 ; 102 : 614.
 
21) Dalmau J, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011 ; 10 (1) : 63-74.
PubMed
22) Steiner J, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia : Specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013 ; 70 (3) : 271-278.
 
23) Al-Diwani A, et al. The psychopathology of NMDAR-antibody encephalitis in adults : A systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019 ; 6 (3) : 235-246.
PubMed
池村義明. 原点に帰って原典を読む-症例を中心に 外因性精神病の成立 (その1) Karl Ludwig Bonhoeffer (1868-1948) による外因反応型 (Die exogenen Reaktionstypen) (1908, 1910, 1912) の記述-その後の症候性精神病 (symptomatische Psychosen) 概念の変遷と発展. 精神科治療学 2003 ; 18 (11) : 1347-1354.
 
山下格. 誤診のおこるとき-精神科診断の宿命と使命 [新装版]. みすず書房 ; 2021.
 
原田憲一. 意識障害を診わける (精神科選書 2) 改訂版. 診療新社 ; 1997.
 
P.553 掲載の参考文献
1) Kahlbaum KL. Die Katatonie oder das Spannungsirresein : Eine klinische Form psychischer Krankheit. Verlag August Hirshwald ; 1874/渡辺哲夫 (訳). 緊張病. 星和書店 ; 1979.
 
2) Fink M, Taylor MA. Catatonia : A Clinician's Guide to Diagnosis and Treatment. Cambridge University Press ; 2003/鈴木一正 (訳). カタトニア-臨床医のための診断・治療ガイド. 星和書店 ; 2007.
 
3) Kraepelin E. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte. 6 Auf. Verlag von Johann Ambrosius Barth ; 1899.
 
4) 針間博彦, 古茶大樹. Kraepelinの緊張病-統合失調症の一臨床形態としての緊張病, 臨床精神医学 2009 ; 38 (6) : 765-774.
Medical*Online
5) Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Franz Deutike ; 1911.
 
6) American Psychiatric Association. Diagnostic and Statistical Manual : Mental Disorders. American Psychiatric Association ; 1952.
 
7) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition, Revised. American Psychiatric Association ; 1987.
 
8) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders : Clinical descriptions and diagnostic guidelines. World Health Organization ; 1992.
 
9) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association ; 1994.
 
10) Tandon R, et al. Catatonia in DSM-5. Schizophr Res 2013 ; 150 : 26-30.
PubMed
11) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. American Psychiatric Association ; 2013.
 
12) Fink M. Rediscovering catatonia : The biography of a treatable syndrome. Acta Psychiatr Scand 2013 ; 127 (Suppl. 441) : 1-50.
 
13) Ungvari G, et al. The catatonia conundrum : evidence of psychomotor phenomena disorders. Schizophr Bull 2010 ; 36 : 231-238.
PubMed
14) World Health Organization. ICD-11 for Mortality and Morbidity Statistics (ICD-11 MMS) 02/2022 version. https://icd.who.int/browse11/l-m/en
 
Shorter E, Fink M. The Madness of Fear : A History of Catatonia. Oxford University Press ; 2018.
 
ガボール SU (編), 鈴木一正 (訳). カタトニー論文集-精神医学の古典逍遥. 星和書店 ; 2021.
 

書評

最近チェックした商品履歴

Loading...